Extracellular microcellular components

JP2022549328A5Inactive Publication Date: 2024-12-06CODIAK BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2022518957
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-09-26
Filing Date
2020-09-25
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing formulations for extracellular vesicles (EVs) such as exosomes are prone to aggregation and stability issues due to pH fluctuations during freezing and thawing, compromising their therapeutic efficacy.

Method used

A composition comprising extracellular vesicles, saccharides like sucrose or trehalose, sodium chloride, potassium phosphate, and sodium phosphate, maintained at a pH of 7.2, which stabilizes EVs during freezing and thawing, reducing aggregation and improving structural integrity.

Benefits of technology

The composition ensures stable storage and administration of EVs over varying temperatures and times without compromising their structural integrity or the stability of biologically active moieties, enhancing their therapeutic potential.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to compositions for the storage and administration of extracellular vesicles (exosomes), which may include a scaffold protein and one or more (e.g., 1, 2, 3, 4, 5, or more) exogenous biologically active moieties. Also provided herein are methods for producing exosomes and methods for using exosomes to treat and / or prevent a range of medical disorders. Provided herein are compositions for the storage and administration of extracellular vesicles, e.g., exosomes. The compositions of the present disclosure provide reduced EV aggregation, improved EV stability, improved EV structural integrity, improved stability of engineered proteins on or contained within EVs, and improved stability of passively loaded or complexed materials, such as small molecule drugs or proteins.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] References to sequence listings submitted electronically via EFS-WEB The contents of the electronically submitted sequence listing (title: 4000_069PC02_Seqlisting_ST25; size: 68,911 bytes; and creation date: September 24, 2020) submitted in the course of this application are incorporated herein by reference in their entirety.

[0002] Cross-reference of related applications This PCT application claims priority to U.S. Provisional Application No. 62 / 906,018, filed on 25 September 2019, and U.S. Provisional Application No. 62 / 906,485, filed on 26 September 2019, each of which is incorporated herein by reference in its entirety.

[0003] Areas of disclosure This disclosure relates to compositions for the storage and administration of extracellular vesicles (EVs), such as exosomes, which may contain one or more exogenous biologically active moieties, and to methods for preparing and using such compositions. [Background technology]

[0004] EVs, such as exosomes, are important mediators of intercellular communication. They are also important biomarkers in the diagnosis and prognosis of many diseases, including cancer. As a drug delivery vehicle, EVs offer advantages over conventional drug delivery methods (e.g., peptide immunization, DNA vaccines) as a novel therapeutic modality in many therapeutic areas. One area of ​​research is the formulation of compositions that can stably contain EVs during long-term storage before patient administration without compromising their efficacy. Known formulations have drawbacks. For example, certain formulations, such as those containing TRIS buffer, do not prevent pH fluctuations at various temperatures (i.e., when the formulation is frozen or thawed). Even slight pH fluctuations can induce EV aggregation, thereby reducing or interfering with EV function. Furthermore, known compositions contain exogenous components such as exogenously added polypeptides, e.g., human serum albumin, or chelating agents.

[0005] Therefore, there is a need for effective compositions for the storage and administration of EVs that can overcome the shortcomings of known formulations and thus better enable the therapeutic and other applications of EV-based technologies. [Overview of the Initiative] [Means for solving the problem]

[0006] Provided herein are compositions for the storage and administration of extracellular vesicles, such as exosomes. The compositions of this disclosure provide reduced aggregation of EVs, improved stability of EVs, improved structural integrity of EVs, improved stability of engineered proteins on or contained within EVs, and improved stability of passively loaded or complexed materials such as small molecule drugs or proteins. Such compositions can be frozen, stored over a range of temperatures for various time periods, and thawed without impairing the stability of the EVs contained in the composition. The EVs of this disclosure may contain biologically active moieties, and as a result, the compositions can be used to treat a number of diseases or conditions in which administration of EVs, for example, EVs modified to contain the biologically active moieties disclosed herein, has a beneficial effect on the subject.

[0007] In some embodiments, the present disclosure provides a pharmaceutical composition comprising (a) extracellular vesicles; (b) sugars; (c) sodium chloride; (d) potassium phosphate; and (e) sodium phosphate, wherein the composition is in a solution with a pH of about 7.2. In some embodiments, the extracellular vesicles are exosomes.

[0008] In some embodiments, the composition may be stored at a temperature of 4°C for at least about 4 hours, at least about 5 hours, at least about 6 hours, at least about 7 hours, at least about 8 hours, at least about 9 hours, at least about 10 hours, at least about 11 hours, at least about 12 hours, at least about 15 hours, at least about 20 hours, at least about 24 hours, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, or at least about 7 days.

[0009] In some embodiments, the composition can be frozen and thawed, and the thawed composition has a pH of about 7.2. In some embodiments, the composition has a pH of 7.0, 7.1, 7.2, 7.3, or 7.4.

[0010] In some embodiments, pI is in the range of approximately 1 to approximately 6.5.

[0011] In some embodiments, the composition has the following advantages: (i) reduced aggregation, (ii) improved stability of EVs, (iii) improved structural integrity of EVs, (iv) improved stability of manipulated proteins on or contained within EVs, and (v) improved stability of passively loaded or complexed materials such as small molecule drugs or proteins.

[0012] In some embodiments, the sugars include monosaccharides, disaccharides, trisaccharides, oligosaccharides, polysaccharides, sugar alcohols, or any combination thereof. In some embodiments, the sugars have a molecular weight of about 340.00 g / mol to about 380.00 g / mol. In some embodiments, the sugars include lactose, glucose, sucrose, trehalose, dextrose, and / or combinations thereof. In some embodiments, the sugars are sugar alcohols having a molecular weight of about 90.00 g / mol to about 190.00 g / mol. In some embodiments, the sugar alcohols include glycerol, sorbitol, mannitol, xylitol, and / or combinations thereof. In some embodiments, the sugars are sucrose or trehalose. In some embodiments, the sugars are present in the composition at a concentration of about 5% w / v.

[0013] In some embodiments, the disclosure provides pharmaceutical compositions comprising (i) extracellular vesicles and (ii) sugars, which are sucrose or trehalose at a concentration of about 5% w / v. In some embodiments, the compositions have improved stability compared to a reference composition comprising sucrose or trehalose at a concentration of 1% w / v to 4% w / v.

[0014] In some embodiments, the composition has an conductivity of about 6 mS / cm to about 10 mS / cm. In some embodiments, the conductivity is 6 mS / cm to about 7 mS / cm, about 7 mS / cm to about 8 mS / cm, about 8 mS / cm to about 9 mS / cm, or about 9 mS / cm to about 10 mS / cm. In some embodiments, the conductivity is about 6 mS / cm, about 7 mS / cm, about 8 mS / cm, about 9 mS / cm, or about 10 mS / cm.

[0015] In some embodiments, the composition further comprises sodium chloride. In some embodiments, the sodium chloride is present in the composition at a concentration of about 10 mM to about 134 mM. In some embodiments, the concentration of sodium chloride is about 10 mM to about 130 mM, about 20 mM to about 120 mM, about 30 mM to about 110 mM, about 40 mM to about 100 mM, about 50 mM to about 90 mM, about 60 mM to about 80 mM, about 70 mM to about 80 mM, about 45 mM to about 95 mM, about 45 mM to about 80 mM, about 45 mM to about 70 mM, about 45 mM to about 65 mM, about 50 mM to about 65 mM, about 50 mM to about 60 mM, about 50 mM to about 55 mM, about 50 mM to about 55 mM, or about 51 mM to about 54 mM. In some embodiments, the concentration of sodium chloride is about 10 mM, about 20 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about ...........

[0016] In some embodiments, the composition further comprises a phosphate buffer. In some embodiments, the phosphate buffer comprises at least one phosphate compound comprising potassium phosphate, sodium phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium phosphate, and / or combinations thereof.

[0017] In some embodiments, the phosphate buffer comprises potassium phosphate and sodium phosphate in a ratio of about 1:about 2, about 1:about 3, about 1:about 4, or about 1:about 5. In some embodiments, the phosphate buffer comprises potassium phosphate and sodium phosphate in a ratio of about 1:about 3. In some embodiments, the phosphate buffer comprises potassium phosphate and sodium phosphate in a ratio of about 1:about 2.

[0018] It should be noted that the text in seems to be incomplete at the end. You may want to check and correct it if needed.In some embodiments, the present disclosure provides a pharmaceutical composition comprising a solution containing (i) extracellular vesicles, (ii) potassium phosphate, and (iii) sodium phosphate, wherein the ratio of potassium phosphate to sodium phosphate is from about 1 to about 3 or from about 1 to about 2.

[0019] In some embodiments, the solution has a pH of 7.1 to 7.3.

[0020] In some embodiments, potassium phosphate is present in the composition at a concentration of from about 1 mM to about 20 mM, from about 2 mM to about 19 mM, from about 3 mM to about 18 mM, from about 4 mM to about 17 mM, from about 5 mM to about 16 mM, or from about 5 mM to about 15 mM.

[0021] In some embodiments, the concentration of potassium phosphate is about 4.5 mM, about 4.6 mM, about 4.7 mM, about 4.8 mM, about 4.9 mM, about 5.0 mM, about 5.1 mM, about 5.2 mM, about 5.3 mM, about 5.4 mM, or about 5.5 mM. In some embodiments, the concentration of potassium phosphate is 5.15 mM.

[0022] In some embodiments, the concentration of potassium phosphate is about 15.0 mM, about15.1 mM, about 15.2 mM, about 15.3 mM, about 15.4 mM, about 15.5 mM, about 15.6 mM, about 15.7 mM, about 15.8 mM, about 15.9 mM, about 16.0, about 16.1 mM, about 16.2 mM, about 16.3 mM, about 16.4 mM, or about 16.5 mM. In some embodiments, the concentration of potassium phosphate is 15.4 mM.

[0023] In some embodiments, potassium phosphate is monobasic potassium phosphate.

[0024] In some embodiments, sodium phosphate is present in the composition at a concentration of from about 10 mM to about 30, from about 11 mM to about 29 mM, from about 12 mM to about 28 mM, from about 13 mM to about 27 mM, or from about 14 mM to about 26 mM.

[0025] In some embodiments, the composition according to claim 39, wherein sodium phosphate is present in the composition at concentrations of about 14.5 mM, about 14.6 mM, about 14.7 mM, about 14.8 mM, about 14.9 mM, about 15.0 mM, about 15.1 mM, about 15.2 mM, about 15.3 mM, about 15.4 mM, or about 15.5 mM.

[0026] In some embodiments, the concentration of sodium phosphate is 14.9 mM.

[0027] In some embodiments, sodium phosphate is present in the composition at concentrations of approximately 26.5 mM, 26.6 mM, 26.7 mM, 26.8 mM, 26.9 mM, 27.0 mM, 27.1 mM, 27.2 mM, 27.3 mM, 27.4 mM, or 27.5 mM. In some embodiments, the concentration of sodium phosphate is 27.1 mM.

[0028] In some embodiments, sodium phosphate is dibasic sodium phosphate heptahydrate.

[0029] In some embodiments, the composition further comprises antioxidants. In some embodiments, the antioxidants include D-methionine, L-methionine, ascorbic acid, erythorbic acid, sodium ascorbate, thioglycerol, cysteine, acetylcysteine, cystine, dithioerythreitol, glutathione, tocopherol, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), sodium bisulfate, sodium dithionate, α-tocopherol, γ-tocopherol, propyl gallate, ascorbyl palmitate, sodium metabisulfite, thiourea, sodium thiosulfate, propyl gallate, and sodium thioglycolate.

[0030] In some embodiments, the composition is not freeze-dried.

[0031] In some embodiments, the composition does not contain a chelating agent.

[0032] In some embodiments, the composition does not contain albumin.

[0033] In some embodiments, the Disclosure provides a composition comprising (a) sucrose at a concentration of about 5% w / v; (b) sodium chloride at a concentration of about 50 mM; (c) monobasic potassium phosphate at a concentration of about 5 mM; and (d) dibasic sodium phosphate heptahydrate at a concentration of about 15 mM, wherein the composition is in a solution with a pH of 7.2 and a conductivity of 8.8 mS / cm.

[0034] In some embodiments, the Disclosure provides a composition comprising (a) sucrose at a concentration of about 5% w / v; (b) sodium chloride at a concentration of about 40 mM; (c) monobasic potassium phosphate at a concentration of about 15 mM; and (d) dibasic sodium phosphate heptahydrate at a concentration of about 27 mM, wherein the composition is in a solution with pH 7.2 and conductivity 7.2 mS / cm.

[0035] In some embodiments, the composition can be stored at temperatures of approximately -20°C to approximately -80°C without a decrease in the stability of the extracellular vesicles. In some embodiments, the composition can be stored for approximately 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, or 5 years.

[0036] In some embodiments, extracellular vesicles are exosomes.

[0037] In some embodiments, the extracellular vesicle further comprises a scaffold protein. In some embodiments, the scaffold protein is scaffold X. In some embodiments, the payload is ligated to the scaffold protein. In some embodiments, the payload is ligated to the scaffold protein by a linker. In some embodiments, the linker is a polypeptide. In some embodiments, the linker is a non-polypeptide portion. In some embodiments, scaffold X is a scaffold protein capable of anchoring the payload to the outer surface of the extracellular vesicle.

[0038] In some embodiments, the scaffold protein includes a negative regulator (PTGFRN protein) of the prostaglandin F2 receptor.

[0039] In some embodiments, the scaffold protein comprises a PTGFRN protein or a fragment thereof. In some embodiments, the scaffold protein comprises an amino acid sequence described in any one of SEQ ID NOs: 1-7 and 33. In some embodiments, the scaffold protein comprises an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% identical to SEQ ID NO: 1.

[0040] In some embodiments, the extracellular vesicle contains a biologically active site. In some embodiments, a scaffolding protein is fused to the biologically active site. In some embodiments, the scaffolding protein is not fused to the biologically active site.

[0041] In some embodiments, the biologically active moiety comprises a STING agonist. In some embodiments, the STING agonist comprises CL656. In some embodiments, the STING agonist is isomer A, isomer B, isomer C, or isomer D of CL656. In some embodiments, the STING agonist is not fused to a scaffold protein.

[0042] In some embodiments, the biologically active moiety is IL-12. In some embodiments, the biologically active moiety is CD40L. In other embodiments, the biologically active moiety is FTL3L.

[0043] In some embodiments, the biologically active portion is fused to a scaffold protein.

[0044] In some embodiments, the composition may be administered parenterally, topically, intravenously, orally, subcutaneously, intra-arterially, intradermally, percutaneously, intrarectally, intracranially, intraperitoneally, intranasally, intratumorally, intramuscularly, or as an inhalant.

[0045] In some embodiments, the present disclosure provides a method for preparing a pharmaceutical composition comprising combining (a) extracellular vesicles; (b) sugars; (c) sodium chloride; (d) potassium phosphate; and (e) sodium phosphate. In some embodiments, the extracellular vesicles are exosomes.

[0046] In some embodiments, the present disclosure provides a method for preparing a pharmaceutical composition comprising combining extracellular vesicles and sugars, wherein the sugars are sucrose or trehalose at a concentration of about 5% w / v, and the composition exhibits improved stability compared to a composition comprising sucrose or trehalose at a concentration of 1-4%.

[0047] In some embodiments, the present disclosure provides a method for preparing a pharmaceutical composition comprising combining an extracellular vesicle with a phosphate compound, wherein the phosphate compound comprises potassium phosphate and sodium phosphate in a ratio that produces a pH of 7.1 to 7.3.

[0048] In some embodiments, the conductivity of the composition can be adjusted. In some embodiments, the conductivity of the composition is about 7.1 to about 7.3 mS / cm. In some embodiments, the present disclosure provides a conductivity of 7.23 mS / cm.

[0049] In some embodiments, the Disclosure provides a method for treating a disease or condition in a subject in need of such treatment, comprising administering compositions disclosed herein to the subject. In some embodiments, the diseases or conditions are cancer, fibrosis, hemophilia, diabetes mellitus, growth factor deficiency, ocular diseases, Pompe disease, lysosomal storage disorders, mucobicidosis, cystic fibrosis, Duchenne and Becker muscular dystrophy, trans tyretin amyloidosis, hemophilia A, hemophilia B, adenosine deaminase deficiency, Lieber congenital amaurosis, X-linked adrenal leukemia, metachromatic leukodystrophy, OTC deficiency, glycogen storage disease 1A, Crigler-Nadjar syndrome, primary hyperoxaluria type 1, acute intermittent porphyria, phenylketonuria, familial hypercholesterolemia, mucopolysaccharidosis type VI, α1 antitrypsin deficiency, and hypercholesterolemia. In some embodiments, cancer is bladder cancer, cervical cancer, renal cell carcinoma, testicular cancer, colorectal cancer, lung cancer, head and neck cancer, ovarian cancer, lymphoma, liver cancer, glioblastoma, melanoma, myeloma, leukemia, pancreatic cancer, or a combination thereof.

[0050] In some embodiments, the disclosure provides pharmaceutical compositions for treating a disease or condition in a subject in need thereof.

[0051] In some embodiments, the disclosure provides the use of compositions disclosed herein in the manufacture of a pharmacopoeia for the treatment of a disease or condition. [Brief explanation of the drawing]

[0052] [Figure 1A] This is a schematic diagram of an exosome containing protein X and a biologically active moiety according to one aspect of the present disclosure. Surface proteins CD9, CD81, and TSG101, and the sphingomyelin lipid domain are shown. mRNA, miRNA, and metabolites of exosome components are further shown. [Figure 1B] This graph shows the zeta potential (mV) of natural (black squares) and protein X-containing exosomes (circles) according to one aspect of the present disclosure. The X-axis represents pH, and the Y-axis represents zeta potential (mV). [Figure 2A] This graph, according to one aspect of the present disclosure, shows the Z-mean (nm) of innate exosomes (black squares) and protein X exosomes (circles) at different pH values. The X-axis represents pH, and the Y-axis represents the Z-mean (nm). [Figure 2B] This is a schematic diagram showing the stable pH range (rounded rectangle) of EV according to one aspect of this disclosure. The stable pH range shown is 7-8. The arrows indicate the results of pH changes of EV when the pH is too low (EV aggregation) or too high (lipid hydrolysis). [Figure 2C] This is a magnified cryogenic transmission electron microscope image showing protein X EV according to one aspect of this disclosure. The exosome is vitrified in water and is not dehydrated. This image shows an exosome in water without ice crystals. The theoretical isoelectric point (pI) of protein X EV is stated to be 6.2. The size of protein X-containing EV is stated to be approximately 100 nm. [Figure 2D] These are photographs of microcentrifuge tubes containing various compositions according to embodiments of the present disclosure. Tube A contains sucrose + buffer that has been freeze-thawed three times. Tube B contains buffer only that has been freeze-thawed three times. Tube C contains Milli-Q water only that has been freeze-thawed three times. These tubes show the presence of both color change and turbidity, and it is also shown that salt provides some degree of protection compared to pure water samples. [Figure 3A] In one aspect of the disclosure, a graph is provided showing the distribution of STING agonist concentration (μM) in exosomes, compared to STING agonist in supernatant, along with exosome-containing buffer stored at -80°C, 4°C, and 22°C for periods of 0 to 12 hours. This graph shows the time points from 0 to 12 hours in Figure 3B. The X-axis represents time (in hours). The Y-axis represents the concentration of STING agonist (μM). [Figure 3B]In one aspect of this disclosure, a graph is provided showing the distribution of STING agonist concentrations (μM) in exosomes, compared to STING agonist in supernatant, with exosome-containing buffer stored at -80°C, 4°C, and 22°C for periods of 12 to 72 hours. The X-axis represents time (in hours), and the Y-axis represents the concentration of STING agonist (μM). [Figure 3C] This bar graph shows the effects of administration of phosphate-buffered saline, a buffer containing intrinsic exosomes, and a buffer containing exosomes with a STING agonist, four hours after administration, on gene expression in C57BL / 6 mice, according to one aspect of this disclosure. The exosome-containing buffers were stored at 4°C and 22°C for 24 hours or 72 hours. The X-axis represents various test parameters. The Y-axis represents the normalized gene expression level. [Figure 3D] This graph shows the intratumoral concentrations of free STING agonist (dashed line, bottom) and exosome-encapsulated STING agonist (solid line, top) in B16-F10 melanoma tumors of C57BL / 6 mice over time, according to one aspect of this disclosure. The X-axis represents time (in minutes). The Y-axis represents the concentration of STING agonist (nM). [Figure 4] This diagram shows a schematic process for preparing an exosome-encapsulated STING agonist according to one aspect of the present disclosure. A shows the loading of the STING agonist into the exosome by saturating the buffer containing the exosome with the STING agonist so that a portion of the STING diffuses into the exosome. B shows the purification of the exosome (i.e., removal of the STING agonist that did not diffuse into the exosome). C shows the equilibration of the exosome containing the STING agonist (i.e., passive diffusion of the STING agonist from the exosome into the surrounding buffer). [Figure 5]This graph shows the IL-12 content (ng / mL) associated with exosomes. The X-axis represents the time (days) that the exosomes are preserved. The Y-axis represents the IL-12 content (ng / mL). From left to right, the bar graph shows the following: (1) control, no peroxide; (2) control, 0.05% peroxide; (3) thiosulfate, no peroxide; (4) thiosulfate, 0.05% peroxide; (5) ascorbate, no peroxide; (6) ascorbate, 0.05% peroxide; (7) glutathione, no peroxide; (8) glutathione, 0.05% peroxide; (9) methionine, no peroxide; (10) methionine, 0.05% peroxide. [Figure 6] This graph shows the exosome diameter (nm) after different time periods. The X-axis represents the time (days) that the exosomes are preserved. The Y-axis represents the exosome diameter (nm). From left to right, the bar graph shows: (1) control; (2) control and hydrogen peroxide; (3) thiosulfate; (4) thiosulfate and hydrogen peroxide; (5) ascorbate; (6) ascorbate and hydrogen peroxide; (7) glutathione; (8) glutathione and hydrogen peroxide; (9) methionine; (10) methionine and hydrogen peroxide. [Figure 7] This graph shows the PDI of exosome solutions after different time periods. The X-axis represents the time (days) that the exosomes are preserved. The Y-axis represents the polydispersity index. [Modes for carrying out the invention]

[0053] This disclosure relates to compositions for the preservation and administration of extracellular vehicles (e.g., exosomes) that include one or more biologically active moieties, which maintain the stability and integrity of the extracellular vehicle and payload over various periods and temperatures (such as freezing and thawing). Multiple biologically active moieties can be attached to (or linked to) one or more scaffolding portions on the outer surface of the extracellular vehicle (e.g., exosome). Various non-limiting embodiments are disclosed herein.

[0054] I. Definition To facilitate understanding of this document, certain terms are defined first. Further definitions are provided throughout the descriptions of the modes for carrying out the invention.

[0055] It should be noted that the term "a" or "an" entity refers to one or more of those entities; for example, "nucleotide sequence" is understood to represent one or more nucleotide sequences. Therefore, the terms "a" (or "an"), "one or more," and "at least one" are used interchangeably in this specification.

[0056] Furthermore, as used herein, “and / or” shall be interpreted as each specific disclosure of two designated functions or components, with or without the other. Accordingly, the term “and / or” as used in phrases such as “A and / or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Similarly, the term “and / or” as used in phrases such as “A, B, and / or C” is intended to include each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0057] Whenever an aspect is described herein in the language of “including,” it is understood that similar aspects described with respect to “consisting of” and / or “essentially consisting of” are also provided.

[0058] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art relating to this disclosure. For example, *Concise Dictionary of Biomedicine and Molecular Biology*, Juo, Pei-Show, 2nd ed., 2002, CRC Press; *The Dictionary of Cell and Molecular Biology*, 3rd ed., 1999, Academic Press; and *Oxford Dictionary of Biochemistry and Molecular Biology*, Revised, 2000, Oxford University Press provide one of these technical dictionaries along with a general dictionary of many of the terms used herein.

[0059] Units, prefixes, and symbols are given in the format approved by the Systeme International de Unites (SI). Numerical ranges include the number defining the range. Unless otherwise specified, nucleotide sequences are written from left to right in a 5' to 3' direction. Amino acid sequences are written from left to right in an amino to carboxy direction. The headings provided herein are not intended to limit the various aspects of this disclosure that may be found by referring to the entire specification. Thus, the terms defined immediately below are more fully defined by referring to the entire specification.

[0060] The term "approximately" is used herein to mean roughly, nearly, roughly, or proximal. When used in conjunction with a numerical range, the term modifies the range by extending the boundaries of the given numerical value above or below. Generally, the term "approximately" can modify numerical values ​​above or below a given value, for example, by a variation of 10% above or below (higher or lower).

[0061] As used herein, the term “extracellular vesicle” or “EV” refers to a cell-derived vesicle containing a membrane that encloses an internal space. Extracellular vesicles include all membrane-bound vesicles (e.g., exosomes, nanovesicles) having a diameter smaller than the cell from which they originate. In some embodiments, extracellular vesicles may contain a variety of macromolecular payloads, either within an internal space (i.e., lumen), presented on the outer surface of the extracellular vesicle, and / or across the membrane, with a diameter ranging from 20 nm to 1000 nm. In some embodiments, the payloads may include nucleic acids, proteins, carbohydrates, lipids, small molecules, and / or combinations thereof. In some embodiments, an EV may contain multiple (e.g., two or more) payloads or other exogenous biologically active parts. In certain embodiments, the extracellular vehicle may further contain one or more scaffolding parts. Extracellular vesicles include, for example and without limitation, apoptotic bodies, cell fragments, cell-derived vesicles by direct or indirect manipulation (e.g., by serial extrusion or treatment with alkaline solution), vesicled organelles, and vesicles produced by living cells (e.g., by direct plasma membrane budding or fusion with the plasma membrane of late endosomes). Extracellular vesicles may originate from living or dead organisms, explanted tissues or organs, prokaryotic or eukaryotic cells, and / or cultured cells. In some embodiments, extracellular vesicles are produced by cells expressing one or more transgene products. The EVs disclosed herein are modified and therefore do not include naturally occurring EVs.

[0062] As used herein, the term “exosome” refers to an extracellular vesicle having a diameter of 20–300 nm (e.g., 40–200 nm). Exosomes include a membrane surrounding an internal space (i.e., lumen) and, in some embodiments, may be generated from a cell (e.g., a producer cell) by direct plasma membrane budding or by fusion of a late endosome with the plasma membrane. In some embodiments, an exosome comprises multiple (e.g., two or more) exogenous biologically active parts (e.g., as described herein). In certain embodiments, an exosome further comprises one or more scaffold parts. As described below, exosomes may originate from producer cells and may be isolated from producer cells based on their size, density, biochemical parameters, or a combination thereof. In some embodiments, the EVs (e.g., exosomes) of this disclosure are produced by cells expressing one or more transgene products. The exosomes of this disclosure are modified and therefore do not include naturally occurring exosomes.

[0063] As used herein, the term “nanopes” refers to extracellular vesicles having a diameter of 20–250 nm (e.g., 30–150 nm) and are produced from cells (e.g., producer cells) by direct or indirect manipulation such that nanovesicles would not otherwise be produced by the cells. Appropriate manipulation of cells for nanovesicle production includes, but is not limited to, serial extrusion, treatment with alkaline solutions, sonication, or a combination thereof. In some embodiments, nanovesicle production may result in the destruction of producer cells. In some embodiments, the nanovesicle populations described herein substantially contain no vesicles derived from cells by direct budding from the plasma membrane or fusion with the plasma membrane of late endosomes. In some embodiments, nanovesicles contain multiple (e.g., at least two) exogenous biologically active moieties. In certain embodiments, nanovesicles further contain one or more scaffolding moieties. Nanovesicles previously derived from producer cells may be isolated from producer cells based on their size, density, biochemical parameters, or a combination thereof. As used herein, the nanovesicles have been modified and therefore do not contain naturally occurring nanovesicles.

[0064] As used herein, the term “surface-modified EV, e.g., exosome” (e.g., scaffold-modified EV, e.g., exosome) refers to an EV (e.g., exosome) having a membrane or surface whose composition has been modified such that the membrane or surface of the modified EV (e.g., exosome) differs from the surface of the EV before modification or the surface of a native EV. The modification may be performed on the surface of the EV (e.g., exosome) or within the membrane of the EV (e.g., exosome), resulting in a change in the surface of the EV (e.g., exosome). For example, the composition of the membrane, such as proteins, lipids, small molecules, and carbohydrates, may be modified. The composition may be altered by chemical, physical, or biological methods, or by production from cells that have been modified beforehand or concurrently by chemical, physical, or biological methods. Specifically, the composition may be altered by genetic engineering, or by production from cells that have been modified beforehand by genetic engineering. In some embodiments, the surface-modified EV, e.g., exosome, contains multiple (e.g., at least two) exogenous biologically active moieties. In certain embodiments, the exogenous biologically active portion comprises an exogenous protein (i.e., a protein not naturally expressed by the EV (e.g., exosome)) or a fragment or variant thereof, which may be exposed on the surface of the EV (e.g., exosome) or may be anchorage points (adhesion sites) of the portion exposed on the surface of the EV (e.g., exosome). In other embodiments, the surface-engineered EV (e.g., exosome) comprises a higher expression (e.g., a greater number) of a native exosome protein (e.g., scaffold X) or a fragment or variant thereof, which may be exposed on the surface of the EV (e.g., exosome) or may be anchorage points (adhesion sites) of the portion exposed on the surface of the EV (e.g., exosome).

[0065] The term “modified,” as used herein in reference to EVs (e.g., exosomes), means modifying or manipulating EVs (e.g., exosomes) and / or their producer cells so that the modified EVs (e.g., exosomes) differ from native EVs (e.g., exosomes). In some embodiments, the modified EVs (e.g., exosomes) described herein include a membrane with a different composition of proteins, lipids, small molecules, carbohydrates, etc., compared to the membrane of a native EV (e.g., exosome) (e.g., the membrane contains a higher density or number of native exosomal proteins, and / or the membrane contains multiple (at least two) biologically active sites not naturally found in exosomes. When used herein, biologically active sites not naturally found in exosomes are also referred to as “exogenous biologically active sites.” In certain embodiments, such modifications to the membrane alter the outer surface of the EV (e.g., exosome) (e.g., the surface-manipulated EVs (e.g., exosomes) described herein).

[0066] As used herein, the term “scaffold portion” refers to a molecule that can be used to immobilize a payload or any other exogenous biologically active portion for an extracellular matrix (EV) (e.g., exosome) on either the luminal or ventral surface of the EV (e.g., exosome). In certain embodiments, the scaffold portion includes a synthetic molecule. In some embodiments, the scaffold portion includes a non-polypeptide portion. In other embodiments, the scaffold portion includes a lipid, carbohydrate, or protein that is naturally present in the EV (e.g., exosome). In some embodiments, the scaffold portion includes a lipid, carbohydrate, or protein that is not naturally present in the EV (e.g., exosome). In certain embodiments, the scaffold portion is scaffold X. In further embodiments, the scaffold portion includes scaffold X and another scaffold portion. Non-limiting examples of other scaffolding components that can be used in this disclosure include aminopeptidase N (CD13), neprilysin, also known as membrane metalloendopeptidase (MME); ectonucleotide pyrophosphatase / phosphodiesterase family member 1 (ENPP1); neuropyrin-1 (NRP1); CD9, CD63, CD81, PDGFR, GPI anchored protein, lactoadherin, LAMP2, and LAMP2B.

[0067] As used herein, the term “Scaffold X” refers to exosomal proteins recently identified on the surface of exosomes. See, for example, U.S. Patent No. 10,195,290 (the entire patent is incorporated herein by reference). Non-exclusive examples of scaffold X proteins include: negative regulators of prostaglandin F2 receptors ("PTGFRN proteins"). Basigin ("BSG protein"); immunoglobulin superfamily member 2 ("IGSF2 protein"); immunoglobulin superfamily member 3 ("IGSF3 protein"); immunoglobulin superfamily member 8 ("IGSF8 protein"); integrin beta 1 ("ITGB1 protein"); integrin alpha 4 ("ITGA4 protein"); 4F2 cell surface antigen heavy chain ("SLC3A2 protein"); and classes of ATP transporter proteins ("ATP1A1 protein", "ATP1A2 protein", "ATP1A3 protein", "ATP1A4 protein", "ATP1B3 protein", "ATP2B1 protein", "ATP2B2 protein", "ATP2B3 protein", "ATP2B protein"). In some embodiments, the scaffold X protein may be a complete protein or a fragment thereof (e.g., a functional fragment, e.g., a minimal fragment that can fix another part onto the outer or luminal surface of an EV (e.g., an exosome)). In some embodiments, the scaffold X can fix a part (e.g., a payload) onto the outer or luminal surface of an exosome.

[0068] As used herein, the term “scaffold Y” refers to a newly identified exosomal protein within the luminal surface of an exosome. See, for example, International Publication No. WO / 2019 / 099942 (the entire publication is incorporated herein by reference). Non-limiting examples of scaffold Y proteins include: myristoylated alanine-rich protein kinase C substrate ("MARCKS protein"); myristoylated alanine-rich protein kinase C substrate-like 1 ("MARCKSL1 protein"); and brain acid-soluble protein 1 ("BASP1 protein"). In some embodiments, the scaffold Y protein may be a complete protein or a fragment thereof (e.g., a functional fragment, e.g., a minimal fragment capable of fixing a portion onto the luminal surface of an EV, e.g., an exosome). In some embodiments, scaffold Y may fix any portion (e.g., a STING agonist and / or IL-12 portion) to the lumen of an EV (e.g., an exosome).

[0069] As used herein, the term “fragment” of a protein (e.g., therapeutic protein or scaffold X) means an amino acid sequence of a protein that is shorter than the native sequence, has a deletion at the N-terminus and / or C-terminus, or has a deletion at any part of the protein compared to the native protein. As used herein, the term “functional fragment” means a protein fragment that retains protein function. Thus, in some embodiments, a functional fragment of the scaffold X protein retains the ability to fix the portion to the luminal surface and / or outer surface of an EV (e.g., exosome). Whether a fragment is a functional fragment can be assessed by any known method for determining the protein content of an EV (e.g., exosome), including Western blotting, FACS analysis, and fusion of the fragment with an autofluorescent protein such as GFP. In certain embodiments, a functional fragment of the scaffold X protein retains at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% of the ability of the native scaffold X protein, e.g., the ability to fix the portion.

[0070] As used herein, the term “variant” refers to a molecule (e.g., a functional molecule, antigen, or scaffold X) that, when compared by methods known in the art, shares a specific structural and functional identity with another molecule. For example, a variant of a protein may include substitutions, insertions, deletions, frameshifts, or rearrangements in another protein.

[0071] In some embodiments, the variant of scaffold X includes a variant having at least about 70% identity with full-length mature PTGFRN, BSG, IGSF2, IGSF3, IGSF8, ITGB1, ITGA4, SLC3A2, or ATP transporter protein, or a fragment (e.g., a functional fragment) of PTGFRN, BSG, IGSF2, IGSF3, IGSF8, ITGB1, ITGA4, SLC3A2, or ATP transporter protein. In some embodiments, the variant of PTGFRN or the variant of a fragment of PTGFRN shares at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with the PTGFRN or its functional fragment described in SEQ ID NO: 1.

[0072] A "conservative amino acid substitution" is one in which an amino acid residue is replaced by an amino acid residue having a similar side chain. The family of amino acid residues having similar side chains is defined in the art and includes amino acids having basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), non-charged side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, if an amino acid in a polypeptide is substituted with another amino acid from the same side chain family, the substitution is considered conservative. In another embodiment, the amino acid string can be conservatively replaced with a structurally similar string that differs in the order and / or composition of its side-chain family members.

[0073] The term “percentage of sequence identity” or “percentage of identity” between two polynucleotide or polypeptide sequences refers to the number of identical matched positions shared by the sequences on the comparison window, taking into account any additions or deletions (i.e., gaps) that must be introduced for optimal alignment of the two sequences. A matched position is any position where the same nucleotide or amino acid is presented in both the target sequence and the reference sequence. Gaps present in the target sequence are not counted because they are not nucleotides or amino acids. Similarly, gaps presented in the reference sequence are not counted because we count nucleotides or amino acids from the target sequence, not from the reference sequence.

[0074] The percentage of sequence identity is calculated by determining the number of positions where identical amino acid residues or nucleic acid bases occur in both sequences, obtaining the number of matching positions, dividing the number of matching positions within the comparison window by the total number of positions, and multiplying the result by 100 to obtain the percentage of sequence identity. Sequence comparison between two sequences and determination of the percentage of sequence identity can be achieved using readily available software, both for online use and download. Suitable software programs are available from various suppliers and are available for both protein and nucleotide sequence alignments. One suitable program for determining the percentage of sequence identity is bl2seq, part of the BLAST suite of programs available from the U.S. government's National Center for Biotechnology Information (BLAST) website (blast.ncbi.nlm.nih.gov). Bl2seq performs the comparison between two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. Other suitable programs include Needle, Stretcher, Water, or Matcher, which are part of the EMBOSS suite of bioinformatics programs and are also available from the European Bioinformatics Institute (EBI) (www.ebi.ac.uk / Tools / psa).

[0075] Different regions within a single polynucleotide or polypeptide target sequence aligned with a polynucleotide or polypeptide reference sequence may each have their own percentage of sequence identity. Note that the percentage of sequence identity value is rounded to the nearest tenth of the approximate value. For example, 80.11, 80.12, 80.13, and 80.14 are rounded down to 80.1, while 80.15, 80.16, 80.17, 80.18, and 80.19 are rounded up to 80.2. Also note that the length value is always an integer.

[0076] The generation of sequence alignments for calculating the percentage of sequence identity is not limited to pairwise sequence-to-sequence comparisons performed exclusively by primary sequence data. Sequence alignments can be derived from multiple sequence alignments. One preferred program for generating multiple sequence alignments is ClustalW2, available from www.clustal.org. Another preferred program is MUSCLE, available from www.drive5.com / muscle / . ClustalW2 and MUSCLE are alternatively available from sources such as EBI.

[0077] It will also be understood that sequence alignments can be generated by integrating sequence data with data from heterogeneous sources such as structural data (e.g., crystallographic protein structure), functional data (e.g., mutation sites), or phylogenetic data. A suitable program for integrating heterogeneous data and generating multiple sequence alignments is T-Coffee, which is available at www.tcoffee.org or, for example, from EBI. It will also be understood that the final alignment used to calculate the percentage of sequence identity can be curated either automatically or manually.

[0078] Polynucleotide variants may include modifications in the coding region, non-coding region, or both. In one embodiment, a polynucleotide variant includes modifications that result in silent substitutions, additions, or deletions but do not alter the properties or activity of the encoded polypeptide. In another embodiment, a nucleotide variant is generated by silent substitutions due to degeneracy of the genetic code. In yet another embodiment, the variant is one in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination. Polynucleotide variants may be generated for a variety of reasons, such as optimizing codon expression in a particular host (changing codons in human mRNA to those in other hosts, e.g., bacterial hosts such as E. coli).

[0079] Natural variants are called “allelemic variants” and refer to one of several alternative forms of a gene that occupies a given locus on a chromosome of an organism (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985)). These allelemic variants may differ in various ways at either the polynucleotide and / or polypeptide level and are also included in this disclosure. Alternatively, non-natural variants can be generated by mutagenesis techniques or direct synthesis.

[0080] Variants can be generated using known methods of protein engineering and recombinant DNA technology to enhance or modify the characteristics of polypeptides. For example, one or more amino acids can be deleted from the N-terminus or C-terminus of a secreted protein without substantially losing its biological function. Ron et al., J. Biol. Chem. 268:2984-2988 (1993) (the whole document is incorporated herein by reference) reported that variant KGF proteins retained heparin-binding activity even after the deletion of 3, 8, or 27 amino acid residues from the amino-terminal end of the protein. Similarly, interferon-γ showed up to 10-fold higher activity after the deletion of 8-10 amino acid residues from the carboxyl terminus of this protein (Dobeli et al., J. Biotechnology 7:199-216 (1988) (the whole document is incorporated herein by reference)).

[0081] Furthermore, much evidence indicates that variants often retain similar biological activity to the native protein. For example, Gayle and collaborators (J. Biol. Chem 268:22105-22111 (1993), the entire work of which is incorporated herein by reference) conducted an extensive mutational analysis of the human cytokine IL-1a. Using random mutagenesis, they generated over 3,500 individual IL-1a variants showing an average change of 2.5 amino acids per variant across the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The researchers found that "most of the molecule can be altered with little effect on [binding or biological activity]." (See abstract.) In fact, of the more than 3,500 nucleotide sequences examined, only 23 unique amino acid sequences produced proteins with significantly different activity from the wild type.

[0082] As described above, polypeptide variants include, for example, modified polypeptides. Modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent bonding of flavin, covalent bonding of heme moiety, covalent bonding of nucleotides or nucleotide derivatives, covalent bonding of lipids or lipid derivatives, covalent bonding of phosphotidylinositol, crosslinking, cyclization, disulfide bond formation, demethylation, covalent crosslinking, cysteine ​​formation, pyroglutamic acid formation, formylation, γ-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodization, methylation, myristoylation, oxidation, pegylation (Mei et al., Blood 116:270-79 (2010), which is incorporated herein by reference in its entirety), proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, and amino acid transfer to proteins - RNA-mediated addition, such as arginylation and ubiquitination. In some embodiments, the scaffolding X is modified at any convenient location.

[0083] As used herein, the terms “linked to” or “complexed to” and “immobilized to” are used interchangeably and refer to the covalent or noncovalent bond formed between the first and second parts, for example, scaffold X and the exogenous biologically active moiety, for example, the scaffold moiety expressed in or on an extracellular vesicle and the antigen, for example, scaffold X (e.g., a PTGFRN protein) on the luminal or ventral surface of the extracellular vesicle.

[0084] The term “encapsulated,” or any grammatically different forms thereof (e.g., encapsulation, or encapsulation), refers to a state or process in which a first part (e.g., an exogenous biologically active site, e.g., a STING agonist) is inside a second part (e.g., an EV, e.g., an exosome) without the two parts being chemically or physically linked. In some embodiments, the term “encapsulated” can be used synonymously with “luminal.” Non-limiting examples of encapsulating a first part (e.g., an exogenous biologically active site, e.g., an antigen, adjuvant, or immunomodulator) into a second part (e.g., an EV, e.g., an exosome) are disclosed elsewhere herein.

[0085] As used herein, the term “producer cells” refers to cells used to generate extracellular viable cells (EVs), e.g., exosomes. Producer cells may be cells cultured in vitro or in vivo. Producer cells include, but are not limited to, cells known to be effective in generating EVs (e.g., exosomes), such as HEK293 cells, Chinese hamster ovary (CHO) cells, mesenchymal stem cells (MSCs), BJ human precipitous fibroblasts, fHDF fibroblasts, AGE.HN® neural progenitor cells, CAP® amniotic cells, adipose-derived mesenchymal stem cells, and RPTEC / TERT1 cells. In certain embodiments, producer cells are not antigen-presenting cells. In some embodiments, producer cells are not dendritic cells, B cells, mast cells, macrophages, neutrophils, Kupffer-Browitz cells, cells derived from any of these cells, or any combination thereof. In some embodiments, the extracellular matrix (e.g., exosomes) useful in this disclosure do not possess antigens on MHC class I or class II molecules exposed on the surface of the extracellular matrix (e.g., exosomes), but instead may possess antigens within the lumen of the extracellular matrix (e.g., exosomes) or on the surface of the extracellular matrix (e.g., exosomes) by adhesion to a scaffold X.

[0086] As used herein, the terms “isolate,” “isolated,” and “to isolate” or “purify,” “purified,” and “to purify,” as well as “extracted” and “to extract,” are used interchangeably and refer to a state of preparation of desired EVs (e.g., multiple known or unknown amounts and / or concentrations) obtained by purification, e.g., selection or concentration of the desired EV preparation, or one or more such processes. In some embodiments, isolation or purification as used herein is a process of removing, partially removing (e.g., fractionating) EVs from a sample containing producer cells. In some embodiments, the isolated EV composition does not have detectable undesirable activity, or alternatively, the level or amount of undesirable activity is at or below an acceptable level or amount. In other embodiments, the isolated EV composition has an amount and / or concentration of desired EVs at or above an acceptable amount and / or concentration. In other embodiments, the isolated EV composition is concentrated compared to the starting material (e.g., producer cell preparation) from which the composition is obtained. This concentration may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99%, 99.999%, 99.9999%, or greater than 99.9999% compared to the starting material. In some embodiments, the isolated EV preparation is substantially free of residual biological products. In some embodiments, the isolated EV preparation is 100%, 99%, 98%, 97%, 96%, or 95%, 94%, 93%, 92%, 91%, or 90% free of any contaminating biological substances. Residual biological products may include non-biological substances (including chemicals) or unwanted nucleic acids, proteins, lipids, or metabolites. Being substantially free of residual biological products may also mean that the EV composition does not contain detectable producer cells and that only EVs are detectable.

[0087] As used herein, the term “immunomodulator” refers to an agent that acts on a target (e.g., a target cell) in contact with an extracellular vesicle and modulates the immune system. Non-limiting examples of immunomodulators that can be introduced into EVs (e.g., exosomes) and / or producer cells include agents such as checkpoint inhibitor modifiers, checkpoint inhibitor ligands, cytokines, derivatives thereof, or any combination thereof. Immunomodulators may also include agonists, antagonists, antibodies, antigen-binding fragments, polynucleotides, such as siRNA, miRNA, lncRNA, mRNA, DNA, or small molecules.

[0088] In this specification, the term “payload” refers to an agent that acts on a target (e.g., a target cell) in contact with an EV. Non-limiting examples of payloads that can be contained in an EV, e.g., an exosome, are biologically active molecules, e.g., therapeutic molecules, adjuvants, and / or immunomodulators. Agents that can be introduced into an EV (e.g., an exosome) and / or producer cell include nucleotides (e.g., nucleotides containing detectable moieties or toxins, or nucleotides that interfere with transcription), nucleic acids (e.g., DNA or mRNA molecules encoding polypeptides such as enzymes, or RNA molecules with regulatory functions such as miRNA, dsDNA, lncRNA, and siRNA), amino acids (e.g., amino acids containing detectable moieties or toxins, or amino acids that interfere with translation), polypeptides (e.g., enzymes), lipids, carbohydrates, and small molecules (e.g., small molecule drugs and toxins). In certain embodiments, the payload includes an exogenous biologically active moiety (e.g., those disclosed herein). In some embodiments, the payload includes a targeting moiety. In some embodiments, the payload is “passively loaded” onto or into an EV, such as an exosome. As used herein, the term “passively loaded” refers to the association between an EV, such as an exosome, and a payload present in the same solution. Under passive loading, the payload is associated with the EV by means of spontaneous diffusion and / or attraction.

[0089] As used herein, the term “targeting moiety” refers to an agent capable of modifying the distribution of extracellular vesicles (e.g., exosomes, nanovesicles) in vivo or in vitro (e.g., in mixed cultures of different types of cells). The targeting moiety may be a biomolecule such as a protein, peptide, lipid, or carbohydrate, or a synthetic molecule. For example, the targeting moiety may be, but is not limited to, an antibody (e.g., anti-CD19 nanobody, anti-CD22 nanobody), a synthetic polymer (e.g., PEG), a native ligand (e.g., CD40L, albumin), or a recombinant protein (e.g., XTEN). In certain embodiments, the targeting moiety is presented on the surface of the EV. The targeting moiety may be presented on the EV surface by fusing it to a scaffold protein (e.g., scaffold X) (e.g., as a genetically encoded fusion molecule). In some embodiments, the targeting moiety may be presented on the EV surface by a chemical reaction that causes the targeting moiety to attach to the EV surface molecule. A non-limiting example is PEGylation. In some embodiments, the EVs (e.g., exosomes) disclosed herein may further include a targeting moiety (in addition to the payload). In some embodiments, the targeting moiety may be combined with a functional moiety such as a small molecule (e.g., STING, ASO), a drug, and / or a therapeutic protein (e.g., an anti-CD3 / anti-CD19 antibody, an anti-mesothelin antibody / pro-apoptotic protein).

[0090] As used herein, the term “biologically active portion” means, but is not limited to, a protein, polypeptide, or peptide; an agent having activity in a biological system (e.g., a cell or human subject), such as a structural protein, enzyme, cytokine (e.g., interferon and / or interleukin), antibiotic, polyclonal or monoclonal antibody, or its active portion (e.g., Fv fragment) (the antibody or a portion thereof may be natural, synthetic or humanized, a peptide hormone, receptor, signaling molecule or other protein); nucleic acids, but are not limited to, oligonucleotides or modified oligonucleotides, antisense oligonucleotides or modified antisense oligonucleotides, cDNA, genomic DNA, artificial or natural chromosomes (e.g., yeast artificial chromosomes) or a portion thereof, RNA (e.g., mRNA, tRNA, rRNA or ribozyme), or peptide nucleic acid (PNA); a virus or virus-like particle; a nucleotide or ribonucleotide or synthetic analogue thereof (modified or unmodified); an amino acid or analogue thereof (modified or unmodified); a non-peptide (e.g., steroid) hormone; a proteoglycan; a lipid; or a carbohydrate. In some embodiments, antisense oligonucleotides include phosphorodiamidate morpholino oligomers (PMOs) or peptide-bonded phosphorodiamidate morpholino oligomers (PPMOs). In certain embodiments, the biologically active moiety includes a therapeutic molecule (e.g., an antigen), a targeting moiety (e.g., an antibody or its antigen-binding fragment), an adjuvant, an immunomodulator, or any combination thereof. In some embodiments, the biologically active moiety includes a macromolecule (e.g., a protein, antibody, enzyme, peptide, DNA, RNA, or any combination thereof). In some embodiments, the biologically active moiety includes a small molecule (e.g., an antisense oligomer (ASO), siRNA, STING, a drug, or any combination thereof). In some embodiments, the biologically active moiety is exogenous to the exosome, i.e., not naturally found in the exosome.

[0091] As used herein, the term “therapeutic molecule” means any molecule that can treat and / or prevent a disease or disorder in a subject (e.g., a human subject). In some embodiments, the therapeutic molecule includes an antigen. As used herein, the term “antigen” means any agent that, when introduced into a subject, elicits an immune response (cellular or humoral) against itself.

[0092] As used herein, the term “antibody” encompasses immunoglobulins, and fragments thereof, produced in nature, partially, or entirely by synthesis. The term also encompasses any protein having a binding domain homologous to an immunoglobulin-binding domain. “Antibody” further includes polypeptides containing a framework region from an immunoglobulin gene or fragment thereof that specifically binds to and recognizes an antigen. The use of the term “antibody” is intended to include whole antibodies, polyclonal, monoclonal, and recombinant antibodies, and fragments thereof, and further includes single-chain antibodies, humanized antibodies, mouse antibodies, chimeric, mouse-human, mouse-primate, primate-human monoclonal antibodies, anti-idiotype antibodies, and antibody fragments, such as scFv, (scFv)2, Fab, Fab', and F(ab')2, F(ab1)2, Fv, dAb, and Fd fragments, diabodies, and antibody-associated polypeptides. Antibodies include bispecific and multispecific antibodies, insofar as they exhibit the desired biological activity or function. In some embodiments, the antibody or its antigen-binding fragment comprises scFv, scFab, scFab-Fc, nanobody, or any combination thereof. In some embodiments, the antibody or its antigen-binding fragment comprises an agonist antibody, a blocking antibody, a targeted antibody, a fragment thereof, or a combination thereof. In some embodiments, the agonist antibody is a CD40L agonist. In some embodiments, the blocking antibody binds to a target protein selected from programmed death 1 (PD-1), programmed death ligand 1 (PD-L1), cytotoxic T lymphocyte-associated protein 4, and any combination thereof. In some embodiments, the targeted antibody binds to CD3 and / or CD19.

[0093] The terms “individual,” “subject,” “host,” and “patient” are used interchangeably herein and refer to any mammalian animal subject, in particular humans, for which diagnosis, treatment, or therapy is desired. The compositions and methods described herein are applicable to both therapeutic and veterinary uses in humans. In some embodiments, the subject is a mammal, and in other embodiments, the subject is a human. As used herein, “mammalian subject” includes all mammals, including but not limited to humans, livestock (e.g., dogs, cats, etc.), livestock (e.g., cattle, sheep, pigs, horses, etc.), and laboratory animals (e.g., monkeys, rats, mice, rabbits, guinea pigs, etc.).

[0094] As used herein, the term “substantially free” means that a sample containing extracellular molecules (e.g., exosomes) contains less than 10% of polymers in mass / volume (m / v) percent concentration. Some fractions may contain less than 0.001%, less than 0.01%, less than 0.05%, less than 0.1%, less than 0.2%, less than 0.3%, less than 0.4%, less than 0.5%, less than 0.6%, less than 0.7%, less than 0.8%, less than 0.9%, less than 1%, less than 2%, less than 3%, less than 4%, less than 5%, less than 6%, less than 7%, less than 8%, less than 9%, or less than 10% (m / v) of polymers.

[0095] As used herein, the term “polymer” means nucleic acids, contaminating proteins, lipids, carbohydrates, metabolites, or combinations thereof.

[0096] As used herein, the term “conventional exosomal protein” means a protein, fragment thereof, or peptide that binds thereto, including but not limited to CD9, CD63, CD81, PDGFR, GPI-anchored protein, lactoadherin LAMP2, and LAMP2B, which have been previously known to be abundant in exosomes.

[0097] As used herein, “administration” means giving a composition containing the EVs (e.g., exosomes) disclosed herein to a subject via a pharmaceutically acceptable route. The route of administration may be intravenous, e.g., intravenous injection and intravenous infusion. Additional routes of administration include, for example, subcutaneous, intramuscular, oral, nasal, and pulmonary administration. The EVs (e.g., exosomes) may be administered as part of a pharmaceutical composition comprising at least one excipient.

[0098] As used herein, “immune response” refers to the biological response within a vertebrate to foreign substances or abnormal cells, such as cancerous cells, which protect the organism from these agents and the diseases they cause. The immune response is mediated by the action of one or more cells of the immune system (e.g., T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells, or neutrophils) and soluble macromolecules, which are produced by either these cells or the liver (including antibodies, cytokines, and complement), resulting in the selective targeting, binding, damage, or destruction and / or elimination of invading pathogens, pathogen-infected cells or tissues, cancerous or other abnormal cells, or, in the case of autoimmune or pathological inflammation, normal human cells or tissues in the vertebrate body. Immune responses include, for example, the activation or inhibition of T cells such as effector T cells, Th cells, CD4+ cells, CD8+ T cells, or Treg cells, or the activation or inhibition of any other cells of the immune system, such as NK cells. Therefore, an immune response may include a humoral immune response (e.g., mediated by B cells), a cellular immune response (e.g., mediated by T cells), or both humoral and cellular immune responses. In some embodiments, the immune response is an "inhibitory" immune response. An inhibitory immune response is an immune response that blocks or reduces the effect of a stimulus (e.g., an antigen). In certain embodiments, an inhibitory immune response involves the production of inhibitory antibodies against the stimulus. In some embodiments, the immune response is an "stimulative" immune response. A stimulative immune response is an immune response that results in the generation of effector cells (e.g., cytotoxic T lymphocytes) that can destroy and eliminate a target antigen (e.g., a tumor antigen or virus).

[0099] As used herein, “to treat,” “to cure,” or “to treat” means, for example, reducing the severity of a disease or condition, shortening the duration of the disease, improving or eliminating one or more symptoms associated with the disease or condition, or providing a beneficial effect to an object having the disease or condition without necessarily curing the disease or condition. The term also includes the protection or prevention of a disease or condition or its symptoms. In one embodiment, the term “to treat” or “to cure” means inducing an immune response in an object to an antigen.

[0100] As used herein, the terms “prevent” or “prevention” mean reducing or decreasing the occurrence or severity of a particular outcome. In some embodiments, prevention of an outcome is achieved through protective treatment.

[0101] II. Pharmaceutical Compositions Provided herein are compositions for the preservation and administration of extracellular vesicles, such as exosomes. As described above, but not limited to, the compositions of this disclosure offer several advantages, including reduced EV aggregation, improved EV stability, improved EV structural integrity, improved stability of manipulated proteins contained on or within EVs, and improved stability of passively loaded or complexed materials such as small molecule drugs or proteins. The compositions of this disclosure can be frozen, stored over a range of temperatures for various time periods, and thawed without impairing the stability of the EVs contained in the composition.

[0102] The various components and considerations relating to the formulation of the compositions of this disclosure are described below.

[0103] II.A.EV Composition This disclosure provides a pharmaceutical composition comprising extracellular vesicles, wherein the pharmaceutical composition is stable to freeze and / or storage and / or suitable for administration to mammals, e.g., humans. Instability of biologics during storage may be caused by aggregation, deamination, isomerization, hydrolysis, oxidation, and / or denaturation. These structural alterations may occur due to various different factors; the properties of the biologic, and / or other factors such as temperature, pH, and ionic strength of the biologic and the elements formulated in the biologic.

[0104] In some embodiments, the pharmaceutical compositions of the present disclosure are formulated stably such that the compositions do not require chelating agents and / or albumins, such as recombinant human albumin.

[0105] Human albumin is the most ubiquitous protein in the blood, present at approximately 40 g / L. Its role in the blood is to transport numerous smaller entities, including metals, hormones, fatty acids, and toxins. However, it also constitutes about 75% of the blood's colloidal osmotic pressure (or colloidal osmotic pressure), and a single free cysteine ​​(position 34) in albumin makes up the majority of the reducing equivalents present in the blood. All of these properties are functional traits when using albumin in pharmaceutical formulations.

[0106] Albumin has historically been used in a variety of formulations. Originally, human serum albumin, sourced from plasma, was used, but the industry has shifted to using chemically defined (recombinant) human serum albumin. Recombinant products are advantageous due to factors such as the absence of animal-derived products, reliable supply, high purity, absence of host-derived proteases, high homogeneity, high free thiol content, absence of known or unknown human pathogens, batch-to-batch consistency, and the existence of established regulatory pathways.

[0107] Albumin in pharmaceutical formulations has been reported to prevent surface adsorption, aggregation, fibrillation, and oxidation, and to improve solubility, lyophilization, and / or solubility of APIs from lyophilized powders. Despite these known advantages, this disclosure provides a stable albumin-free pharmaceutical composition containing extracellular vesicles.

[0108] Chelating agents are components that bind to metal ions and play an important role in the stability and efficacy of pharmaceutical formulations. The chelation process stabilizes metal ions by preventing them from chemically reacting with any other substances. This composition may be characterized by not containing chelating agents.

[0109] In some embodiments, the compositions disclosed herein have a pI in the range of about 1 to about 6.5. The pI range of the EV disclosed herein, in which a surface polymer, e.g., PTGFRN, is overexpressed as disclosed herein, enables colloidally stable anionic exosomes at physiological pH values. In some embodiments, the surface molecule may be a polypeptide, oligonucleotide, or carbohydrate. In some embodiments, a pI greater than 6.5 causes the EV, e.g., the exosome, to have either a neutral charge (unstable) or a cationic charge in a useful pH range that can result in toxicity or limited biodistribution.

[0110] In some embodiments, the compositions of the present disclosure are formulated in liquid form and can be frozen for storage by lowering the temperature of the compositions to freezing and subfreezing temperatures. The compositions are not intended to be frozen by dehydration or freeze-drying. In some embodiments, the compositions are not freeze-dried.

[0111] II.B. Composition I (pH) In one embodiment, the Disclosure provides a pH at which extracellular vesicles (EVs) can be stably formulated. The pH may be in the range of about 7.0 to about 7.4, for example, about 7.1 to about 7.3, for example, about 7.2. In some embodiments, the pharmaceutical composition of the Disclosure comprises (a) extracellular vesicles; (b) sugars; (c) sodium chloride; (d) potassium phosphate; and (e) sodium phosphate. In some embodiments, the composition is in a solution at a pH of about 7.2. EVs are disclosed elsewhere in this Specification, and sugars may be monosaccharides, disaccharides, trisaccharides, or any other sugars. Sodium chloride is shown below. Potassium phosphate and sodium phosphate are shown below.

[0112] In some embodiments, the composition before and after freezing remains the same. For example, the pH of the composition before and after freezing is about 7.1. In some embodiments, the composition before and after freezing has a pH of about 7.2. In some embodiments, the composition before and after freezing has a pH of about 7.3. In some embodiments, the composition before and after freezing has a pH of about 7.4.

[0113] In some embodiments, the pH of the composition can be adjusted by changing the concentration of phosphate. In some embodiments, the pH of the composition can be adjusted by changing the concentration of potassium phosphate. In some embodiments, the pH of the composition can be increased by adding potassium phosphate or increasing its concentration. In some embodiments, the concentration of potassium phosphate is higher than the concentration of sodium phosphate.

[0114] In some embodiments, the pH of a pharmaceutical composition can be adjusted using the ratio of monobasic and dibasic forms of sodium phosphate and potassium phosphate. In some embodiments, monobasic sodium phosphate and / or monobasic potassium phosphate may be used to increase the pH of the pharmaceutical composition. In some embodiments, dibasic sodium phosphate and / or dibasic potassium phosphate may be used to decrease the pH of the pharmaceutical composition. In some embodiments, the pH range of the disclosed composition is about 6.8 to about 7.6. Therefore, if the pH of the composition is lower than desired, the pH can be changed by changing the ratio of the monobasic and dibasic forms of the salt (i.e., potassium or sodium). In some embodiments, the pH of the composition can be adjusted using the ratio of monobasic and dibasic forms of sodium phosphate and potassium phosphate until the pH of the composition is 7.0 to 7.4, for example, 7.1 to 7.3, for example, 7.2. In some embodiments, the upper limit of the pH is due to the breakdown of lipids of the disclosed extracellular matrix (EV), such as exosomes, which undergo hydrolysis more commonly known as saponification. In some embodiments, potassium salts stabilize pH during freezing.

[0115] In some embodiments, the sugars for the pharmaceutical composition at pH approximately 7.2 include monosaccharides. In some embodiments, the sugars include disaccharides. In some embodiments, the sugars include trisaccharides. In some embodiments, the sugars include oligosaccharides. In some embodiments, the sugars include polysaccharides. In some embodiments, the sugars include sugar alcohols. In some embodiments, the sugars include any combination of the sugars described herein.

[0116] In some embodiments, the sugars include lactose. In some embodiments, the sugars include glucose. In some embodiments, the sugars include sucrose. In some embodiments, the sugars include trehalose. In some embodiments, the sugars include dextrose. In some embodiments, the sugars include any combination of the sugars described herein.

[0117] In some embodiments, the sugars are sugar alcohols. In some embodiments, the sugars are sugar alcohols having a molecular weight of about 90.00 g / mol to about 190.00 g / mol. In some embodiments, the sugars have a molecular weight of about 180.00 g / mol to about 380.00 g / mol.

[0118] In some embodiments, the sugar alcohol comprises glycerol. In some embodiments, the sugar alcohol comprises sorbitol. In some embodiments, the sugar alcohol comprises mannitol. In some embodiments, the sugar alcohol comprises xylitol. In some embodiments, the sugar alcohol comprises any combination of the sugar alcohols described herein.

[0119] In some embodiments, the sugars are sucrose or trehalose. In some embodiments, the pharmaceutical composition contains sucrose. In other embodiments, the pharmaceutical composition contains trehalose. In some embodiments, the sucrose concentration is about 5% w / v.

[0120] II.C. Composition II (Sucrose) This disclosure also relates to a suitable concentration of sucrose or trehalose in a pharmaceutical composition comprising extracellular vesicles. A suitable amount of sucrose or trehalose in the composition stabilizes the composition and / or reduces any aggregation. In some embodiments, the pharmaceutical composition comprises (i) extracellular vesicles and (ii) sugars, which are sucrose or trehalose at a concentration of about 5% w / v.

[0121] A 5% w / v concentration of the sugars disclosed herein, such as sucrose or trehalose, can provide superior stability compared to a composition containing 1% w / v sucrose. In particular, a pharmaceutical composition containing (i) extracellular vesicles, such as exosomes, and (ii) a sugar (which is sucrose or trehalose) at a concentration of about 5% w / v offers several advantages, including (i) reduced aggregation of EVs, (ii) improved stability of EVs, (iii) improved structural integrity of EVs, (iv) improved stability of manipulated proteins contained on or within EVs, and (v) improved stability of passively loaded or complexed materials such as small molecule drugs or proteins. In some embodiments, the composition exhibits reduced aggregation compared to a reference composition containing 1% w / v to 4% w / v, for example, 1% sucrose or trehalose. In some embodiments, the composition exhibits improved stability compared to a reference composition containing 1% w / v to 4% w / v, for example, 1% sucrose or trehalose. In some embodiments, the composition exhibits improved EV structural integrity compared to a reference composition containing sucrose or trehalose at a concentration of 1% w / v to 4% w / v, for example, 1%.

[0122] In some embodiments, the composition exhibits improved stability of the manipulated protein contained on or within the extracellular matrix (EV) compared to a reference composition containing sucrose or trehalose at a concentration of 1% w / v to 4% w / v, for example, 1%.

[0123] In some embodiments, the composition exhibits improved stability of passively loaded or complexed materials, such as small molecule drugs or proteins, compared to a reference composition containing sucrose or trehalose at a concentration of 1% w / v to 4% w / v, for example, 1%.

[0124] In other embodiments, the compositions exhibit improved stability compared to a reference composition containing sucrose or trehalose at concentrations higher than 5.5% w / v, 6% w / v, 7% w / v, 8% w / v, 9% w / v, or 10% w / v.

[0125] The composition may further include sodium chloride, potassium phosphate, sodium chloride, or any combination thereof as disclosed elsewhere herein.

[0126] II.D. Sodium Chloride In some embodiments, composition I or composition II further comprises sodium chloride.

[0127] In some embodiments, sodium chloride is present in the composition at a concentration of about 10 mM to about 200 mM. In some embodiments, sodium chloride is present in the composition at concentrations of approximately 10 mM to 134 mM, approximately 10 mM to 130 mM, approximately 20 mM to 120 mM, approximately 30 mM to 110 mM, approximately 40 mM to 100 mM, approximately 50 mM to 90 mM, approximately 60 mM to 80 mM, approximately 70 mM to 80 mM, approximately 45 mM to 95 mM, approximately 45 mM to 80 mM, approximately 45 mM to 70 mM, approximately 45 mM to 65 mM, approximately 50 mM to 65 mM, approximately 50 mM to 60 mM, approximately 50 mM to 55 mM, approximately 50 mM to 55 mM, or approximately 51 mM to 54 mM. In some embodiments, the concentration of sodium chloride is approximately 10 mM to approximately 190 mM. In some embodiments, the concentration of sodium chloride is approximately 10 mM to approximately 180 mM. In some embodiments, the concentration of sodium chloride is approximately 10 mM to approximately 170 mM. In some embodiments, the concentration of sodium chloride is approximately 10 mM to approximately 160 mM. In some embodiments, the concentration of sodium chloride is approximately 10 mM to approximately 150 mM. In some embodiments, the concentration of sodium chloride is approximately 10 mM to approximately 140 mM. In some embodiments, the concentration of sodium chloride is approximately 10 mM to approximately 130 mM. In some embodiments, the concentration of sodium chloride is approximately 20 mM to approximately 120 mM. In some embodiments, the concentration of sodium chloride is approximately 30 mM to approximately 110 mM. In some embodiments, the concentration of sodium chloride is approximately 40 mM to approximately 100 mM. In some embodiments, the concentration of sodium chloride is approximately 50 mM to approximately 90 mM. In some embodiments, the concentration of sodium chloride is approximately 60 mM to approximately 80 mM. In some embodiments, the concentration of sodium chloride is approximately 70 mM to approximately 80 mM. In some embodiments, the concentration of sodium chloride is approximately 45 mM to approximately 95 mM. In some embodiments, the concentration of sodium chloride is approximately 45 mM to approximately 80 mM. In some embodiments, the concentration of sodium chloride is approximately 45 mM to approximately 70 mM. In some embodiments, the concentration of sodium chloride is approximately 45 mM to approximately 65 mM. In some embodiments, the concentration of sodium chloride is approximately 50 mM to approximately 65 mM.In some embodiments, the concentration of sodium chloride is approximately 50 mM to approximately 60 mM. In some embodiments, the concentration of sodium chloride is approximately 50 mM to approximately 55 mM. In some embodiments, the concentration of sodium chloride is approximately 50 mM to approximately 55 mM. In some embodiments, the concentration of sodium chloride is approximately 51 mM to approximately 54 mM. In some embodiments, the concentration of sodium chloride is approximately 40 mM to approximately 60 mM. In some embodiments, the concentration of sodium chloride is approximately 45 mM to approximately 55 mM. In some embodiments, the concentration of sodium chloride is approximately 48 mM to approximately 53 mM. In some embodiments, the concentration of sodium chloride is approximately 40 mM to approximately 50 mM. In some embodiments, the concentration of sodium chloride is approximately 45 mM to approximately 50 mM.

[0128] In some embodiments, the concentration of sodium chloride is approximately 10 mM, approximately 20 mM, approximately 30 mM, approximately 40 mM, approximately 50 mM, approximately 60 mM, approximately 70 mM, approximately 80 mM, approximately 90 mM, or approximately 100 mM. In some embodiments, the concentration of sodium chloride is approximately 10 mM. In some embodiments, the concentration of sodium chloride is approximately 20 mM. In some embodiments, the concentration of sodium chloride is approximately 30 mM. In some embodiments, the concentration of sodium chloride is approximately 40 mM. In some embodiments, the concentration of sodium chloride is approximately 50 mM. In some embodiments, the concentration of sodium chloride is approximately 60 mM. In some embodiments, the concentration of sodium chloride is approximately 70 mM. In some embodiments, the concentration of sodium chloride is approximately 80 mM. In some embodiments, the concentration of sodium chloride is approximately 90 mM. In some embodiments, the concentration of sodium chloride is approximately 100 mM.

[0129] In some embodiments, the concentration of sodium chloride is approximately 110 mM, approximately 120 mM, approximately 130 mM, approximately 140 mM, approximately 150 mM, approximately 160 mM, approximately 170 mM, approximately 180 mM, approximately 190 mM, or approximately 200 mM. In some embodiments, the concentration of sodium chloride is approximately 110 mM. In some embodiments, the concentration of sodium chloride is approximately 120 mM. In some embodiments, the concentration of sodium chloride is approximately 130 mM. In some embodiments, the concentration of sodium chloride is approximately 140 mM. In some embodiments, the concentration of sodium chloride is approximately 150 mM. In some embodiments, the concentration of sodium chloride is approximately 160 mM. In some embodiments, the concentration of sodium chloride is approximately 170 mM. In some embodiments, the concentration of sodium chloride is approximately 180 mM. In some embodiments, the concentration of sodium chloride is approximately 190 mM. In some embodiments, the concentration of sodium chloride is approximately 200 mM.

[0130] In some embodiments, the concentration of sodium chloride is approximately 39 mM, 40 mM, 41 mM, 42 mM, 43 mM, 44 mM, 45 mM, 46 mM, 47 mM, 48 mM, 49 mM, or 50 mM. In some embodiments, the concentration of sodium chloride is approximately 39 mM. In some embodiments, the concentration of sodium chloride is approximately 40 mM. In some embodiments, the concentration of sodium chloride is approximately 41 mM. In some embodiments, the concentration of sodium chloride is approximately 42 mM. In some embodiments, the concentration of sodium chloride is approximately 43 mM. In some embodiments, the concentration of sodium chloride is approximately 44 mM. In some embodiments, the concentration of sodium chloride is approximately 45 mM. In some embodiments, the concentration of sodium chloride is approximately 46 mM. In some embodiments, the concentration of sodium chloride is approximately 47 mM. In some embodiments, the concentration of sodium chloride is approximately 48 mM. In some embodiments, the concentration of sodium chloride is approximately 49 mM. In some embodiments, the concentration of sodium chloride is approximately 50 mM. In some embodiments, the concentration of sodium chloride is 40 mM. In some embodiments, the concentration of sodium chloride is 49.6 mM.

[0131] All sodium chloride concentrations disclosed herein can be expressed in weight per volume, for example, mg / ml. Those skilled in the art will be able to easily convert the mM concentrations disclosed herein to weight per volume concentrations. In some embodiments, the sodium chloride concentration is at least about 0.5 mg / ml to at least about 12 mg / ml. In some embodiments, the sodium chloride concentration is at least about 0.5 mg / ml to at least about 11.9 mg / ml, at least about 0.5 mg / ml to at least about 11.8 mg / ml, at least about 0.5 mg / ml to at least about 11.7 mg / ml, at least about 0.5 mg / ml to at least about 11.5 mg / ml, at least about 0.5 mg / ml to at least about 11.5 mg / ml, and at least about 0.5 mg / ml to at least about 11.0 mg / ml. , at least approximately 0.5 mg / ml to at least approximately 10.5 mg / ml, at least approximately 0.5 mg / ml to at least approximately 10 mg / ml, at least approximately 0.5 mg / ml to at least approximately 9.5 mg / ml, at least approximately 0.5 mg / ml to at least approximately 9 mg / ml, at least approximately 0.5 mg / ml to at least approximately 8.5 mg / ml, at least approximately 0.5 mg / ml to at least approximately 8.0 mg / ml, at least approximately 0.5 mg / ml to at least approximately 7.5 mg / ml l, at least about 0.5 mg / ml to at least about 7.0 mg / ml, at least about 0.5 mg / ml to at least about 6.5 mg / ml, at least about 0.5 mg / ml to at least about 6.0 mg / ml, at least about 0.5 mg / ml to at least about 5.5 mg / ml, at least about 0.5 mg / ml to at least about 5.0 mg / ml, at least about 0.5 mg / ml to at least about 4.5 mg / ml, at least about 0.5 mg / ml to at least about 4.0 mg g / ml, at least about 0.5 mg / ml to at least about 3.9 mg / ml, at least about 0.5 mg / ml to at least about 3.8 mg / ml, at least about 0.5 mg / ml to at least about 3.7 mg / ml, at least about 0.5 mg / ml to at least about 3.6 mg / ml, at least about 0.5 mg / ml to at least about 3.5 mg / ml, at least about 0.5 mg / ml to at least about 3.4 mg / ml, at least about 0.5 mg / ml to at least about 3.The recommended dosage is 3 mg / ml, at least approximately 0.5 mg / ml to at least approximately 3.1 mg / ml, at least approximately 0.5 mg / ml to at least approximately 3.0 mg / ml, at least approximately 0.5 mg / ml to at least approximately 2.9 mg / ml, at least approximately 0.5 mg / ml to at least approximately 2.8 mg / ml, at least approximately 0.5 mg / ml to at least approximately 2.7 mg / ml, at least approximately 0.5 mg / ml to at least approximately 2.6 mg / ml, at least approximately 0.5 mg / ml to at least approximately 2.5 mg / ml, at least approximately 0.5 mg / ml to at least approximately 2.4 mg / ml, at least approximately 0.5 mg / ml to at least approximately 2.3 mg / ml, or at least approximately 0.5 mg / ml to at least approximately 2.1 mg / ml.

[0132] In some embodiments, the concentration of sodium chloride is at least about 3.0 mg / ml. In some embodiments, the concentration of sodium chloride is at least about 2.92 mg / ml. In some embodiments, the concentration of sodium chloride is at least about 2.9 mg / ml. In some embodiments, the concentration of sodium chloride is at least about 2.8 mg / ml. In some embodiments, the concentration of sodium chloride is at least about 2.7 mg / ml. In some embodiments, the concentration of sodium chloride is at least about 2.6 mg / ml. In some embodiments, the concentration of sodium chloride is at least about 2.5 mg / ml. In some embodiments, the concentration of sodium chloride is at least about 2.4 mg / ml. In some embodiments, the concentration of sodium chloride is at least about 2.34 mg / ml. In some embodiments, the concentration of sodium chloride is at least about 2.3 mg / ml. In some embodiments, the concentration of sodium chloride is at least about 2.2 mg / ml. In some embodiments, the concentration of sodium chloride is at least about 2.1 mg / ml. In some embodiments, the concentration of sodium chloride is at least about 2.0 mg / ml.

[0133] In some embodiments, composition II further comprises a phosphate buffer containing a phosphate compound. Non-limiting examples of phosphate compounds include potassium phosphate, sodium phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium phosphate, and / or combinations thereof. In some embodiments, the phosphate compound is potassium phosphate. In other embodiments, the phosphate compound is sodium phosphate.

[0134] II.E. Phosphate In some embodiments, composition I or composition II further comprises potassium phosphate, for example, monobasic potassium phosphate. In some embodiments, potassium phosphate, for example, monobasic potassium phosphate is present in the composition at concentrations of about 1 mM to about 20 mM, about 2 mM to about 20 mM, about 3 mM to about 20 mM, about 4 mM to about 20 mM, about 5 mM to about 20 mM, about 6 mM to about 20 mM, about 7 mM to about 20 mM, about 8 mM to about 20 mM, about 1 mM to about 20 mM, about 2 mM to about 19 mM, about 3 mM to about 18 mM, about 4 mM to about 17 mM, about 5 mM to about 16 mM, or about 5 mM to about 15 mM.

[0135] In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is about 4.5 mM, about 4.6 mM, about 4.7 mM, about 4.8 mM, about 4.9 mM, about 5.0 mM, about 5.1 mM, about 5.2 mM, about 5.3 mM, about 5.4 mM, or about 5.5 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 2 mM to about 19 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 3 mM to about 18 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 4 mM to about 17 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 5 mM to about 16 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 5 mM to about 15 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 1 mM to about 10 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 2 mM to about 9 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 3 mM to about 8 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 4 mM to about 7 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 4 mM to about 6 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 3 mM to about 7 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 3 mM to about 6 mM.

[0136] In some embodiments, potassium phosphate, for example monobasic potassium phosphate, is present in the composition at a concentration of about 3.0 mM. In some embodiments, potassium phosphate, for example monobasic potassium phosphate, is present in the composition at a concentration of about 3.5 mM. In some embodiments, potassium phosphate, for example monobasic potassium phosphate, is present in the composition at a concentration of about 4.0 mM. In some embodiments, potassium phosphate, for example monobasic potassium phosphate, is present in the composition at a concentration of about 4.1 mM. In some embodiments, potassium phosphate, for example monobasic potassium phosphate, is present in the composition at a concentration of about 4.2 mM. In some embodiments, potassium phosphate, for example monobasic potassium phosphate, is present in the composition at a concentration of about 4.3 mM. In some embodiments, potassium phosphate, for example monobasic potassium phosphate, is present in the composition at a concentration of about 4.4 mM. In some embodiments, potassium phosphate, for example monobasic potassium phosphate, is present in the composition at a concentration of about 4.5 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 4.6 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 4.7 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 4.8 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 4.9 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 5.0 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 5.1 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 5.2 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 5.3 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 5.4 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 5.5 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 5.6 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 5.7 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 5.8 mM. In some embodiments, potassium phosphate is present in the composition at a concentration of about 5.9 mM.In some embodiments, potassium phosphate is present in the composition at a concentration of approximately 6.0 mM. In some embodiments, the concentration of potassium phosphate in the composition is 5.15 mM.

[0137] In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is approximately 15.0 mM. In some embodiments, the concentration of potassium phosphate is approximately 15.1 mM. In some embodiments, the concentration of potassium phosphate is approximately 15.2 mM. In some embodiments, the concentration of potassium phosphate is approximately 15.3 mM. In some embodiments, the concentration of potassium phosphate is approximately 15.4 mM. In some embodiments, the concentration of potassium phosphate is approximately 15.5 mM. In some embodiments, the concentration of potassium phosphate is approximately 15.6 mM. In some embodiments, the concentration of potassium phosphate is approximately 15.7 mM. In some embodiments, the concentration of potassium phosphate is approximately 15.8 mM. In some embodiments, the concentration of potassium phosphate is approximately 15.9 mM. In some embodiments, the concentration of potassium phosphate is approximately 16.0 mM. In some embodiments, the concentration of potassium phosphate is approximately 16.1 mM. In some embodiments, the concentration of potassium phosphate is approximately 16.2 mM. In some embodiments, the concentration of potassium phosphate is approximately 16.3 mM. In some embodiments, the concentration of potassium phosphate is approximately 16.4 mM. In some embodiments, the concentration of potassium phosphate is approximately 16.5 mM. In some embodiments, the concentration of potassium phosphate in the composition is 15.4 mM.

[0138] In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is approximately 14.0 mM. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is approximately 14.1 mM. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is approximately 14.2 mM. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is approximately 14.3 mM. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is approximately 14.4 mM. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is approximately 14.5 mM. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is approximately 14.6 mM. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is approximately 14.7 mM. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is approximately 14.8 mM. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is approximately 14.9 mM.

[0139] Any of the concentrations of monobasic potassium phosphate disclosed herein can be expressed in weight per volume, for example, mg / ml. Those skilled in the art will be able to easily convert the mM concentrations disclosed herein to weight per volume concentrations. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is at least about 0.14 mg / ml to at least about 2.75 mg / ml. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is at least about 0.14 mg / ml. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is about 0.15 mg / ml. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is about 0.17 mg / ml. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is at least about 0.2 mg / ml. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is at least about 0.23 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 0.25 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 0.5 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 0.60 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 0.61 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 0.62 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 0.63 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 0.64 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 0.65 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 0.66 mg / ml.In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is at least about 0.67 mg / ml. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is at least about 0.68 mg / ml. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is at least about 0.69 mg / ml. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is at least about 0.70 mg / ml. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is at least about 0.71 mg / ml. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is at least about 0.72 mg / ml. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is at least about 0.73 mg / ml. In some embodiments, the concentration of potassium phosphate, for example, monobasic potassium phosphate, is at least about 0.74 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 0.75 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 1.0 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 1.25 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 1.50 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 1.75 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.0 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.03 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.04 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.05 mg / ml.In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.1 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.2 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.3 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.4 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.5 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.6 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.7 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.8 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 2.9 mg / ml. In some embodiments, the concentration of potassium phosphate, for example monobasic potassium phosphate, is at least about 3.0 mg / ml.

[0140] In some embodiments, composition I or composition II further comprises sodium phosphate. In some embodiments, sodium phosphate, for example, dibasic sodium phosphate heptahydrate, is present in the composition at concentrations of about 10 mM to about 100 mM, about 10 mM to about 90 mM, about 10 mM to about 80 mM, about 10 mM to about 70 mM, about 10 mM to about 60 mM, about 10 mM to about 50 mM, about 10 mM to about 40 mM, about 11 mM to about 29 mM, about 12 mM to about 28 mM, about 13 mM to about 27 mM, or about 14 mM to about 26 mM. In some embodiments, sodium phosphate is present in the composition at concentrations of about 11 mM to about 29 mM. In some embodiments, sodium phosphate is present in the composition at concentrations of about 12 mM to about 28 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 13 mM to about 27 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 14 mM to about 26 mM.

[0141] In some embodiments, sodium phosphate is present in the composition at concentrations of approximately 14.5 mM, approximately 14.6 mM, approximately 14.7 mM, approximately 14.8 mM, approximately 14.9 mM, approximately 15.0 mM, approximately 15.1 mM, approximately 15.2 mM, approximately 15.3 mM, approximately 15.4 mM, or approximately 15.5 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of approximately 14.5 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of approximately 14.6 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of approximately 14.7 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of approximately 14.8 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of approximately 14.9 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of approximately 15.0 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 15.1 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 15.2 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 15.3 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 15.4 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 15.5 mM. In some embodiments, the concentration of sodium phosphate is 14.9 mM.

[0142] In some embodiments, sodium phosphate is present in the composition at a concentration of about 15.6 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 15.7 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 15.8 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 15.9 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 16.0 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 16.1 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 16.2 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 16.3 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 16.4 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 16.5 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 16.6 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 16.7 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 16.8 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 16.9 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 17.0 mM.

[0143] In some embodiments, sodium phosphate is present in the composition at a concentration of about 26.5 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 26.6 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 26.7 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 26.8 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 26.9 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 27.0 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 27.1 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 27.2 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 27.3 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 27.4 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 27.5 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 27.6 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 27.7 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 27.8 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 27.9 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of about 28.0 mM. In some embodiments, sodium phosphate is present in the composition at a concentration of 27.1 mM.

[0144] Any of the monobasic sodium phosphate concentrations disclosed herein can be expressed in terms of weight per volume, for example, mg / ml. Those skilled in the art will be able to easily convert the mM concentrations disclosed herein to weight per volume concentrations. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 1.42 mg / ml to at least about 14.2 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 1.4 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 1.5 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 1.6 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 1.7 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 1.8 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 1.9 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.1 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.13 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.2 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.25 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.3 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.4 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.5 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.6 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.7 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.75 mg / ml.In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.8 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 2.9 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 3.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 3.25 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 3.5 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 3.75 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 3.8 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 3.83 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 3.85 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 3.9 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 4.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 4.25 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 4.5 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 4.75 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 5.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 5.5 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 6.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 6.5 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 7.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 7.5 mg / ml.In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 8.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 8.5 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 9.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 9.5 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 10.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 11.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 12.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 13.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 14.0 mg / ml. In some embodiments, sodium phosphate is present in the composition at a concentration of at least about 14.0 mg / ml.

[0145] In some embodiments, the sodium phosphate is dibasic sodium phosphate heptahydrate. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 6.0 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 6.1 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 6.2 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 6.3 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 6.4 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 6.5 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 6.6 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 6.7 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 6.8 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 6.9 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 7.0 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 7.1 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 7.2 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 7.24 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 7.3 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 7.4 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 7.5 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 7.6 mg / ml.In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 7.7 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 7.8 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 7.9 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 8.0 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 8.5 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 9.0 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 9.5 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 10.0 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 10.5 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 11.0 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 11.5 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 12.0 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 12.5 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 13.0 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 13.5 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 14.0 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 14.1 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 14.2 mg / ml.In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 14.3 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 14.4 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 14.5 mg / ml. In some embodiments, the composition contains dibasic sodium phosphate heptahydrate at a concentration of at least about 15.0 mg / ml.

[0146] In some embodiments, the phosphate buffer contains potassium phosphate and sodium phosphate in a ratio of about 1:about 2. In some embodiments, the phosphate buffer contains potassium phosphate and sodium phosphate in a ratio of about 1:about 3. In some embodiments, the phosphate buffer contains potassium phosphate and sodium phosphate in a ratio of about 1:about 4. In some embodiments, the phosphate buffer contains potassium phosphate and sodium phosphate in a ratio of about 1:about 5. In some embodiments, the phosphate buffer contains potassium phosphate and sodium phosphate in a ratio of about 1:about 3. In some embodiments, the phosphate buffer contains potassium phosphate and sodium phosphate in a ratio of about 1:about 2.

[0147] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a solution containing (i) extracellular vesicles, (ii) potassium phosphate, and (iii) sodium phosphate, wherein the molar ratio of potassium phosphate to sodium phosphate is about 1 to about 3 or about 1 to about 2.

[0148] II.F. Sugars Certain aspects of this disclosure relate to pharmaceutical compositions comprising extracellular vesicles, sugars, sodium chloride, potassium phosphate, and sodium phosphate. As described above, the sugars may be monosaccharides, disaccharides, trisaccharides, or any other sugars. In some aspects, the sugar is sucrose. In some aspects, the sugar is trehalose.

[0149] In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at concentrations of at least about 1% to at least about 10%, at least about 2% to at least about 9%, at least about 3% to at least about 8%, at least about 4% to at least about 7%, at least about 4% to at least about 6%, at least about 3% to at least about 7%, at least about 5% to at least about 10%, at least about 5% to at least about 9%, at least about 5% to at least about 8%, or at least about 5% to at least about 7%. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 1%. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 2%. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 3%. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 4%. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 5%. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 6%. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 7%. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 8%. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 9%. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 10%.

[0150] In some embodiments, the composition contains at least about 1% sucrose. In some embodiments, the composition contains at least about 2% sucrose. In some embodiments, the composition contains at least about 2.5% sucrose. In some embodiments, the composition contains at least about 3% sucrose. In some embodiments, the composition contains at least about 4% sucrose. In some embodiments, the composition contains at least about 5% sucrose. In some embodiments, the composition contains at least about 6% sucrose. In some embodiments, the composition contains at least about 7% sucrose. In some embodiments, the composition contains at least about 8% sucrose. In some embodiments, the composition contains at least about 9% sucrose. In some embodiments, the composition contains at least about 10% sucrose.

[0151] In some embodiments, the composition contains at least about 1% trehalose. In some embodiments, the composition contains at least about 2% trehalose. In some embodiments, the composition contains at least about 3% trehalose. In some embodiments, the composition contains at least about 4% trehalose. In some embodiments, the composition contains at least about 5% trehalose. In some embodiments, the composition contains at least about 6% trehalose. In some embodiments, the composition contains at least about 7% trehalose. In some embodiments, the composition contains at least about 8% trehalose. In some embodiments, the composition contains at least about 9% trehalose. In some embodiments, the composition contains at least about 10% trehalose.

[0152] In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at concentrations of at least about 10 mg / ml to at least about 100 mg / ml, at least about 20 mg / ml to at least about 90 mg / ml, at least about 30 mg / ml to at least about 80 mg / ml, at least about 40 mg / ml to at least about 70 mg / ml, at least about 40 mg / ml to at least about 60 mg / ml, at least about 30 mg / ml to at least about 70 mg / ml, at least about 50 mg / ml to at least about 100 mg / ml, at least about 50 mg / ml to at least about 90 mg / ml, at least about 50 mg / ml to at least about 80 mg / ml, or at least about 50 mg / ml to at least about 70 mg / ml. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 10 mg / ml. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 20 mg / ml. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 30 mg / ml. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 40 mg / ml. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 50 mg / ml. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 60 mg / ml. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 70 mg / ml. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 80 mg / ml. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 90 mg / ml. In some embodiments, sugars, such as sucrose or trehalose, are present in the composition at a concentration of at least about 100 mg / ml.

[0153] In some embodiments, the composition contains at least about 10 mg / ml of sucrose. In some embodiments, the composition contains at least about 20 mg / ml of sucrose. In some embodiments, the composition contains at least about 30 mg / ml of sucrose. In some embodiments, the composition contains at least about 40 mg / ml of sucrose. In some embodiments, the composition contains at least about 50 mg / ml of sucrose. In some embodiments, the composition contains at least about 60 mg / ml of sucrose. In some embodiments, the composition contains at least about 70 mg / ml of sucrose. In some embodiments, the composition contains at least about 80 mg / ml of sucrose. In some embodiments, the composition contains at least about 90 mg / ml of sucrose. In some embodiments, the composition contains at least about 100 mg / ml of sucrose.

[0154] In some embodiments, the composition contains at least about 10 mg / ml of trehalose. In some embodiments, the composition contains at least about 20 mg / ml of trehalose. In some embodiments, the composition contains at least about 30 mg / ml of trehalose. In some embodiments, the composition contains at least about 40 mg / ml of trehalose. In some embodiments, the composition contains at least about 50 mg / ml of trehalose. In some embodiments, the composition contains at least about 60 mg / ml of trehalose. In some embodiments, the composition contains at least about 70 mg / ml of trehalose. In some embodiments, the composition contains at least about 80 mg / ml of trehalose. In some embodiments, the composition contains at least about 90 mg / ml of trehalose. In some embodiments, the composition contains at least about 100 mg / ml of trehalose.

[0155] In certain embodiments, the composition contains at least about 2.5% sucrose, and the composition has improved stability compared to similar compositions containing less than about 2% sucrose.

[0156] II.G. Conductivity In some embodiments, Composition I or Composition II of the Disclosure have an conductivity of about 6 mS / cm+ / -10% to about 10 mS / cm+ / -10%. In some embodiments, the conductivity is 6 mS / cm+ / -10% to about 7 mS / cm+ / -10%, about 7 mS / cm+ / -10% to about 8 mS / cm+ / -10%, about 8 mS / cm+ / -10% to about 9 mS / cm+ / -10%, or about 9 mS / cm+ / -10% to about 10 mS / cm+ / -10%. In some embodiments, the conductivity is about 6 mS / cm+ / -10%, about 7 mS / cm+ / -10%, about 8 mS / cm+ / -10%, about 9 mS / cm+ / -10%, or about 10 mS / cm+ / -10%.

[0157] In some embodiments, the composition has an conductivity of about 6 mS / cm ±10% to about 10 mS / cm ±10%. In some embodiments, the conductivity is about 6 mS / cm ±10%. In some embodiments, the conductivity is about 7 mS / cm ±10%. In some embodiments, the conductivity is about 8 mS / cm ±10%. In some embodiments, the conductivity is about 9 mS / cm ±10%. In some embodiments, the conductivity is about 10 mS / cm ±10%. In some embodiments, the conductivity is about 7.23 mS / cm ±10%. In some embodiments, the conductivity is about 8.8 mS / cm ±10%.

[0158] II.H. Antioxidants In some embodiments, composition I or composition II of the present disclosure further comprises an antioxidant. In some embodiments, the antioxidant comprises D-methionine, L-methionine, ascorbic acid, erythorbic acid, sodium ascorbate, thioglycerol, cysteine, acetylcysteine, cystine, dithioerythreitol, glutathione, tocopherol, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), sodium bisulfate, sodium dithionate, α-tocopherol, γ-tocopherol, propyl gallate, ascorbyl palmitate, sodium metabisulfite, thiourea, sodium thiosulfate, propyl gallate, vitamin C, N-acetylcysteine, selenium, and sodium thioglycolate. In some embodiments, the antioxidant is methionine. In other embodiments, the antioxidant is D-methionine. In other embodiments, the antioxidant is L-methionine.

[0159] In some embodiments, the antioxidant of composition I or II comprises a thiosulfate or a salt thereof. In some embodiments, the thiosulfate or a salt thereof comprises sodium thiosulfate.

[0160] In some embodiments, the compositions disclosed herein include an anti-reducing agent. In some embodiments, the anti-reducing agent includes EDTA, EGTA, CuSO4, S-adenosylmethionine, cysteine, or any combination thereof.

[0161] II.I. Protease Inhibitors In some embodiments, the compositions disclosed herein include protease inhibitors. Proteins such as thioredoxin can reduce proteins having disulfide bonds. By adding inhibitors such as EDTA, EGTA, and CuSO4, the activity of metalloproteinases, particularly hexokinases, can be reduced. EEGTA / EDTA inhibition by chelation of divalent cations. Therefore, in some embodiments, the compositions further include protease inhibitors selected from EDTA, EGTA, CuSO4, and any combination thereof. In some embodiments, the temperature is reduced to reduce the activity of the protease.

[0162] II.J. Characteristics of the Composition The compositions of the present disclosure are formulated such that the extracellular vesicles (EVs) of the compositions are stable under fluctuating temperature conditions, for example, when frozen and / or thawed and / or administered to a subject. Although we do not wish to restrict them, the combination of the currently disclosed sugars, e.g., about 5% w / v sucrose, and potassium phosphate and sodium phosphate in the specific ratios currently disclosed, provides excellent stability for the compositions and the EVs contained therein. For example, in some embodiments, the compositions of the present disclosure can be stored for various time lengths and at various temperatures without any decrease in the stability of extracellular vesicles, e.g., exosomes. Furthermore, in some embodiments, the currently disclosed compositions can be formulated as a liquid at ambient temperature, then frozen by placing the composition in a freezer at -80°C, and then thawed. Thus, in some embodiments, as described below, the compositions can be stored as a liquid before freezing, as a solid while frozen, and as a liquid after thawing, without impairing the stability of the EVs.

[0163] In some embodiments, the composition can be stored as a liquid before freezing. In some embodiments, the composition can be stored as a liquid at a temperature of about 25°C to about 1°C before freezing without compromising the stability of extracellular molecules (EVs), such as exosomes. In some embodiments, the composition can be stored as a liquid at about 25°C to about 1°C before freezing without compromising the stability of extracellular molecules (EVs), such as exosomes.

[0164] In some embodiments, the composition can be stored as a liquid for at least about 4 hours, at least about 10 hours, at least about 12 hours, at least about 15 hours, at least about 20 hours, or at least about 24 hours before freezing. In some embodiments, the composition is stored as a liquid for about 4 to about 12 hours, about 5 to about 12 hours, about 6 to about 12 hours, about 4 to about 24 hours, about 6 to about 24 hours, about 12 to about 24 hours, or about 4 to about 16 hours before freezing. In some embodiments, the composition may be stored as a liquid for less than 36 hours, less than 30 days, less than 24 hours, less than 23 hours, less than 22 hours, less than 21 hours, less than 20 hours, less than 19 hours, less than 18 hours, less than 17 hours, less than 16 hours, less than 15 hours, less than 14 hours, less than 13 hours, less than 12 hours, less than 11 hours, less than 10 hours, less than 9 hours, less than 8 hours, less than 7 hours, less than 6 hours, less than 5 hours, or less than 4 hours before freezing.

[0165] In some embodiments, the composition can be stored as a liquid at approximately 4°C for approximately one week before freezing. In some embodiments, the composition may be stable at 4°C for up to one week. In some embodiments, the composition may be stored as a liquid at approximately 4°C for approximately one week before freezing and then administered to subjects requiring it.

[0166] In some embodiments, the composition can be stored as a frozen solid for a certain period of time before thawing. In some embodiments, the composition can be stored as a solid at temperatures of zero and below zero, e.g., between approximately 0°C and / or -80°C, without any reduction in EV (e.g., exosome) stability. In some embodiments, the composition can be stored as a frozen solid at temperatures between approximately 0°C and / or -80°C. In some embodiments, the composition can be stored as a frozen solid at temperatures between approximately 0°C and / or -50°C. In some embodiments, the composition can be stored as a frozen solid at temperatures between approximately 0°C and -20°C. In some embodiments, the composition can be stored as a frozen solid at temperatures between approximately 0°C and -15°C. In some embodiments, the composition can be stored at -80°C for up to 6 months. In some embodiments, the composition may be stable for 1 year at -80°C. In some embodiments, the composition may be stable for 2 years at -80°C.

[0167] The compositions currently disclosed may be stored as frozen solids for varying lengths of time in preparation for administration to subjects requiring them, and then thawed. In some embodiments, the thawed liquid may be stored for varying lengths and temperatures before administration without impairing the stability of extracellular viables (EVs), such as exosomes. In some embodiments, the compositions may be thawed at temperatures between approximately 1°C and approximately 25°C and stored as liquids, where the stability of EVs, such as exosomes, is not impaired.

[0168] In some embodiments, the composition can be stored as a thawed liquid at approximately 1°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 2°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 3°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 4°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 5°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 6°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 7°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 8°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 9°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 10°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 11°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 12°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 13°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 14°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 15°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 16°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 17°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 18°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 19°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 20°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 21°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 22°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 23°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 24°C. In some embodiments, the composition can be stored as a thawed liquid at approximately 25°C. In some embodiments, the composition can be stored as a thawed liquid at 4°C for about one week.The composition can be stable as a thawed liquid for up to one week at 4°C.

[0169] In some embodiments, the composition may be stored and then directly administered to subjects who need it. In some embodiments, the composition may be stored at 25°C for up to 24 hours and then directly administered to subjects who need it. In some embodiments, the composition may be stored at 4°C for up to 3 days and then directly administered to subjects who need it. In some embodiments, the composition may be stored at 4°C for up to 7 days and then directly administered to subjects who need it. In some embodiments, the composition may be stored at -80°C for up to 6 months, thawed, and then directly administered to subjects who need it.

[0170] II.K. Exemplary Compositions In some aspects, the compositions of this disclosure (a) Extracellular vesicles; (b) concentrations of approximately 4% w / v to approximately 6% w / v, for example, 5% w / v sucrose; (c) Sodium chloride at a concentration of 40 mM to approximately 60 mM; (d) Monobasic potassium phosphate at concentrations of 4 mM to 6 mM; (e) comprising dibasic sodium phosphate heptahydrate at a concentration of about 10 mM to about 20 mM, the pH of the composition is about 7.2. In some embodiments, the conductivity of the composition is about 7.2 mS / cm ± 10%. In some embodiments, the composition is in a solution, such as a liquid formulation.

[0171] In some aspects, the compositions of this disclosure (a) Extracellular vesicles; (b) Sucrose at a concentration of approximately 5% w / v; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) comprising dibasic sodium phosphate heptahydrate at a concentration of approximately 15 mM, the pH of the composition is approximately 7.2. In some embodiments, the conductivity of the composition is approximately 7.2 mS / cm ± 10%. In some embodiments, the composition is in a solution, such as a liquid formulation.

[0172] In some aspects, the compositions of this disclosure (a) Extracellular vesicles; (b) concentrations of approximately 4% w / v to approximately 6% w / v, for example, 5% w / v sucrose; (c) Sodium chloride at a concentration of 30 mM to approximately 50 mM; (d) monobasic potassium phosphate at concentrations of 10 mM to 20 mM; (e) comprising dibasic sodium phosphate heptahydrate at a concentration of about 20 mM to about 40 mM, the pH of the composition is about 7.2. In some embodiments, the conductivity of the composition is about 8.8 mS / cm ± 10%. In some embodiments, the composition is in a solution, such as a liquid formulation.

[0173] In some aspects, the compositions of this disclosure (a) Extracellular vesicles; (b) Sucrose at a concentration of approximately 5% w / v; (c) Sodium chloride at a concentration of approximately 40 mM; (d) with monobasic potassium phosphate at a concentration of approximately 15 mM; (e) comprising dibasic sodium phosphate heptahydrate at a concentration of approximately 27 mM, the pH of the composition is approximately 7.2. In some embodiments, the conductivity of the composition is approximately 8.8 mS / cm ± 10%. In some embodiments, the composition is in a solution, such as a liquid formulation.

[0174] In some aspects, the compositions of this disclosure (a) Extracellular vesicles; (b) concentrations of approximately 4% w / v to approximately 6% w / v, for example, 5% w / v sucrose; (c) Sodium chloride at a concentration of 30 mM to approximately 50 mM; (d) Monobasic potassium phosphate at concentrations of 1 mM to 20 mM; (e) comprising dibasic sodium phosphate heptahydrate at a concentration of about 20 mM to about 40 mM, the pH of the composition is about 7.2. In some embodiments, the composition is in a solution, such as a liquid formulation.

[0175] In some aspects, the compositions of this disclosure (a) Extracellular vesicles; (b) Sucrose at a concentration of approximately 5% w / v; (c) Sodium chloride at a concentration of approximately 40 mM; (d) monobasic potassium phosphate at a concentration of approximately 11 mM; (e) comprising dibasic sodium phosphate heptahydrate at a concentration of approximately 32 mM, the composition having a pH of approximately 7.2. In some embodiments, the composition is in a solution, such as a liquid formulation.

[0176] In some aspects, the compositions of this disclosure (a) Extracellular vesicles; (b) concentrations of approximately 4% w / v to approximately 6% w / v, for example, 5% w / v sucrose; (c) Sodium chloride at a concentration of 30 mM to approximately 60 mM; (d) Monobasic potassium phosphate at concentrations of 1 mM to 20 mM; (e) comprising dibasic sodium phosphate heptahydrate at a concentration of about 10 mM to about 40 mM, the pH of the composition is about 7.2. In some embodiments, the composition is in a solution, such as a liquid formulation.

[0177] In some aspects, the compositions of this disclosure (a) Extracellular vesicles; (b) concentrations of approximately 4% w / v to approximately 6% w / v, for example, 5% w / v sucrose; (c) Sodium chloride at a concentration of 40 mM to approximately 50 mM; (d) Monobasic potassium phosphate at concentrations of 5 mM to 15 mM; (e) comprising dibasic sodium phosphate heptahydrate at a concentration of approximately 15 mM to approximately 35 mM, the pH of the composition is approximately 7.2. In some embodiments, the composition is in a solution, such as a liquid formulation.

[0178] II.K.1. Exemplary Composition 02 In some aspects, the compositions of this disclosure (a) Extracellular vesicles; (b) concentrations of approximately 4% w / v to approximately 6% w / v, for example, 5% w / v sucrose; (c) Sodium chloride at a concentration of 30 mM to approximately 50 mM; (d) monobasic potassium phosphate at concentrations of approximately 5 mM to 25 mM; (e) containing dibasic sodium phosphate heptahydrate at a concentration of approximately 15 mM to approximately 35 mM, (f) The pH of the composition is approximately 6.7 to 7.7.

[0179] In some embodiments, the composition, (a) Extracellular vesicles; (b) Sucrose at a concentration of approximately 5% w / v; (c) Sodium chloride at a concentration of 30 mM to approximately 50 mM; (d) monobasic potassium phosphate at concentrations of approximately 5 mM to 25 mM; (e) containing dibasic sodium phosphate heptahydrate at a concentration of approximately 15 mM to approximately 35 mM, (f) The pH of the composition is approximately 6.7 to 7.7.

[0180] In some embodiments, the composition, (a) Extracellular vesicles; (b) concentrations of approximately 4% w / v to approximately 6% w / v, for example, 5% w / v sucrose; (c) Sodium chloride at a concentration of approximately 40 mM; (d) monobasic potassium phosphate at concentrations of approximately 5 mM to 25 mM; (e) containing dibasic sodium phosphate heptahydrate at a concentration of approximately 15 mM to approximately 35 mM, (f) The pH of the composition is approximately 6.7 to 7.7.

[0181] In some embodiments, the composition, (a) Extracellular vesicles; (b) concentrations of approximately 4% w / v to approximately 6% w / v, for example, 5% w / v sucrose; (c) Sodium chloride at a concentration of approximately 30 mM to approximately 50 mM; (d) with monobasic potassium phosphate at a concentration of approximately 15 mM; (e) containing dibasic sodium phosphate heptahydrate at a concentration of approximately 15 mM to approximately 35 mM, (f) The pH of the composition is approximately 6.7 to 7.7.

[0182] In some embodiments, the composition, (a) Extracellular vesicles; (b) concentrations of approximately 4% w / v to approximately 6% w / v, for example, 5% w / v sucrose; (c) Sodium chloride at a concentration of 30 mM to approximately 50 mM; (d) monobasic potassium phosphate at concentrations of approximately 5 mM to 25 mM; (e) containing dibasic sodium phosphate heptahydrate at a concentration of approximately 30 mM, (f) The pH of the composition is approximately 6.7 to 7.7.

[0183] In some embodiments, the composition, (a) Extracellular vesicles; (b) concentrations of approximately 4% w / v to approximately 6% w / v, for example, 5% w / v sucrose; (c) Sodium chloride at a concentration of 30 mM to approximately 50 mM; (d) monobasic potassium phosphate at concentrations of approximately 5 mM to 25 mM; (e) containing dibasic sodium phosphate heptahydrate at a concentration of approximately 27 mM, (f) The pH of the composition is approximately 6.7 to 7.7.

[0184] In some embodiments, the composition, (a) Extracellular vesicles; (b) concentrations of approximately 4% w / v to approximately 6% w / v, for example, 5% w / v sucrose; (c) Sodium chloride at a concentration of 30 mM to approximately 50 mM; (d) monobasic potassium phosphate at concentrations of approximately 5 mM to 25 mM; (e) containing dibasic sodium phosphate heptahydrate at a concentration of approximately 15 mM to approximately 35 mM, (f) The pH of the composition is approximately 7.0 to 7.4.

[0185] In some embodiments, the composition, (a) Extracellular vesicles; (b) concentrations of approximately 4% w / v to approximately 6% w / v, for example, 5% w / v sucrose; (c) Sodium chloride at a concentration of 30 mM to approximately 50 mM; (d) monobasic potassium phosphate at concentrations of approximately 5 mM to 25 mM; (e) containing dibasic sodium phosphate heptahydrate at a concentration of approximately 15 mM to approximately 35 mM, (f) The pH of the composition is approximately 7.2.

[0186] In certain embodiments, this composition, (a) Extracellular vesicles; (b) Sucrose at a concentration of approximately 5% w / v; (c) Sodium chloride at a concentration of approximately 40 mM; (d) with monobasic potassium phosphate at a concentration of approximately 15 mM; (e) containing dibasic sodium phosphate heptahydrate at a concentration of approximately 27 mM, (f) The pH of the composition is approximately 7.2.

[0187] In some embodiments, the extracellular vesicle comprises a STING agonist. In some embodiments, the STING agonist comprises a cyclic dinucleotide (CDN) STING agonist or an acyclic dinucleotide STING agonist. In some embodiments, the STING agonist comprises cGMP, cyclic di-GMP (c-di-GMP), cAMP, cyclic di-AMP (c-di-AMP), cyclic-GMP-AMP (cGAMP), cyclic di-IMP (c-di-IMP), cyclic AMP-IMP (cAIMP), and their analogues, which are known to stimulate or enhance immune or inflammatory responses in patients. In some embodiments, the CDN comprises a 2'2', 2'3', 2'5', 3'3', or 3'5' linkage of the cyclic dinucleotide, or any combination thereof.

[0188] In some embodiments, the composition is freeze-dried.

[0189] II.K.1. Exemplary Composition 03 In certain embodiments, this composition, (a) Extracellular vesicles; (b) Sucrose in a concentration of at least about 50 mM to at least about 300 mM; (c) Sodium chloride in a concentration of at least about 10 mM to at least about 200 mM; (d) monobasic potassium phosphate at a concentration of at least about 1 mM to at least about 20 mM; (e) containing dibasic sodium phosphate in a concentration of at least about 5 mM to at least about 35 mM; (f) The pH of the composition is approximately 6.7 to 7.7.

[0190] In certain embodiments, this composition, (a) Extracellular vesicles; (b) With sucrose at a concentration of approximately 146 mM; (c) Sodium chloride in a concentration of at least about 10 mM to at least about 200 mM; (d) monobasic potassium phosphate at a concentration of at least about 1 mM to at least about 20 mM; (e) containing dibasic sodium phosphate in a concentration of at least about 5 mM to at least about 35 mM; (f) The pH of the composition is approximately 6.7 to 7.7.

[0191] In certain embodiments, this composition, (a) Extracellular vesicles; (b) Sucrose in a concentration of at least about 50 mM to at least about 300 mM; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of at least about 1 mM to at least about 20 mM; (e) containing dibasic sodium phosphate in a concentration of at least about 5 mM to at least about 35 mM; (f) The pH of the composition is approximately 6.7 to 7.7.

[0192] In certain embodiments, this composition, (a) Extracellular vesicles; (b) Sucrose in a concentration of at least about 50 mM to at least about 300 mM; (c) Sodium chloride in a concentration of at least about 10 mM to at least about 200 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate in a concentration of at least about 5 mM to at least about 35 mM; (f) The pH of the composition is approximately 6.7 to 7.7.

[0193] In certain embodiments, this composition, (a) Extracellular vesicles; (b) Sucrose in a concentration of at least about 50 mM to at least about 300 mM; (c) Sodium chloride in a concentration of at least about 10 mM to at least about 200 mM; (d) monobasic potassium phosphate at a concentration of at least about 1 mM to at least about 20 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 6.7 to 7.7.

[0194] In certain embodiments, this composition, (a) Extracellular vesicles; (b) Sucrose in a concentration of at least about 50 mM to at least about 300 mM; (c) Sodium chloride in a concentration of at least about 10 mM to at least about 200 mM; (d) monobasic potassium phosphate at a concentration of at least about 1 mM to at least about 20 mM; (e) containing dibasic sodium phosphate in a concentration of at least about 5 mM to at least about 35 mM; (f) The pH of the composition is approximately 7.2.

[0195] In certain embodiments, this composition, (a) Extracellular vesicles; (b) With sucrose at a concentration of approximately 146 mM; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0196] In certain embodiments, this composition, (a) Extracellular vesicles; (b) with sucrose in a concentration of at least about 1% to at least about 10%; (c) Sodium chloride in a concentration of at least about 10 mM to at least about 200 mM; (d) monobasic potassium phosphate at a concentration of at least about 1 mM to at least about 20 mM; (e) containing dibasic sodium phosphate in a concentration of at least about 5 mM to at least about 35 mM; (f) The pH of the composition is approximately 6.7 to 7.7.

[0197] In certain embodiments, this composition, (a) Extracellular vesicles; (b) with sucrose at a concentration of approximately 5%; (c) Sodium chloride in a concentration of at least about 10 mM to at least about 200 mM; (d) monobasic potassium phosphate at a concentration of at least about 1 mM to at least about 20 mM; (e) containing dibasic sodium phosphate in a concentration of at least about 5 mM to at least about 35 mM; (f) The pH of the composition is approximately 6.7 to 7.7.

[0198] In certain embodiments, this composition, (a) Extracellular vesicles; (b) with sucrose in a concentration of at least about 1% to at least about 10%; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of at least about 1 mM to at least about 20 mM; (e) containing dibasic sodium phosphate in a concentration of at least about 5 mM to at least about 35 mM; (f) The pH of the composition is approximately 6.7 to 7.7.

[0199] In certain embodiments, this composition, (a) Extracellular vesicles; (b) with sucrose in a concentration of at least about 1% to at least about 10%; (c) Sodium chloride in a concentration of at least about 10 mM to at least about 200 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate in a concentration of at least about 5 mM to at least about 35 mM; (f) The pH of the composition is approximately 6.7 to 7.7.

[0200] In certain embodiments, this composition, (a) Extracellular vesicles; (b) with sucrose in a concentration of at least about 1% to at least about 10%; (c) Sodium chloride in a concentration of at least about 10 mM to at least about 200 mM; (d) monobasic potassium phosphate at a concentration of at least about 1 mM to at least about 20 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 6.7 to 7.7.

[0201] In certain embodiments, this composition, (a) Extracellular vesicles; (b) with sucrose in a concentration of at least about 1% to at least about 10%; (c) Sodium chloride in a concentration of at least about 10 mM to at least about 200 mM; (d) monobasic potassium phosphate at a concentration of at least about 1 mM to at least about 20 mM; (e) containing dibasic sodium phosphate in a concentration of at least about 5 mM to at least about 35 mM; (f) The pH of the composition is approximately 7.2.

[0202] In certain embodiments, this composition, (a) Extracellular vesicles; (b) with sucrose at a concentration of approximately 5%; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0203] In some embodiments, the extracellular vesicle contains an IL-12 moiety. In certain embodiments, the IL-12 moiety is disclosed herein. In certain embodiments, the IL-12 moiety contains an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to the amino acid sequence shown in SEQ ID NO: 11, 12, or 13 (Table 1A). In certain embodiments, IL-12 contains the amino acid sequence shown in SEQ ID NO: 11. In certain embodiments, IL-12 contains the amino acid sequence shown in SEQ ID NO: 12. In certain embodiments, IL-12 contains an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to the amino acid sequence shown in SEQ ID NO: 13. In certain embodiments, IL-12 comprises the amino acid sequence shown in SEQ ID NO: 13.

[0204] In certain embodiments, this composition, (a) Extracellular vesicles containing an IL-12 moiety, wherein the IL-12 moiety contains an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 11, 12, or 13; (b) With sucrose at a concentration of approximately 146 mM; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0205] In some embodiments, the composition, (a) An extracellular vesicle comprising an IL-12 moiety, wherein the IL-12 moiety comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 11, 12, or 13; (b) Sucrose at a concentration of about 5%; (c) Sodium chloride at a concentration of about 50 mM; (d) Potassium monobasic phosphate at a concentration of about 5 mM; (e) Sodium dibasic phosphate at a concentration of about 15 mM, and (f) The pH of the composition is about 7.2.

[0206] In certain embodiments, the composition is (a) An extracellular vesicle comprising an IL-12 moiety, wherein the IL-12 moiety comprises the amino acids set forth in SEQ ID NO: 13; (b) Sucrose at a concentration of about 146 mM; (c) Sodium chloride at a concentration of about 50 mM; (d) Potassium monobasic phosphate at a concentration of about 5 mM; (e) Sodium dibasic phosphate at a concentration of about 15 mM, and (f) The pH of the composition is about 7.2.

[0207] In some embodiments, the composition is (a) An extracellular vesicle comprising an IL-12 moiety, wherein the IL-12 moiety comprises the amino acids set forth in SEQ ID NO: 13; (b) Sucrose at a concentration of about 5%; (c) Sodium chloride at a concentration of about 50 mM; (d) Potassium monobasic phosphate at a concentration of about 5 mM; (e) Sodium dibasic phosphate at a concentration of about 15 mM, and (f) The pH of the composition is about 7.2.

[0208] In some embodiments, the extracellular vesicle contains an ASO. In some embodiments, the ASO contains a sequence of nucleotides 10 to 30 nucleotides in length that is complementary to the nucleic acid sequence in the STAT6 transcript (SEQ ID NO: 23; Table 1B). In some embodiments, the ASO contains a nucleic acid sequence selected from SEQ ID NOs: 91 to 193. In some embodiments, the ASO contains the nucleic acid sequence GAAAGGTTCCGTCGGGC (SEQ ID NO: 144). In some embodiments, the ASO contains the nucleic acid sequence CTGAGTCGCTGAAGCGG (SEQ ID NO: 145). In some embodiments, the ASO contains the nucleic acid sequence GCCCTTGTACTTTTGCATAG (SEQ ID NO: 193). In some embodiments, the ASO contains the nucleic acid sequence GCAAGATCCCGGATTCGGTC (SEQ ID NO: 185).

[0209] In certain embodiments, this composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a sequence of nucleotides 10 to 30 nucleotides in length that is complementary to the nucleic acid sequence in the STAT6 transcript; (b) sucrose and; (c) sodium chloride and; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2; Sucrose is available in concentrations selected from approximately 73 mM, 80 mM, 85 mM, 90 mM, 95 mM, 100 mM, 105 mM, 110 mM, 115 mM, 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM, 146 mM, and 150 mM; The sodium chloride concentration is selected from approximately 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, 100 mM, 105 mM, 110 mM, 115 mM, 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM, 146 mM, and 150 mM.

[0210] In certain embodiments, this composition, (a) Extracellular vesicles containing ASO; (b) sucrose and; (c) sodium chloride and; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2; Sucrose is available in concentrations selected from approximately 73 mM, 80 mM, 85 mM, 90 mM, 95 mM, 100 mM, 105 mM, 110 mM, 115 mM, 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM, 146 mM, and 150 mM; The sodium chloride concentration is selected from approximately 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, 100 mM, 105 mM, 110 mM, 115 mM, 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM, 146 mM, and 150 mM. In some embodiments, the ASO contains a nucleic acid sequence selected from sequence numbers 91-193.

[0211] In some embodiments, the composition, (a) Extracellular vesicles containing ASO; (b) sucrose and; (c) sodium chloride and; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2; Sucrose is available in concentrations selected from approximately 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, and 5.0%; The sodium chloride concentration is selected from approximately 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, 100 mM, 105 mM, 110 mM, 115 mM, 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM, 146 mM, and 150 mM. In some embodiments, the ASO contains a nucleic acid sequence selected from sequence numbers 91-193.

[0212] In certain embodiments, this composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a sequence of nucleotides 10 to 30 nucleotides in length that is complementary to the nucleic acid sequence in the STAT6 transcript; (b) Sucrose at concentrations of approximately 73 mM to 146 mM; (c) Sodium chloride at a concentration of approximately 50 mM to approximately 150 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0213] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a sequence of nucleotides 10 to 30 nucleotides in length that is complementary to the nucleic acid sequence in the STAT6 transcript; (b) With sucrose at a concentration of approximately 2.5% to approximately 5%; (c) Sodium chloride at a concentration of approximately 50 mM to approximately 150 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) Sodium dibasic phosphate at a concentration of about 15 mM, and (f) The pH of the composition is about 7.2.

[0214] In certain embodiments, the composition (a) An extracellular vesicle containing an ASO, wherein the ASO contains a nucleic acid sequence selected from SEQ ID NOs: 91 - 193; (b) Sucrose at a concentration of about 73 mM to about 146 mM; (c) Sodium chloride at a concentration of about 50 mM to about 150 mM; (d) Potassium monobasic phosphate at a concentration of about 5 mM; (e) Sodium dibasic phosphate at a concentration of about 15 mM, and (f) The pH of the composition is about 7.2.

[0215] In some embodiments, the composition (a) An extracellular vesicle containing an ASO, wherein the ASO contains a nucleic acid sequence selected from SEQ ID NOs: 91 - 193; (b) Sucrose at a concentration of about 2.5% to about 5%; (c) Sodium chloride at a concentration of about 50 mM to about 150 mM; (d) Potassium monobasic phosphate at a concentration of about 5 mM; (e) Sodium dibasic phosphate at a concentration of about 15 mM, and (f) The pH of the composition is about 7.2.

[0216] In certain embodiments, the composition (a) An extracellular vesicle containing an ASO, wherein the ASO contains a continuous nucleotide sequence of 10 - 30 nucleotides complementary to a nucleic acid sequence within the STAT6 transcript; (b) Sucrose at a concentration of about 146 mM; (c) Sodium chloride at a concentration of about 50 mM; (d) Potassium monobasic phosphate at a concentration of about 5 mM; (e) Sodium dibasic phosphate at a concentration of about 15 mM, and (f) The pH of the composition is approximately 7.2.

[0217] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a sequence of nucleotides 10 to 30 nucleotides in length that is complementary to the nucleic acid sequence in the STAT6 transcript; (b) with sucrose at a concentration of approximately 5%; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0218] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a sequence of nucleotides 10 to 30 nucleotides in length that is complementary to the nucleic acid sequence in the STAT6 transcript; (b) with sucrose at a concentration of approximately 5%; (c) Sodium chloride at a concentration of approximately 100 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0219] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a sequence of nucleotides 10 to 30 nucleotides in length that is complementary to the nucleic acid sequence in the STAT6 transcript; (b) with sucrose at a concentration of approximately 5%; (c) Sodium chloride at a concentration of approximately 150 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0220] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a sequence of nucleotides 10 to 30 nucleotides in length that is complementary to the nucleic acid sequence in the STAT6 transcript; (b) with sucrose at a concentration of approximately 2.5%; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0221] In some embodiments, the ASO includes a nucleic acid sequence selected from sequence numbers 91-93.

[0222] In certain embodiments, this composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a nucleic acid sequence selected from sequence numbers 91-193; (b) With sucrose at a concentration of approximately 146 mM; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0223] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a nucleic acid sequence selected from sequence numbers 91-193; (b) with sucrose at a concentration of approximately 5%; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0224] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a nucleic acid sequence selected from sequence numbers 91-193; (b) with sucrose at a concentration of approximately 4.5%; (c) Sodium chloride at a concentration of approximately 50 mM to approximately 150 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0225] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a nucleic acid sequence selected from sequence numbers 91-193; (b) with sucrose at a concentration of approximately 4%; (c) Sodium chloride at a concentration of approximately 50 mM to approximately 150 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0226] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a nucleic acid sequence selected from sequence numbers 91-193; (b) with sucrose at a concentration of approximately 3.5%; (c) Sodium chloride at a concentration of approximately 50 mM to approximately 150 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0227] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a nucleic acid sequence selected from sequence numbers 91-193; (b) with sucrose at a concentration of approximately 3%; (c) Sodium chloride at a concentration of approximately 50 mM to approximately 150 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0228] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains a nucleic acid sequence selected from sequence numbers 91-193; (b) with sucrose at a concentration of approximately 2.5%; (c) Sodium chloride at a concentration of approximately 50 mM to approximately 150 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0229] In certain embodiments, this composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains the nucleic acid sequence GAAAGGTTCCGTCGGGC (SEQ ID NO: 144); (b) With sucrose at a concentration of approximately 146 mM; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0230] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains the nucleic acid sequence GAAAGGTTCCGTCGGGC (SEQ ID NO: 144); (b) with sucrose at a concentration of approximately 5%; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0231] In certain embodiments, this composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains the nucleic acid sequence CTGAGTCGCTGAAGCGG (SEQ ID NO: 145); (b) With sucrose at a concentration of approximately 146 mM; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0232] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains the nucleic acid sequence CTGAGTCGCTGAAGCGG (SEQ ID NO: 145); (b) with sucrose at a concentration of approximately 5%; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0233] In certain embodiments, this composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains the nucleic acid sequence GCCCTTGTACTTTTGCATAG (SEQ ID NO: 193); (b) With sucrose at a concentration of approximately 146 mM; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0234] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains the nucleic acid sequence GCCCTTGTACTTTTGCATAG (SEQ ID NO: 193); (b) with sucrose at a concentration of approximately 5%; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0235] In certain embodiments, this composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains the nucleic acid sequence GCAGATCCCGGATTCGGTC (SEQ ID NO: 185); (b) With sucrose at a concentration of approximately 146 mM; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0236] In some embodiments, the composition, (a) an extracellular vesicle containing an ASO, wherein the ASO contains the nucleic acid sequence GCAGATCCCGGATTCGGTC (SEQ ID NO: 185); (b) with sucrose at a concentration of approximately 5%; (c) Sodium chloride at a concentration of approximately 50 mM; (d) monobasic potassium phosphate at a concentration of approximately 5 mM; (e) containing dibasic sodium phosphate at a concentration of approximately 15 mM, (f) The pH of the composition is approximately 7.2.

[0237] In some embodiments, the composition is freeze-dried.

[0238] III. Extracellular vesicles, e.g., exosomes Disclosed herein are modified extracellular organisms (EVs), e.g., exosomes, that can modulate the immune system of a target. EVs useful in this disclosure, e.g., exosomes, are engineered to produce at least one exogenous biologically active moiety. In some embodiments, the EV (e.g., exosome) comprises two exogenous biologically active moieties. In some embodiments, the EV (e.g., exosome) comprises three exogenous biologically active moieties. In other embodiments, the EV (e.g., exosome) comprises four exogenous biologically active moieties. In further embodiments, the EV (e.g., exosome) comprises five or more exogenous biologically active moieties. In some embodiments, the EV (e.g., exosome) comprises six, seven, eight, nine, ten, eleven, twelve, thirteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more exogenous biologically active moieties.

[0239] As described above, the EVs (e.g., exosomes) described herein are extracellular vesicles with a diameter of approximately 20-300 nm. In certain embodiments, the EVs (e.g., exosomes) of this disclosure are approximately 20-290 nm, 20-280 nm, 20-270 nm, 20-260 nm, 20-250 nm, 20-240 nm, 20-230 nm, 20-220 nm, 20-210 nm, 20-200 nm, 20-190 nm, 20-180 nm, 20-170 nm, 20-160 nm, 20-150 nm, 20-140 nm, 20-130 nm, 20-120 nm, 20-110 nm, 20-100 nm, 20-90 nm, 20-80 nm, 20-70 nm, 20- 60nm, 20~50nm, 20~40nm, 20~30nm, 30~300nm, 30~290nm, 30~280nm, 30~ 270nm, 30~260nm, 30~250nm, 30~240nm, 30~230nm, 30~220nm, 30~210nm , 30~200nm, 30~190nm, 30~180nm, 30~170nm, 30~160nm, 30~150nm, 30~1 40nm, 30~130nm, 30~120nm, 30~110nm, 30~100nm, 30~90nm, 30~80nm, 30 ~70nm, 30~60nm, 30~50nm, 30~40nm, 40~300nm, 40~290nm, 40~280nm, 40 ~270nm, 40~260nm, 40~250nm, 40~240nm, 40~230nm, 40~220nm, 40~210nm m, 40~200nm, 40~190nm, 40~180nm, 40~170nm, 40~160nm, 40~150nm, 40~ 140nm, 40~130nm, 40~120nm, 40~110nm, 40~100nm, 40~90nm, 40~80nm, 4 0~70nm, 40~60nm, 40~50nm, 50~300nm, 50~290nm, 50~280nm, 50~270nm, 50~260nm, 50~250nm, 50~240nm, 50~230nm, 50~220nm, 50~210nm, 50~20 0nm, 50~190nm, 50~180nm, 50~170nm, 50~160nm, 50~150nm, 50~140nm, 5 0~130nm, 50~120nm, 50~110nm, 50~100nm, 50~90nm, 50~80nm, 50~70nm,50~60nm, 60~300nm, 60~290nm, 60~280nm, 60~270nm, 60~260nm, 60~250nm, 60~240nm, 60~230nm, 60~220nm, 60~210nm, 60~200nm, 60~190nm , 60~180nm, 60~170nm, 60~160nm, 60~150nm, 60~140nm, 60~130nm, 60~120nm, 60~110nm, 60~100nm, 60~90nm, 60~80nm, 60~70nm, 70~300nm, 70~290nm, 70~280nm, 70~270nm, 70~260nm, 70~250nm, 70~240nm, 70~230nm, 70~220nm, 70~210nm, 70~200nm, 70~190nm, 70~180nm, 70~170n m, 70~160nm, 70~150nm, 70~140nm, 70~130nm, 70~120nm, 70~110nm, 70~100nm, 70~90nm, 70~80nm, 80~300nm, 80~290nm, 80~280nm, 80~270nm , 80~260nm, 80~250nm, 80~240nm, 80~230nm, 80~220nm, 80~210nm, 80~200nm, 80~190nm, 80~180nm, 80~170nm, 80~160nm, 80~150nm, 80~140 nm, 80~130nm, 80~120nm, 80~110nm, 80~100nm, 80~90nm, 90~300nm, 90~290nm, 90~280nm, 90~270nm, 90~260nm, 90~250nm, 90~240nm, 90~23 Having a diameter of 0 nm, 90-220 nm, 90-210 nm, 90-200 nm, 90-190 nm, 90-180 nm, 90-170 nm, 90-160 nm, 90-150 nm, 90-140 nm, 90-130 nm, 90-120 nm, 90-110 nm, 90-100 nm, 100-300 nm, 110-290 nm, 120-280 nm, 130-270 nm, 140-260 nm, 150-250 nm, 160-240 nm, 170-230 nm, 180-220 nm, or 190-210 nm. The size of the EV (e.g., exosome) described herein can be measured according to the method described below.

[0240] In some embodiments, the EV (e.g., exosome) of the present disclosure comprises a dilipid membrane ("EV (e.g., exosome) membrane") including an inner and outer surface. In certain embodiments, the inner surface faces the inner core (i.e., lumen) of the EV (e.g., exosome). In certain embodiments, the outer surface may be in contact with the endosome, polyendoplasmic reticulum, or membrane / cytoplasm of a producer cell or target cell.

[0241] In some embodiments, the EV (e.g., exosome) membrane comprises lipids and fatty acids. In some embodiments, the EV (e.g., exosome) membrane comprises phospholipids, glycolipids, fatty acids, sphingolipids, phosphoglycerides, sterols, cholesterol, and phosphatidylserine.

[0242] In some embodiments, the EV (e.g., exosome) membrane includes an inner leaflet and an outer leaflet. The compositions of the inner and outer leaflets can be determined by transbilayer distribution assays known in the art; see, for example, Kuypers et al. Biohim Biophys Acta 1985 819:170. In some embodiments, the composition of the outer leaflet is approximately 70–90% choline phospholipids, approximately 0–15% acidic phospholipids, and approximately 5–30% phosphatidylethanolamine. In some embodiments, the composition of the inner leaflet is approximately 15–40% choline phospholipids, approximately 10–50% acidic phospholipids, and approximately 30–60% phosphatidylethanolamine.

[0243] In some embodiments, the EV (e.g., exosome) membrane contains one or more polysaccharides, such as glycans.

[0244] In some embodiments, the EV (e.g., exosome) membrane further comprises one or more scaffolding portions that can immobilize multiple exogenous biologically active moieties on the EV (e.g., on either the luminal or luminal surface). In some embodiments, the scaffolding portion immobilizes or ligates at least one of the multiple exogenous biologically active moieties to the EV. In some embodiments, the scaffolding portion immobilizes or ligates each of multiple (e.g., at least two) exogenous biologically active moieties to the EV. In certain embodiments, the scaffolding portion is a polypeptide ("exosome protein"). In other embodiments, the scaffolding portion is a non-polypeptide portion. In some embodiments, the exosome protein comprises various membrane proteins concentrated on the exosome membrane, such as transmembrane proteins, endogenous proteins, and peripheral proteins. These include various CD proteins, transporters, integrins, lectins, and cadherins. In certain embodiments, the scaffolding portion (e.g., exosome protein) comprises scaffolding X. In a further embodiment, the scaffold portion (e.g., an exosome protein) comprises multiple scaffold X portions.

[0245] In some embodiments, the extracellular proteins (EVs) disclosed herein (e.g., exosomes) can deliver one or more payloads (e.g., biologically active sites) to a target. Thus, in certain embodiments, the EVs (e.g., exosomes) may contain one, two, three, four, five, or more different payloads. The payloads are agents that act on a target (e.g., a target cell) that comes into contact with the EV. Contact can occur in vitro or in the subject. Non-limiting examples of payloads that can be introduced into the EV include agents such as nucleotides (e.g., nucleotides containing detectable sites or toxins, or nucleotides that interfere with transcription), nucleic acids (e.g., DNA or mRNA molecules encoding polypeptides such as enzymes, or RNA molecules with regulatory functions such as miRNA, dsDNA, lncRNA, or siRNA), RNA-binding proteins such as MS2, amino acids (e.g., amino acids containing detectable sites or toxins that interfere with translation), polypeptides (e.g., enzymes), lipids, carbohydrates, and small molecules (e.g., small molecule drugs and toxins). In some embodiments, the payload includes an exogenous biologically active moiety (e.g., one disclosed herein).

[0246] IIIA. Payload, e.g., biologically active portion In some embodiments, the payload includes a biologically active moiety. In some embodiments, the payload includes a therapeutic molecule. In certain embodiments, the therapeutic molecule includes an antigen that can induce an immune response in a target. In certain embodiments, the antigen includes a tumor antigen. Non-limiting examples of tumor antigens include alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), epithelial tumor antigen (ETA), mucin 1 (MUC1), Tn-MUC1, mucin 16 (MUC16), tyrosinase, melanoma-associated antigen (MAGE), tumor protein p53 (p53), CD4, CD8, CD45, CD47, CD80, CD86, programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), NY-ESO-1, PSMA, TAG-72, HER2, GD2, cMET, EGFR, mesoserine, VEGFR, alpha-folate receptor, CE7R, IL-3, cancer-testis antigen (CTA), MART-1 gp100, and TNF-associated apoptosis-inducing ligands, Brachyury (an antigen preferentially expressed in melanoma (PRAME)), or combinations thereof. In further embodiments, the antigen may include a novel antigen. As used herein, the term “novel antigen” refers to an antigen encoded by a tumor-specific mutation gene. In some embodiments, the antigen is derived from bacteria, viruses, fungi, protozoa, or any combination thereof. In some embodiments, the antigen is derived from a carcinogenic virus.In a further embodiment, the antigens include human gamma herpesvirus 4 (Epstein-Barr virus), influenza A virus, influenza B virus, cytomegalovirus, staphylococcus aureus, mycobacterium tuberculosis, chlamydia trachomatis, HIV-1, HIV-2, coronavirus (e.g., MERS-CoV and SARS-CoV), filovirus (e.g., Marburg and Ebola), Streptococcus pyogenes, Streptococcus pneumoniae, Plasmodia species (e.g., vivax and falciparum), Chikungunya virus, human papillomavirus (HPV), hepatitis B, hepatitis C, human herpesvirus 8, herpes simplex virus 2 (HSV2), Klebsiella sp., Pseudomonas aeruginosa, Enterococcus sp., Proteus sp., Enterobacter sp., and Actinobacter. It originates from a group consisting of sp., coagulase-negative staphylococci (CoNS), Mycoplasma sp., or a combination thereof.

[0247] In some embodiments, the antigen is derived from Mycobacterium tuberculosis to induce a cellular and / or humoral immune response. In some embodiments, the antigen comprises one or more epitopes of Mycobacterium tuberculosis (TB antigens). Various antigens are associated with Mycobacterium tuberculosis infection, such as ESAT-6, TB10.4, CFP10, Rv2031(hspX), Rv2654c(TB7.7), and Rv1038c(EsxJ). See, for example, Lindestam et al., J.Immunol. 188(10):5020-31 (2012), which is incorporated herein in its entirety.

[0248] In some embodiments, the antigen includes autoantigens. As used herein, the term “autoantigen” refers to an antigen expressed by a host cell or tissue.

[0249] In some embodiments, the therapeutic molecule comprises an antibody or an antigen-binding fragment thereof. In some embodiments, the therapeutic molecule comprises at least two, at least three, at least four, or at least five antibodies or their antigen-binding fragments. In some embodiments, the biologically active portion is an antibody that targets a cell surface protein. In some embodiments, the antibody or its antigen-binding fragment comprises scFv, scFab, scFab-Fc, nanobody, or any combination thereof. In some embodiments, the antibody or its antigen-binding fragment comprises an agonist antibody, a blocking antibody, a targeted antibody, a fragment thereof, or a combination thereof. In some embodiments, the agonist antibody is a CD40L agonist. In some embodiments, the blocking antibody binds to a target protein selected from programmed death 1 (PD-1), programmed death ligand 1 (PD-L1), cytotoxic T lymphocyte-associated protein 4, and any combination thereof. In some embodiments, the targeted antibody binds to CD3 and / or CD19. In some embodiments, the EV (e.g., exosome) comprises an anti-IL12 antibody or its antigen-binding fragment, and an anti-CD40L antibody or its antigen-binding fragment. In some embodiments, the EV (e.g., exosome) comprises BITES, e.g., an anti-CD3 antibody, and an anticancer agent, e.g., an anti-CD19 antibody.

[0250] In some embodiments, the therapeutic molecule comprises antibody fragments, e.g., scFv, (scFv)2, Fab, Fab', and F(ab')2, F(ab1)2, Fv, dAb, or Fd-targeted antigens, e.g., CD33, ICAM4, CD40, CDLEC9A, DEC205, and TfR, and any combination thereof.

[0251] In some embodiments, the therapeutic molecule is a blood coagulation factor, such as FVIII.

[0252] In some embodiments, the therapeutic molecule is a targeted peptide, such as a cysteine ​​knot peptide.

[0253] In some embodiments, the therapeutic molecules are enzymes such as Cas9 and zinc finger nucleases, CD39, CD73, and lysosomal acid glucosylceramidase.

[0254] In some embodiments, the therapeutic molecule is a protein dimerization system such as FRB-FKBP.

[0255] As stated above, the EVs (e.g., exosomes) of this disclosure may include adjuvants. In some embodiments, the EVs (e.g., exosomes) disclosed herein may include 1, 2, 3, 4, 5, or more different adjuvants. As used herein, the term “adjuvant” refers to any substance that enhances the therapeutic effect of a payload (e.g., increases the immune response to an antigen). Accordingly, the EVs (e.g., exosomes) described herein may increase the immune response to an antigen by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, or more, compared to a reference (e.g., a corresponding EV without an adjuvant or a non-EV delivery vehicle containing an antigen and an adjuvant). Non-limiting examples of adjuvants include interferon gene stimulators (STING) agonists, Toll-like receptor (TLR) agonists, inflammatory mediators, and combinations thereof.

[0256] In some embodiments, adjuvants induce activation of cytosolic pattern recognition receptors. Non-limiting examples of cytosolic pattern recognition receptors include interferon gene stimulants (STINGs), retinoic acid-inducible gene I (RIG-1), melanoma differentiation-associated protein 5 (MDA5), nucleotide-binding oligomerized domains, leucine-rich repeats and pyrine domain-containing (NLRPs), inflammasomes, or combinations thereof. In certain embodiments, the adjuvant is a STING agonist. Interferon gene stimulants (STINGs) are cytosolic sensors of cyclic dinucleotides typically produced by bacteria. Upon activation, they lead to the production of type I interferon, initiating an immune response. In certain embodiments, STING agonists include cyclic dinucleotide STING agonists or acyclic dinucleotide STING agonists.

[0257] Cyclic purine dinucleotides, such as but not limited to cGMP, cyclic di-GMP (c-di-GMP), cAMP, cyclic di-AMP (c-di-AMP), cyclic-GMP-AMP (cGAMP), cyclic di-IMP (c-di-IMP), cyclic AMP-IMP (cAIMP), and their analogues, are known to stimulate or enhance a patient's immune or inflammatory response. CDNs may have 2'2', 2'3', 2'5', 3'3', or 3'5' links, or any combination thereof, that ligate the cyclic dinucleotides.

[0258] Cyclic purine dinucleotides can be modified via standard organic chemistry techniques to produce analogs of the purine dinucleotide. Suitable purine dinucleotides include, but are not limited to, adenine, guanine, inosine, hypoxanthine, xanthine, isoguanine, or other suitable purine dinucleotides known in the art. The cyclic dinucleotide may be a modified analog. Any suitable modification known in the art, but not limited to, phosphorothioate, biphosphothioate, fluorineate, and difluorineate modifications, can be used.

[0259] Acyclic dinucleotide agonists such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) or any other acyclic dinucleotide agonists known in the art may also be used.

[0260] Non-limiting examples of STING agonists that may be used in conjunction with this disclosure include DMXAA, STING agonist-1, ML RR-S2 CDA, ML RR-S2 c-di-GMP, ML-RR-S2 cGAMP, 2'3'-c-di-AM(PS)2, 2'3'-cGAMP, 2'3'-cGAMPdFHS, 3'3'-cGAMP, 3'3'-cGAMPdFSH, cAIMP, cAIM(PS)2, 3'3'-cAIMP, 3'3'-cAIMPdFSH, 2'2'-cGAMP, 2'3'-cGAM(PS)2, 3'3'-cGAMP, or combinations thereof. Non-restrictive examples of STING agonists can be found in U.S. Patent Nos. 9,695,212, WO2014 / 189805(A1), WO2014 / 179335(A1), WO2018 / 100558(A1), U.S. Patent Nos. 10,011,630(B2), WO2017 / 027646(A1), WO2017 / 161349(A1), and WO2016 / 096174(A1). These are incorporated in their entirety by reference, respectively.

[0261] In some embodiments, STING agonists useful to this disclosure include compounds or pharmaceutically acceptable salts thereof disclosed in WO2016 / 096174, WO2016 / 096174(A1), WO2014 / 093936, WO2014 / 189805, and WO2015 / 077354 (the contents of which are incorporated herein by reference in their entirety). See also Cell reports 11, 1018-1030 (2015).

[0262] In some embodiments, STING agonists useful to this disclosure include c-di-AMP, c-di-GMP, c-di-IMP, c-AMP-GMP, c-AMP-IMP, and c-GMP-IMP. These are described in WO2013 / 185052 and Sci.Transl.Med.283,283ra52(2015), and are incorporated herein by reference in their entirety.

[0263] In some embodiments, STING agonists useful to this disclosure include compounds or pharmaceutically acceptable salts thereof disclosed in WO2014 / 189806, WO2015 / 185565, WO2014 / 179760, WO2014 / 179335, WO2015 / 017652, WO2016 / 096577, WO2016 / 120305, WO2016 / 145102, WO2017 / 027646, WO2017 / 075477, WO2017 / 027645, WO2018 / 100558, WO2017 / 175147, or WO2017 / 175156. Each of these contents is incorporated herein by reference to its entirety.

[0264] In some embodiments, STING agonists useful to this disclosure are CL606, CL611, CL602, CL655, CL604, CL609, CL614, CL656, CL647, CL626, CL629, CL603, CL632, CL633, CL659, or pharmaceutically acceptable salts thereof. In some embodiments, STING agonists useful to this disclosure are CL606 or pharmaceutically acceptable salts thereof. In some embodiments, STING agonists useful to this disclosure are CL611 or pharmaceutically acceptable salts thereof. In some embodiments, STING agonists useful to this disclosure are CL602 or pharmaceutically acceptable salts thereof. In some embodiments, STING agonists useful to this disclosure are CL655 or pharmaceutically acceptable salts thereof. In some embodiments, STING agonists useful to this disclosure are CL604 or pharmaceutically acceptable salts thereof. In some embodiments, a STING agonist useful for this disclosure is CL609 or a pharmaceutically acceptable salt thereof. In some embodiments, a STING agonist useful for this disclosure is CL614 or a pharmaceutically acceptable salt thereof. In some embodiments, a STING agonist useful for this disclosure is CL647 or a pharmaceutically acceptable salt thereof. In some embodiments, a STING agonist useful for this disclosure is CL626 or a pharmaceutically acceptable salt thereof. In some embodiments, a STING agonist useful for this disclosure is CL629 or a pharmaceutically acceptable salt thereof. In some embodiments, a STING agonist useful for this disclosure is CL603 or a pharmaceutically acceptable salt thereof. In some embodiments, a STING agonist useful for this disclosure is CL632 or a pharmaceutically acceptable salt thereof. In some embodiments, a STING agonist useful for this disclosure is CL633 or a pharmaceutically acceptable salt thereof. In some embodiments, a STING agonist useful to this disclosure is CL659 or a pharmaceutically acceptable salt thereof.

[0265] In some embodiments, the STING agonist useful for this disclosure is CL656 or a pharmaceutically acceptable salt thereof. In some embodiments, the STING agonist useful for this disclosure is isomer A of CL656 or a pharmaceutically acceptable salt thereof. In some embodiments, the STING agonist useful for this disclosure is isomer B of CL656 or a pharmaceutically acceptable salt thereof. In some embodiments, the STING agonist useful for this disclosure is isomer C of CL656 or a pharmaceutically acceptable salt thereof. In some embodiments, the STING agonist useful for this disclosure is isomer D of CL656 or a pharmaceutically acceptable salt thereof.

[0266] The STING agonists of this disclosure may also be modified to increase or control agonist encapsulation in extracellular vesicles or exosomes. This modification may include the addition of lipid-binding tags by treating the agonist with a chemical or enzyme, or by physically or chemically altering the polarity or charge of the STING agonist. STING agonists can be modified by a single treatment or a combination of treatments, for example, by adding only lipid-binding tags, or by adding lipid-binding tags and altering polarity. The above examples are intended to be non-limiting and illustrative. Any combination of modifications is intended to be implementable in this disclosure. The modifications can increase or control agonist encapsulation in exosomes by 2- to 10,000-, 10- to 1,000-, or 100- to 500-fold compared to encapsulation of an unmodified agonist. Modification can increase agonist encapsulation in exosomes by at least 2x, 5x, 10x, 20x, 30x, 40x, 50x, 60x, 70x, 80x, 90x, 100x, 200x, 300x, 400x, 500x, 600x, 700x, 800x, 900x, 1000x, 2000x, 3000x, 4000x, 5000x, 6000x, 7000x, 8000x, 9000x, or 10,000x compared to encapsulation of unmodified agonists.

[0267] In some embodiments, one or more exogenous biological active moieties, e.g., adjuvants, are TLR agonists. Non-limiting examples of TLR agonists include TLR2 agonists (e.g., lipoteichoic acid, atypical LPS, MALP-2 and MALP-404, OspA, porin, LcrV, lipomannan, GPI anchor, lysophosphatidylserine, lipophosphoglycan (LPG), glycophosphatidylinositol (GPI)), zymosan, hsp60, gH / gL glycoprotein, hemagglutinin), and TLR3 agonists (e.g., two-pronged Examples include single-stranded RNA, e.g., poly(I:C)), TLR4 agonists (e.g., lipopolysaccharide (LPS), lipoteichoic acid, β-defensin 2, fibronectin EDA, HMGB1, snapin, tenascin C), TLR5 agonists (e.g., flagellin), TLR6 agonists, TLR7 / 8 agonists (e.g., single-stranded RNA, CpG-A, polyG10, polyG3, resikimod), TLR9 agonists (e.g., unmethylated CpG DNA), and combinations thereof. Non-restrictive examples of TLR agonists can be found in WO2008115319(A2), US20130202707(A1), US20120219615(A1), US20100029585(A1), WO2009030996(A1), WO2009088401(A2), and WO2011044246(A1), each of which is incorporated in its entirety by reference.

[0268] In some embodiments, one or more exogenous biologically active sites, such as adjuvants, are inflammatory mediators.

[0269] In some embodiments, the extracellular organism (EV) of this disclosure (e.g., exosome) may contain one or more exogenous biologically active moieties, such as immunomodulators. In certain embodiments, one or more immunomodulators are expressed in combination with other active biological molecules, such as those disclosed herein. In some embodiments, one or more immunomodulators may be expressed on a surface (e.g., outer or luminal surface) or in the lumen of the EV (e.g., exosome). Thus, in certain embodiments, one or more immunomodulators are ligated to a scaffold (e.g., scaffold X) on the outer surface of the EV (e.g., exosome) or on the luminal surface of the EV (e.g., exosome). In further embodiments, one or more immunomodulators are located within the lumen of the exosome (i.e., not ligated to scaffold X). In certain embodiments, the immunomodulators are polynucleotides. In some of these embodiments, polynucleotides include, but are not limited to, mRNA, miRNA, siRNA, antisense RNA, shRNA, lncRNA, and dsDNA. In some embodiments, the immunomodulator is a protein, peptide, glycolipid, or glycoprotein.

[0270] In some embodiments, the EV (e.g., exosome) formulated for the composition contains IL-12. In some embodiments, the EV (e.g., exosome) formulated for the composition contains CD40L. In some embodiments, the EV (e.g., exosome) formulated for the composition contains FLT3L. In some embodiments, the EV (e.g., exosome) formulated for the composition contains IL-12 and CD40L. In other embodiments, the EV (e.g., exosome) contains IL-12, CD40L, and FLT3L. In some embodiments, IL-12 contains an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, and at least about 99% identical to the amino acid sequence shown in SEQ ID NO: 11, 12, or 13 (Table 1A). In certain embodiments, IL-12 contains the amino acid sequence shown in SEQ ID NO: 11. In certain embodiments, IL-12 includes the amino acid sequence shown in SEQ ID NO: 12. In certain embodiments, IL-12 includes an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, and at least about 99% identical to the amino acid sequence shown in SEQ ID NO: 13. In certain embodiments, IL-12 includes the amino acid sequence shown in SEQ ID NO: 13. [Table 1]

[0271] In some embodiments, the IL-12 portion comprises the p35 polypeptide or a fragment thereof. In some embodiments, IL-12 comprises an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to SEQ ID NO: 11. In some embodiments, IL-12 comprises an amino acid sequence having at least about 90% sequence identity with respect to SEQ ID NO: 11. In some embodiments, IL-12 comprises an amino acid sequence having at least about 95% sequence identity with respect to SEQ ID NO: 11. In some embodiments, IL-12 comprises an amino acid sequence having at least about 96% sequence identity with respect to SEQ ID NO: 11. In some embodiments, IL-12 comprises an amino acid sequence having at least about 97% sequence identity with respect to SEQ ID NO: 11. In some embodiments, IL-12 contains an amino acid sequence having at least approximately 98% sequence identity with SEQ ID NO: 11. In some embodiments, IL-12 contains an amino acid sequence having at least approximately 99% sequence identity with SEQ ID NO: 11. In some embodiments, IL-12 contains the amino acid sequence shown in SEQ ID NO: 11. In some embodiments, the IL-12 portion does not contain the signal peptide (see Table 1A).

[0272] In some embodiments, the IL-12 portion comprises a p40 polypeptide or a fragment thereof. In some embodiments, IL-12 comprises an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to SEQ ID NO: 12. In some embodiments, IL-12 comprises an amino acid sequence having at least about 90% sequence identity with respect to SEQ ID NO: 12. In some embodiments, IL-12 comprises an amino acid sequence having at least about 95% sequence identity with respect to SEQ ID NO: 12. In some embodiments, IL-12 comprises an amino acid sequence having at least about 96% sequence identity with respect to SEQ ID NO: 12. In some embodiments, IL-12 comprises an amino acid sequence having at least about 97% sequence identity with respect to SEQ ID NO: 12. In some embodiments, IL-12 contains an amino acid sequence having at least approximately 98% sequence identity with SEQ ID NO: 12. In some embodiments, IL-12 contains an amino acid sequence having at least approximately 99% sequence identity with SEQ ID NO: 12. In some embodiments, IL-12 contains the amino acid sequence shown in SEQ ID NO: 3. In some embodiments, the IL-12 portion does not contain the signal peptide (see Table 1A).

[0273] In some embodiments, the IL-12 moiety comprises a p35 polypeptide or a fragment thereof and a p40 polypeptide or a fragment thereof. In some embodiments, the IL-12 moiety comprises a single polypeptide in which the p35 polypeptide or a fragment thereof is linked to the p40 polypeptide or a fragment thereof. In some embodiments, the p35 polypeptide or a fragment thereof is linked to the p40 polypeptide or a fragment thereof by a linker. In some embodiments, the linker is a peptide linker. In some embodiments, the linker comprises one or more amino acids. In some embodiments, the linker comprises a Gly-Ser (GS) linker. In some embodiments, the GS linker is (G4S) nThis includes, where n is an integer from 1 to 10. In some embodiments, the GS linker is (G3S) n This includes n, where n is an integer between 1 and 10.

[0274] In certain embodiments, the IL-12 portion includes an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with SEQ ID NO: 13. In some embodiments, IL-12 includes an amino acid sequence having at least about 90% sequence identity with SEQ ID NO: 13. In some embodiments, IL-12 includes an amino acid sequence having at least about 95% sequence identity with SEQ ID NO: 13. In some embodiments, IL-12 includes an amino acid sequence having at least about 96% sequence identity with SEQ ID NO: 13. In some embodiments, IL-12 includes an amino acid sequence having at least about 97% sequence identity with SEQ ID NO: 13. In some embodiments, IL-12 includes an amino acid sequence having at least about 98% sequence identity with SEQ ID NO: 13. In some embodiments, IL-12 contains an amino acid sequence having at least approximately 99% sequence identity with SEQ ID NO: 13. In some embodiments, IL-12 contains the amino acid sequence shown in SEQ ID NO: 13. In some embodiments, IL-12 consists of the amino acid sequence shown in SEQ ID NO: 13. In some embodiments, IL-12 essentially consists of the amino acid sequence shown in SEQ ID NO: 13. In some embodiments, the IL-12 portion does not contain the signal peptide (see Table 1A).

[0275] In some embodiments, the EV (e.g., exosome) formulated for the composition comprises an antisense oligonucleotide (ASO) containing a sequence of nucleotides 10 to 30 nucleotides in length that is complementary to the nucleic acid sequence in the STAT6 transcript (SEQ ID NO: 23; Table 1B). In some embodiments, the ASO comprises a nucleic acid sequence selected from SEQ ID NOs: 91 to 193. In some embodiments, the ASO comprises the nucleic acid sequence GAAAGGTTCCGTCGGGC (SEQ ID NO: 144). In some embodiments, the ASO comprises the nucleic acid sequence CTGAGTCGCTGAAGCGG (SEQ ID NO: 145). In some embodiments, the ASO comprises the nucleic acid sequence GCCCTTGTACTTTTGCATAG (SEQ ID NO: 193). In some embodiments, the ASO comprises the nucleic acid sequence GCAAGATCCCGGATTCGGTC (SEQ ID NO: 185). [Table 2-1] [Table 2-2]

[0276] IIIB. Scaffolding section, e.g., scaffolding X or scaffolding Y In some embodiments, the extracellular molecules (EVs) of this disclosure (e.g., exosomes) include membranes with modified compositions. For example, their membrane compositions can be modified by altering the protein, lipid, or glycan content of the membrane.

[0277] In some embodiments, surface-manipulated EVs (e.g., exosomes) are generated by chemical and / or physical methods such as PEG-induced fusion and / or sonication fusion. In other embodiments, surface-manipulated EVs, e.g., exosomes, are generated by genetic engineering. EVs (e.g., exosomes) produced from genetically modified producer cells or offspring of genetically modified cells may comprise a modified membrane composition. In some embodiments, surface-manipulated EVs (e.g., exosomes) have a higher or lower density (e.g., a larger number) of scaffolding portions (e.g., exosome proteins, e.g., scaffold X) or comprise variants or fragments of scaffolding portions.

[0278] For example, surface-manipulated (e.g., scaffold X) EVs may be produced from cells (e.g., HEK293 cells) or variants or fragments thereof transformed with an exogenous sequence encoding a scaffold portion (e.g., an exosome protein, e.g., scaffold X). EVs containing a scaffold portion expressed from an exogenous sequence may comprise a modified membrane composition.

[0279] Various modifications or fragments of the scaffold portion can be used in embodiments of this disclosure. For example, a scaffold portion modified to enhance affinity to a binder can be used to produce a surface-modified EV that can be purified using the binder. A scaffold portion modified to more effectively target the EV and / or membrane can be used. A scaffold portion modified to contain the minimum fragments necessary for specific and effective targeting of the exosome membrane can also be used.

[0280] Non-limiting examples of scaffold portions include the negative regulator of prostaglandin F2 receptors (PTGFRN), basidine (BSG), immunoglobulin superfamily member 2 (IGSF2), immunoglobulin superfamily member 3 (IGSF3), immunoglobulin superfamily member 8 (IGSF8), integrin beta-1 (ITGB1), integrin alpha-4 (ITGA4), 4F2 cell surface antigen heavy chain (SLC3A2), and classes of ATP transporter proteins (ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B). In certain embodiments, the scaffold portion is a complete protein. In other embodiments, the scaffold portion is a protein fragment (e.g., a functional fragment).

[0281] In other embodiments, the scaffold portions useful for the present invention include, but are not limited to, conventional exosomal proteins, tetraspanin molecules (e.g., CD63, CD81, CD9, etc.), lysosome-associated membrane proteins 2 (LAMP2 and LAMP2B), platelet-derived growth factor receptor (PDGFR), GPI-anchored proteins, lactoadherins and their fragments, peptides having affinity for any of these proteins or their fragments, or any combination thereof.

[0282] In some embodiments, the surface (e.g., scaffold X)-operated EVs described herein exhibit superior properties compared to EVs known in the art. For example, the surface (e.g., scaffold X)-operated EVs contain modified proteins that are more highly concentrated on the surface than naturally occurring EVs or EVs produced using conventional exosomal proteins. Furthermore, the surface (e.g., scaffold X)-operated EVs of this disclosure may have greater, more specific, or more controlled bioactivity compared to naturally occurring EVs or EVs produced using conventional exosomal proteins.

[0283] In some embodiments, scaffold X contains a negative regulator of the prostaglandin F2 receptor (PTGFRN polypeptide). The PTGFRN protein may also be referred to as CD9 partner 1 (CD9P-1), Glu-Trp-Ile EWI motif-containing protein F (EWI-F), prostaglandin F2 alpha receptor regulatory protein, prostaglandin F2 alpha receptor-related protein, or CD315. The full-length amino acid sequence of the human PTGFRN protein (Uniprot accession number Q9P2B2) is shown in Table 2 as SEQ ID NO: 1. The PTGFRN polypeptide includes a signal peptide (amino acids 1-25 of SEQ ID NO: 1), an extracellular domain (amino acids 26-832 of SEQ ID NO: 1), a transmembrane domain (amino acids 833-853 of SEQ ID NO: 1), and a cytoplasmic domain (amino acids 854-879 of SEQ ID NO: 1). The mature PTGFRN polypeptide consists of SEQ ID NO: 1 without the signal peptide, i.e., amino acids 26-879 of SEQ ID NO: 1. In some embodiments, a PTGFRN polypeptide fragment useful for the present disclosure comprises a transmembrane domain of a PTGFRN polypeptide. In other embodiments, a PTGFRN polypeptide fragment useful for the present disclosure comprises a transmembrane domain of a PTGFRN polypeptide and (i) at the N-terminus of the transmembrane domain at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150 amino acids, or (ii) at the C-terminus of the transmembrane domain at least 5, at least 10, at least 15, at least 20, or at least 25 amino acids, or both (i) and (ii).

[0284] In some embodiments, the PTGFRN polypeptide fragment lacks one or more functional or structural domains, such as IgV.

[0285] In other embodiments, scaffold X includes an amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to amino acids 26-879 of SEQ ID NO: 1. In other embodiments, scaffold X includes an amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 9. In other embodiments, scaffold X includes the amino acid sequence of SEQ ID NO: 9, excluding one, two, three, four, five, six, or seven amino acid mutations. Mutations may be substitutions, insertions, deletions, or any combination thereof. In some embodiments, scaffold X includes the amino acid sequence of SEQ ID NO: 9 and 1 amino acid, 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, 10 amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids or more at the N-terminus and / or C-terminus of SEQ ID NO: 9.

[0286] In other embodiments, scaffold X comprises an amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to sequence numbers 2, 3, 4, 5, 6, or 7. In other embodiments, scaffold X comprises the amino acid sequence of sequence numbers 2, 3, 4, 5, 6, or 7, excluding one, two, three, four, five, six, or seven amino acid mutations. Mutations may be substitutions, insertions, deletions, or any combination thereof. In some embodiments, scaffold X includes the amino acid sequence of SEQ ID NOs: 2, 3, 4, 5, 6, or 7, and 1 amino acid, 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, 10 amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids or more at the N-terminus and / or C-terminus of SEQ ID NOs: 2, 3, 4, 5, 6, or 7, and 20 amino acids or more. [Table 3-1] [Table 3-2] [Table 3-3]

[0287] Non-restrictive examples of other scaffold X proteins can be found in U.S. Patents 10,195,290(B1) and 10,561,740(B2), each of which is incorporated in whole by reference.

[0288] In some embodiments, the scaffold portion expressed in the EV is not fused to the payload, for example, the biologically active portion, for example, the STING agonist.

[0289] In some embodiments, scaffold X may be used to simultaneously ligate any portion to the luminal surface and / or outer surface of an EV (e.g., exosome). For example, a PTGFRN polypeptide can be used to ligate antigens, adjuvants, and / or immunomodulators in addition to the outer surface of the EV (e.g., exosome) to the luminal surface (e.g., on the luminal surface). Thus, in certain embodiments, scaffold X can be used for dual purposes, such as, for example, an antigen on the luminal surface and an adjuvant or immunomodulator on the outer surface of the EV (e.g., exosome), an antigen on the outer surface of the EV (e.g., exosome) and an adjuvant or immunomodulator on the luminal surface, an adjuvant on the luminal surface and an immunomodulator on the outer surface of the EV (e.g., exosome), or an immunomodulator on the luminal surface and an adjuvant on the outer surface of the EV (e.g., exosome).

[0290] In some embodiments, the scaffold protein comprises scaffold Y. Non-limiting examples of scaffold Y proteins that may be used in the compositions and methods disclosed herein include, for example, those scaffold Y proteins disclosed in International Publication Nos. WO / 2019 / 099942 or WO2020 / 101740. Each of these is incorporated herein in whole by reference. In some embodiments, the scaffold Y protein is selected from myristoylated alanine-rich protein kinase C substrate ("MARCKS protein"); myristoylated alanine-rich protein kinase C substrate-like 1 ("MARCKSL1 protein"); and brain acid-soluble protein 1 ("BASP1 protein"). In some embodiments, the scaffold Y protein may be a complete protein or a fragment thereof (e.g., a functional fragment, e.g., a minimal fragment that can fix any portion on the luminal surface of an EV (e.g., an exosome)). In some embodiments, the scaffold Y can fix any portion (e.g., a STING agonist and / or an IL-12 portion) to the lumen of an EV (e.g., an exosome).

[0291] IIIC. Fixing of the section In some embodiments, one or more payloads can be attached to the fixation portion. In some embodiments, fixation portions that can be used to attach payloads to the outer and / or luminal surface of an EV (e.g., exosome) include sterols (e.g., cholesterol), GM1, lipids (e.g., fatty acids), vitamins, small molecules, peptides, or combinations thereof.

[0292] In some embodiments, the immobilized portion is a lipid. The lipid immobilized portion may be any lipid known in the art, for example, palmitic acid or glycosylphosphatidylinositol. In some embodiments, the lipid is a fatty acid, phosphatidyl, phospholipid (e.g., phosphatidylcholine, phosphatidylserine, or phosphatidylethanolamine), or an analog thereof (e.g., phosphatidylcholine, lecithin, phosphatidylethanolamine, cephalin, or phosphatidylserine or an analog thereof, or a part thereof, for example, a partially hydrolyzed portion thereof).

[0293] Generally, the fixed portion is chemically attached. However, the fixed portion can also be enzymatically attached to the payload.

[0294] Several types of membrane anchors that can be used to carry out the methods of this disclosure are shown in the table below: [Table 4]

[0295] In some embodiments, the fixed portion of the present disclosure may include two or more types of fixed portions disclosed herein. For example, in some embodiments, the fixed portion may include two lipids, for example, a phospholipid and a fatty acid, or two phospholipids, or two fatty acids, or a lipid and a vitamin, or cholesterol and a vitamin.

[0296] In some embodiments, the immobilized portion useful to the disclosure includes sterols, steroids, hopanoids, hydroxysteroids, secosteroids, or lipophilic analogs thereof. In some embodiments, the immobilized portion includes sterols such as plant sterols, fungal sterols, or animal sterols. Exemplary animal sterols include cholesterol and 24S-hydroxycholesterol. Exemplary plant sterols include ergosterol (fungal sterol), campesterol, sitosterol, and stigmasterol. In some embodiments, the sterol is selected from ergosterol, 7-dehydrocholesterol, cholesterol, 24S-hydroxycholesterol, lanosterol, cycloartenol, fucosterol, salingosterol, campesterol, β-sitosterol, sitostanol, coprostanol, avenasterol, or stigmasterol. Sterols can be found as free sterols, acylated (sterol esters), alkylated (steryl alkyl ethers), sulfated (sterol sulfates), or linked to a glycoside moiety that can itself be acylated (steryl glycosides) (acylated sterol glycosides). In some embodiments, the fixed moiety is cholesterol.

[0297] In some embodiments, the fixed portion includes a steroid. In some embodiments, the steroid is selected from dihydrotestosterone, ubaol, hesigenin, diosgenin, progesterone, or cortisol.

[0298] In some embodiments, the fixed portion is a fatty acid. In some embodiments, the fatty acid is a short-chain, medium-chain, or long-chain fatty acid. In some embodiments, the fatty acid is a saturated fatty acid. In some embodiments, the fatty acid is an unsaturated fatty acid. In some embodiments, the fatty acid is a monounsaturated fatty acid. In some embodiments, the fatty acid is a polyunsaturated fatty acid, such as an omega-3 or omega-6 fatty acid.

[0299] In some embodiments, the fixed portion includes phospholipids. Phospholipids are a class of lipids that are the main components of all cell membranes. They can form lipid bilayers due to their amphiphilic characteristics. The structure of a phospholipid molecule generally consists of two hydrophobic fatty acid "tails" and a hydrophilic "head" consisting of a phosphate group. For example, a phospholipid may be the lipid shown in the following formula: [ka] In the formula, R p R1 represents the phospholipid portion, and R2 represents the fatty acid portions that may or may not be unsaturated, and may be the same or different.

[0300] In some embodiments, the payload is linked to the fixed portion disclosed herein via a combination of linkers (which may include any combination of cleavable and / or non-cleavable linkers). While not bound by any one theory, one function of the combination of linkers is to provide an optimal distance between the fixed portion and the payload.

[0301] IIID Linker As described above, the extracellular vesicles (EVs) (e.g., exosomes and nanovesicles) of this disclosure may include one or more linkers that ligate one or more exogenous biologically active moieties disclosed herein to the EV (e.g., the outer or luminal surface). In some embodiments, one or more exogenous biologically active moieties are ligated to the EV directly or via one or more scaffolding moieties (e.g., scaffold X). For example, in certain embodiments, one or more exogenous biologically active moieties are ligated to the outer surface of an exosome via scaffold X. In further embodiments, one or more exogenous biologically active moieties are ligated to the luminal surface of an exosome via scaffold X. The linkers may be any chemical moieties known in the art.

[0302] As used herein, the term “linker” refers to a peptide or polypeptide sequence (e.g., a synthetic peptide or polypeptide sequence) or a non-polypeptide, such as an alkyl chain. In some embodiments, two or more linkers can be linked in tandem. If multiple linkers are present, each linker may be the same or different. Generally, linkers provide flexibility or prevent / improve steric hindrance. Linkers are typically not cleaved. However, in certain embodiments, such cleavage may be desirable. Thus, in some embodiments, a linker may include one or more protease-cleavable sites that are located within the linker sequence or adjacent to the linker at either end of the linker sequence.

[0303] In some embodiments, the linker is a peptide linker. In some embodiments, the peptide linker may contain at least about 2, at least about 3, at least about 4, at least about 5, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, or at least about 100 amino acids.

[0304] In some embodiments, the peptide linker is synthetic, i.e., non-natural. In one embodiment, the peptide linker comprises a peptide (or polypeptide) (e.g., natural or non-natural peptide) having an amino acid sequence that links or genetically fuses a first linear sequence of amino acids to a second linear sequence of amino acids that are not naturally linked or are not originally genetically fused. For example, in one embodiment, the peptide linker may comprise a non-natural polypeptide (e.g., including mutations such as addition, substitution or deletion) that is a modified form of a natural polypeptide.

[0305] Linkers can be prone to cleavage ("cleavable linkers"), which promotes the release of exogenous biologically active sites.

[0306] In some embodiments, the linker is a "reduction-sensitive linker." In some embodiments, the reduction-sensitive linker contains a disulfide bond. In some embodiments, the linker is an "acid-unstable linker." In some embodiments, the acid-unstable linker contains a hydrazone. Suitable acid-unstable linkers also include, for example, cis-aconitate linkers, hydrazide linkers, thiocarbamoyl linkers, or any combination thereof.

[0307] In some embodiments, the ASO is associated with an EV (e.g., an exosome) via a linker. In some embodiments, the linker includes acrylphosphoramidite (e.g., ACRYDITE®), adenylation, azide (NHS ester), digoxigenin (NHS ester), cholesterol-TEG, I-LINKER®, aminomodifiers (e.g., aminomodifier C6, aminomodifier C12, aminomodifier C6 dT, or Uni-Link® aminomodifier), alkynes, 5'-hexynyl, 5-octadiinyl dU, biotinylation (e.g., biotin, biotin (azide), biotin dT, biotin-TEG, dual biotin, PC biotin, or desthiobiotin), thiol modification (thiol modifier C3 SS, dithiol or thiol modifier C6 SS), or any combination thereof.

[0308] In some embodiments, the linker includes terpenes such as nerolidol, farnesol, limonene, linalool, geraniol, carvone, fencone, or menthol; lipids such as palmitic acid or myristic acid; cholesterol; oleyl; retinyl; cholesteryl residues; cholic acid; adamantane acetate; 1-pyrene butyrate; dihydrotestosterone; 1,3-bis-O(hexadecyl)glycerol; geranyloxyhexyl group; hexadecylglycerol; borneol; 1,3-propanediol; heptadecyl group; O3-(oleoyl)lithocholic acid; O3-(oleoyl)cholenic acid; dimethoxytrityl; phenoxazine, maleimide moiety, glucolinidase type, CL2A-SN38 type, folic acid; carbohydrates; vitamin A; vitamin E; vitamin K; or any combination thereof. In certain embodiments, the ASO includes a cholesterol tag, which associates with the membrane of an EV (e.g., an exosome). In some embodiments, the linker includes a non-cleavable linker.

[0309] In some embodiments, the linker comprises tetraethylene glycol (TEG), hexaethylene glycol (HEG), polyethylene glycol (PEG), succinimide, or any combination thereof. In some embodiments, the linker comprises spacer units for linking biologically active molecules to the linker.

[0310] In some embodiments, one or more linkers include smaller units linked together (e.g., HEG, TEG, glycerol, C2-C12 alkyl, etc.). In one embodiment, the linkage is an ester linkage (e.g., a phosphodiester or phosphorothioate ester) or other linkage.

[0311] In some embodiments, the linker is given by formula R 3 -(O-CH2-CH2) n - or R 3 -(O-CH2-CH2) n Contains polyethylene glycol (PEG) characterized by -O-, R 3n is hydrogen, methyl, or ethyl, and n has a value of 2 to 200. In some embodiments, the linker includes a spacer, and the spacer is PEG.

[0312] In some embodiments, the PEG linker is an oligoethylene glycol, such as diethylene glycol, triethylene glycol, tetraethylene glycol (TEG), pentaethylene glycol, or hexaethylene glycol (HEG) linker.

[0313] IV. Treatment Methods Further considerations include the administration of the pharmaceutical compositions of this disclosure to treat multiple diseases or conditions in which the administration of EVs results in beneficial effects on the subject. In some embodiments, a method of treating a disease or condition in a subject disclosed herein includes administering the pharmaceutical composition to the subject.

[0314] In some embodiments, the Disclosure provides compositions that can be administered by parenteral, topical, intravenous, oral, subcutaneous, intra-arterial, intradermal, transdermal, intrarectal, intracranial, intraperitoneal, intranasal, intratumoral, intramuscular routes, or as inhalants. In some embodiments, pharmaceutical compositions containing EVs are administered intravenously, for example, by injection. For transmucosal or transdermal administration, a penetrating agent suitable for the penetration barrier is used in the formulation. Such penetrating agents are generally known in the art and include, for example, surfactants, bile salts, and fusidic acid derivatives for transmucosal administration. Transmucosal administration can be achieved, for example, through the use of nasal sprays or suppositories. For transdermal administration, the modified exosomes are formulated into ointments, plasters, gels, or creams, as is generally known in the art.

[0315] In some embodiments, EV is administered intravenously into the circulatory system of the subject. In some embodiments, EV is infused into a suitable fluid and administered intravenously to the subject. In some embodiments, EV is administered intra-arterially into the circulatory system of the subject. In some embodiments, EV is infused into a suitable fluid and administered into the artery of the subject. In some embodiments, EV is administered to the subject by intrathecal administration. In some embodiments, EV is administered via injection into the spinal canal or subarachnoid space so that it reaches the cerebrospinal fluid (CSF). In some embodiments, EV is administered intratumorally into one or more tumors of the subject. In some embodiments, EV is administered to the subject by intranasal administration. In some embodiments, EV can be blown through the nose in either a local or systemic form. In certain embodiments, EV is administered as a nasal spray.

[0316] In some embodiments, EV is administered to the subject by intraperitoneal administration. In some embodiments, EV is infused into a suitable fluid and administered into the peritoneal cavity of the subject. In some embodiments, intraperitoneal administration results in the distribution of EV to the lymphatic vessels. In some embodiments, intraperitoneal administration results in the distribution of EV to the thymus, spleen, and / or bone marrow. In some embodiments, intraperitoneal administration results in the distribution of EV to one or more lymph nodes. In some embodiments, intraperitoneal administration results in the distribution of EV to one or more of the cervical lymph nodes, inguinal lymph nodes, mediastinal lymph nodes, or sternal lymph nodes. In some embodiments, intraperitoneal administration results in the distribution of EV to the pancreas.

[0317] In some embodiments, EV (e.g., exosomes) are administered to the subject by periocular administration. In some embodiments, s is injected into the periocular tissue. Periocular drug administration includes subconjunctival, anterior sub-Tenon's capsule, posterior sub-Tenon's capsule, and postocular administration routes.

[0318] In some embodiments, the treatment is preventive. In some embodiments, the EV for this disclosure is used to induce an immune response. In some embodiments, the EV for this disclosure is used to vaccinate a subject.

[0319] In some embodiments, the diseases or conditions include cancer, fibrosis, hemophilia, diabetes mellitus, growth factor deficiency, eye diseases, Pompe disease, lysosomal storage disorders, mucobicidosis, cystic fibrosis, Duchenne and Becker muscular dystrophy, trans-tyretin amyloidosis, hemophilia A, hemophilia B, adenosine deaminase deficiency, Lieber congenital amaurosis, X-linked adrenal leukemia, metachromatic leukodystrophy, OTC deficiency, glycogen storage disease 1A, Crigler-Nadjar syndrome, primary hyperoxalateuria type 1, acute intermittent porphyria, phenylketonuria, familial hypercholesterolemia, mucopolysaccharidosis type VI, α1 antitrypsin deficiency, and hypercholesterolemia.

[0320] In some embodiments, the disease or disorder is a graft-versus-host disease (GvHD). In some embodiments, the disease or disorder that can be treated in this disclosure is an autoimmune disease. Non-limiting examples of autoimmune diseases include multiple sclerosis, peripheral neuritis, Sjögren's syndrome, rheumatoid arthritis, alopecia, autoimmune pancreatitis, Behçet's disease, bullous pemphigoid, celiac disease, Devic's disease (neuromyelitis optica), glomerulonephritis, IgA nephropathy, various vasculitises, scleroderma, diabetes mellitus, arthritis, vitiligo, ulcerative colitis, irritant bowel syndrome, psoriasis, uveitis, systemic lupus erythematosus, and combinations thereof.

[0321] In some embodiments, the disease or disorder is an infectious disease. In certain embodiments, the disease or disorder is a carcinogenic virus. In some embodiments, the infectious diseases treatable by this disclosure include, but are not limited to, human-to-human gamma herpesvirus 4 (Epstein-Barr virus), influenza A virus, influenza B virus, cytomegalovirus, staphylococcus aureus, mycobacterium tuberculosis, chlamydia trachomatis, HIV-1, HIV-2, coronaviruses (e.g., MERS-CoV and SARS-CoV), filoviruses (e.g., Marburg and Ebola), Streptococcus pyogenes, Streptococcus pneumoniae, Plasmodia species (e.g., vivax and falciparum), Chikungunya virus, human papillomavirus (HPV), hepatitis B, hepatitis C, human herpesvirus 8, herpes simplex virus 2 (HSV2), Klebsiella sp., Pseudomonas aeruginosa, Enterococcus sp., Proteus sp., Enterobacter sp., and Actinobacter. Examples include sp., coagulase-negative staphylococci (CoNS), Mycoplasma sp., or combinations thereof.

[0322] In some embodiments, cancer is bladder cancer, cervical cancer, renal cell carcinoma, testicular cancer, colorectal cancer, lung cancer, head and neck cancer, ovarian cancer, lymphoma, liver cancer, glioblastoma, melanoma, myeloma, leukemia, pancreatic cancer, or a combination thereof.

[0323] In certain embodiments, cancer is associated with increased expression of the STAT6 protein. Non-limiting examples of cancers that can be treated in this disclosure include colorectal cancer, lung cancer (e.g., non-small cell lung cancer (NSCLC)), pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), leukemia, uterine cancer, ovarian cancer, bladder cancer, bile duct cancer, gastric cancer, or any combination thereof. In some embodiments, cancer is selected from colorectal adenocarcinoma, rectal adenocarcinoma, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma (PDAC), ovarian serous cystadenocarcinoma, acute myeloid leukemia, testicular cancer (e.g., testicular germ cell tumor, seminoma, non-seminoma, and choroidal cancer), lung adenocarcinoma, low-grade brain glioma, glioblastoma multiforme, uveal melanoma, thyroid cancer, endometrial cancer, uterine carcinosarcoma, pheochromocytoma, paraganglioma, and any combination thereof. In certain embodiments, cancer is myeloid-rich cancer. In some embodiments, cancer includes liver cancer. In some embodiments, cancer includes hepatocellular carcinoma (HCC). In some embodiments, cancer includes pancreatic ductal adenocarcinoma (PDAC), and in some embodiments, cancer includes colorectal cancer (CRC). In some embodiments, cancer includes ovarian cancer. In some embodiments, cancer includes leptomeningeal carcinoma.

[0324] When administered to a subject with cancer, in certain embodiments, the EVs of this disclosure can upregulate the immune response and enhance the tumor targeting of the subject's immune system. In some embodiments, the cancer to be treated is characterized by the infiltration of leukocytes (T cells, B cells, macrophages, dendritic cells, monocytes) into the tumor microenvironment, i.e., a so-called "hot tumor" or "inflammatory tumor." In some embodiments, the cancer to be treated is characterized by low or undetectable levels of leukocyte infiltration into the tumor microenvironment, i.e., a so-called "cold tumor" or "non-inflammatory tumor." In some embodiments, the EVs are administered in amounts and for a duration sufficient to convert the "cold tumor" into a "hot tumor," i.e., the administration results in the infiltration of leukocytes (such as T cells) into the tumor microenvironment. In certain embodiments, cancer includes bladder cancer, cervical cancer, renal cell carcinoma, testicular cancer, colorectal cancer, lung cancer, head and neck cancer, and ovarian cancer, lymphoma, liver cancer, glioblastoma, melanoma, myeloma, leukemia, pancreatic cancer, or combinations thereof. In other terms, “distal tumor” or “distant tumor” means a tumor that has spread to an organ or tissue distant from the original (i.e., primary) tumor, such as lymph nodes. In some embodiments, the EVs of this disclosure treat the tumor after metastatic spread.

[0325] V. Methods for producing manipulated exosomes The extracellular molecules (EVs) of this disclosure (e.g., exosomes) can be produced from cells grown in vitro or in the body fluid of the subject. When exosomes are produced from in vitro cell culture, various producer cells can be used.

[0326] In some embodiments, the producer cell may be a mammalian cell line, plant cell line, insect cell line, fungal cell line, or prokaryotic cell line. In certain embodiments, the producer cell is a mammalian cell line. Non-limiting examples of mammalian cell lines include: human fetal kidney (HEK) cell line, Chinese hamster ovary (CHO) cell line, HT-1080 cell line, HeLa cell line, PERC-6 cell line, CEVEC cell line, fibroblast cell line, amniotic cell line, epithelial cell line, mesenchymal stem cell (MSC) cell line, and combinations thereof. In certain embodiments, the mammalian cell line may include HEK-293 cells, BJ human precipitous fibroblasts, fHDF fibroblasts, AGE.HN® neural progenitor cells, CAP® amniotic cells, adipose mesenchymal stem cells, or RPTEC / TERT1 cells, or combinations thereof. In some embodiments, the producer cell is a primary cell. In certain embodiments, primary cells may be primary mammalian cells, primary plant cells, primary insect cells, primary fungal cells, or primary prokaryotic cells.

[0327] In some embodiments, producer cells are not immune cells such as antigen-presenting cells, T cells, B cells, natural killer cells (NK cells), macrophages, T helper cells, or regulatory T cells (Treg cells). In other embodiments, producer cells are not antigen-presenting cells (e.g., dendritic cells, macrophages, B cells, mast cells, neutrophils, Kupffer-Browitz cells, or cells derived from any of such cells).

[0328] Producer cells can be genetically modified to include one or more exogenous sequences (e.g., one or more exogenous biologically active moieties disclosed herein, e.g., immunomodulators, e.g., IL-12, or ASOs, e.g., STAT6 ASO) in order to produce the exosomes described herein. Genetically modified producer cells may contain the exogenous sequences by transient or stable transformation. The exogenous sequences can be transformed as plasmids. The exogenous sequences can be stably incorporated into the genomic sequence of producer cells at a target site or a random site. In some embodiments, a stable cell line is generated for the production of EVs (e.g., exosomes) disclosed herein.

[0329] Exogenous sequences can be inserted into the genome sequence of producer cells located upstream (5' end) or downstream (3' end) of endogenous sequences encoding exosomal proteins. Various methods known in the art can be used to introduce exogenous sequences into producer cells. For example, cells modified using various gene editing methods (e.g., homologous recombination, transposon-mediated systems, loxP-Cre systems, CRISPR / Cas9, or TALEN) are within the scope of this disclosure.

[0330] The exogenous sequence may include a sequence encoding a scaffold portion or a fragment or variant thereof disclosed herein. Additional copies of the sequence encoding the scaffold portion can be introduced to produce exosomes described herein (e.g., having a higher density of scaffold portions on the surface or luminal surface of EVs (e.g., exosomes), or expressing multiple different scaffold portions thereon). Exogenous sequences encoding modifications or fragments of the scaffold portion can be introduced to generate luminal and / or surface-manipulated exosomes containing the modifications or fragments of the scaffold portion.

[0331] In some embodiments, producer cells can be modified, for example, transfected, with one or more vectors encoding one or more scaffold portions linked to the exogenous biologically active portion described herein.

[0332] VI. Method for producing an EV with a payload How to load a VIA payload The payload, e.g., a biologically active moiety, e.g., a STING agonist, can be encapsulated in an EV (e.g., an exosome) via any suitable technique known in the art. All known methods for loading biomolecules into EVs (e.g., exosomes) are considered suitable for use herein. Such techniques include passive diffusion, electroporation, chemical or polymeric transfection, viral transduction, mechanical membrane disruption or mechanical shearing, or any combination thereof. The payload, e.g., a biologically active moiety, e.g., a STING agonist, and the EV (e.g., an exosome) can be incubated in a suitable buffer during encapsulation.

[0333] In one embodiment, the biologically active moiety, e.g., a STING agonist, is encapsulated by an extracellular matrix (EV) (e.g., an exosome) by passive diffusion. The biologically active moiety, e.g., a STING agonist, and the EV (e.g., an exosome) are mixed together and incubated for a sufficient time for the biologically active moiety, e.g., a STING agonist, to diffuse through the vesicular lipid bilayer, thereby enabling encapsulation by the EV, e.g., an exosome. The biologically active moiety, e.g., a STING agonist, and the EV (e.g., an exosome) can be incubated together for approximately 1–30 hours, 2–24 hours, 4–18 hours, 6–16 hours, 8–14 hours, 10–12 hours, 6–12 hours, 12–20 hours, 14–18 hours, or 20–30 hours. STING agonists and EVs (e.g., exosomes) can be incubated together for approximately 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, or 30 hours.

[0334] The buffering conditions of the EV (e.g., exosome) solution may also be modified to increase or control the encapsulation of the biologically active moiety, e.g., STING agonists. In one embodiment, the buffer may be phosphate-buffered saline (PBS) containing sucrose. Additional buffer modifiers may also be used, such as shear protectants, viscosity modifiers, and / or solutes that affect the structural properties of the vesicles. Excipients such as membrane softeners and molecular densifiers may also be added to improve the efficiency of encapsulation of the biologically active moiety, e.g., STING agonists. Other buffer modifiers may include any combination of the above, such as salts, organic solvents, small molecules, surfactants, amphoteric ions, amino acids, polymers, and / or multiple concentrations in specific pH ranges and / or concentrations.

[0335] The encapsulation of the biologically active site can be increased or controlled by changing the temperature of the solution of EVs (e.g., exosomes) and the biologically active site, e.g., STING agonist, during incubation. The temperature may be room temperature. The temperature may be about 15°C to 90°C, 15 to 30°C, 30 to 50°C, or 50 to 90°C. In some embodiments, the temperature is about 15°C, 20°C, 35°C, 30°C, 35°C, 37°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, or 90°C.

[0336] The concentration of the biologically active moiety, e.g., STING agonist, during incubation with EVs (e.g., exosomes) can also be modified to increase or control the encapsulation of the biologically active moiety, e.g., STING agonist. For example, the concentration of the biologically active moiety, e.g., STING agonist, may be at least 0.01 mM to 100 mM of STING agonist. The concentration of the biologically active moiety, e.g., STING agonist, may be at least 0.01 to 1 mM, 1 to 10 mM, 10 to 50 mM, or 50 to 100 mM. The agonist concentration should be at least 0.01mM, 0.02mM, 0.03mM, 0.04mM, 0.05mM, 0.06mM, 0.07mM, 0.08mM, 0.09mM, 0.1mM, 0.2mM, 0.3mM, 0.4mM, 0.5mM, 0.6mM, 0.7mM, 0.8mM, 0.9mM, 1 The concentration may be mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 15 mM, 20 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, or 100 mM. In some embodiments, the concentration of the biologically active moiety, for example, the STING agonist, is at least about 1 mM.

[0337] In some embodiments, the biologically active moiety, for example, the STING agonist, is incubated in a mixture at a concentration of at least about 500 μM, at least about 600 μM, at least about 700 μM, at least about 800 μM, at least about 900 μM, at least about 1000 μM, at least about 1100 μM, at least about 1200 μM, at least about 1300 μM, at least about 1400 μM, at least about 1500 μM, at least about 1600 μM, at least about 1700 μM, at least about 1800 μM, at least about 1900 μM, or at least about 2000 μM. In some embodiments, the CDN is incubated in the mixture at concentrations of at least about 2500 μM, at least about 2600 μM, at least about 2700 μM, at least about 2800 μM, at least about 2900 μM, at least about 3000 μM, at least about 3100 μM, at least about 3200 μM, at least about 3300 μM, at least about 3400 μM, at least about 3500 μM, at least about 3600 μM, at least about 3700 μM, at least about 3800 μM, at least about 3900 μM, or at least about 3000 μM.

[0338] In some embodiments, the biologically active moiety, for example, the STING agonist, is incubated in a mixture at concentrations of approximately 500 μM to 100 mM, approximately 500 μM to 90 mM, approximately 500 μM to 80 mM, approximately 500 μM to 70 mM, approximately 500 μM to 60 mM, approximately 500 μM to 50 mM, approximately 500 μM to 40 mM, approximately 500 μM to 30 mM, approximately 500 μM to 20 mM, approximately 500 μM to 10 mM, or approximately 500 μM to 1 mM. In some embodiments, the biologically active moiety, for example, the STING agonist, is incubated in a mixture at concentrations of approximately 500 μM to 10 mM, approximately 500 μM to 9 mM, approximately 500 μM to 8 mM, approximately 500 μM to 7 mM, approximately 500 μM to 6 mM, approximately 500 μM to 5 mM, approximately 500 μM to 4 mM, approximately 500 μM to 3 mM, approximately 500 μM to 2 mM, or approximately 500 μM to 1 mM.

[0339] The number of extracellular particles incubated with a biologically active moiety, such as a STING agonist, can also be modified to increase or control encapsulation of the biologically active moiety, such as a STING agonist. The number of purified EV (e.g., exosome) particles is at least about 10 6 ~ at least about 10 20 and can be. The number of purified particles is about 10 of the total particles of the purified vesicles 8 ~ 10 18 、10 10 ~ 10 16 、10 8 ~ 10 14 、or 10 10 ~ 10 12 and can be. The number of purified particles is at least about 10 of the total particles of the purified vesicles 6 、10 8 、10 10 、10 12 、10 14 、10 16 、10 18 [[ID=३4]]、or 10 20 and can be.

[0340] Method for purifying VIB.EV EVs (e.g., exosomes) prepared for this disclosure can be isolated from producer cells. All known methods of isolating EVs (e.g., exosomes) are intended to be suitable for use herein. For example, the physical properties of EVs (e.g., exosomes) can be employed to separate them from culture media or other source materials, including separation based on charge (e.g., electrophoretic separation), size (e.g., filtration, molecular sieving, etc.), density (e.g., conventional centrifugation or gradient centrifugation), and Svedberg constant (e.g., sedimentation with or without external force, etc.). Alternatively or additionally, isolation may be based on one or more biological properties and may include methods that utilize surface markers (e.g., precipitation, reversible binding to a solid phase, FACS separation, specific ligand binding, nonspecific ligand binding, etc.). In further intended methods, EVs (e.g., exosomes) may also be fused using chemical and / or physical methods, such as PEG-induced fusion and / or sonication fusion.

[0341] Prior to formulation, the extracellular matrix (EVs), e.g., exosomes, may be purified after incubation with a biologically active moiety, e.g., a STING agonist, to remove the free, unencapsulated biologically active moiety, e.g., the STING agonist, from the composition. All previously disclosed methods, including separation based on the physical or biological properties of the EVs (EVs), e.g., exosomes, are also considered suitable for use herein.

[0342] Isolation, purification, and concentration may be carried out in a general and non-selective manner (typically involving serial centrifugation). Alternatively, isolation, purification, and concentration may be carried out in a more specific and selective manner (e.g., using producer cell-specific surface markers). For example, specific surface markers may be used in bead-bound ligands for immunoprecipitation, FACS sorting, affinity purification, and magnetic separation.

[0343] In some embodiments, size exclusion chromatography may be used to isolate or purify extracellular molecules (e.g., exosomes). Size exclusion chromatography techniques are known in the art. Exemplary and non-limiting techniques are provided herein. In some embodiments, a void volume fraction is isolated and contains the EVs of interest (e.g., exosomes). In some embodiments, the EVs can be further isolated, for example, by density gradient centrifugation. Furthermore, in some embodiments, it may be desirable to further separate producer cell-derived EVs (e.g., exosomes) from EVs of other origins. For example, producer cell-derived EVs (e.g., exosomes) can be separated from non-producer cell-derived EVs (e.g., exosomes) by immunoadsorption using antigen antibodies specific to producer cells.

[0344] In some embodiments, isolation of extracellular molecules (e.g., exosomes) may involve size exclusion chromatography or ion chromatography, such as anion exchange, cation exchange, or mixed-mode chromatography. In some embodiments, isolation of extracellular molecules (e.g., exosomes) may involve desalting, dialysis, tangential flow filtration, ultrafiltration, or diafiltration, or any combination thereof. In some embodiments, isolation of extracellular molecules (e.g., exosomes) may involve a combination of methods, including but not limited to differential centrifugation, size-based membrane filtration, and concentration and / or speed zone centrifugation. In some embodiments, isolation of extracellular molecules (e.g., exosomes) may involve one or more centrifugation steps. Centrifugation may be performed at approximately 50,000 to 150,000 xg. Centrifugation may be performed at approximately 50,000 xg, 75,000 xg, 100,000 xg, 125,000 xg, or 150,000 xg.

[0345] EVs (e.g., exosomes) prepared for this disclosure can be isolated by multimodal chromatography. The method of this disclosure is useful for preparing compositions comprising extracellular vesicles that associate with a biologically active moiety, e.g., a STING agonist, e.g., one or more cyclic dinucleotides (CDNs, e.g., STING agonists), the method comprising incubating the extracellular vesicles with a biologically active moiety, e.g., a STING agonist, e.g., one or more cyclic dinucleotides (CDNs) in a mixture, and separating the extracellular vesicles using multimodal chromatography.

[0346] Multimodal chromatography can be used to remove free biologically active moieties, such as STING agonists, from EV preparations. All known methods of isolating EVs (e.g., exosomes) are intended to be suitable for use herein. For example, the physical properties of EVs (e.g., exosomes) can be employed to separate them from culture media or other source materials, including separation based on charge (e.g., electrophoretic separation), size (e.g., filtration, molecular sieving, etc.), density (e.g., conventional centrifugation or gradient centrifugation), and Svedberg constant (e.g., sedimentation with or without external force, etc.). Alternatively or additionally, isolation may be based on one or more biological properties and may include methods that utilize surface markers (e.g., precipitation, reversible binding to solid phase, FACS separation, specific ligand binding, nonspecific ligand binding, etc.). In further intended methods, EVs (e.g., exosomes) may also be fused using chemical and / or physical methods, such as PEG-induced fusion and / or sonication fusion. In some embodiments, the multimodal column is selected from the group including CaptoCore 700, Capto MMC, or Capto MMC ImpRes. In some embodiments, the multimodal column is Captocore 700. In some embodiments, the multimodal column is Captocore MMC. In some embodiments, the multimodal column is Capto MMC ImpRes.

[0347] All references cited above, and all references cited herein, are incorporated herein by reference in their entirety.

[0348] The following examples are provided for illustrative purposes only and are not intended to be limiting. [Examples]

[0349] The present disclosure will be further illustrated by the following examples. These examples are provided for illustrative purposes only and are not intended to limit the scope or content of the present invention. Unless otherwise indicated, the implementation of the present disclosure will employ conventional methods of protein chemistry, biochemistry, recombinant DNA techniques and pharmacology within the art. Such techniques are fully described in the literature. See, for example, TECreighton, Proteins: Structures and Molecular Properties (WH Freeman and Company, 1993); Green & Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th Edition (Cold Spring Harbor Laboratory Press, 2012); Colowick & Kaplan, Methods In Enzymology (Academic Press); Remington: The Science and Practice of Pharmacy, 22nd Edition (Pharmaceutical Press, 2012); Sundberg & Carey, Advanced Organic Chemistry: Parts A and B, 5th Edition (Springer, 2007).

[0350] Example 1: Evaluation of the stability of natural and protein X exosomes The stability of native exosomes and protein X-containing exosomes was evaluated under different pH conditions. The chosen evaluation approach for assessing stability was to monitor size and surface charge via dynamic light scattering and zeta potential analysis.

[0351] material Exosomes from native human embryonic kidney (HEK) cells were manipulated and prepared to approximately 5E12 in Milli-Q ultrapure water. Protein X extracellular vesicles (CB-101) were manipulated and prepared to approximately 5E12 P / mL in phosphate-buffered saline. Calcium or magnesium-free Gibco phosphate-buffered saline pH 7.2 was purchased (PN 20012027, Thermo Fisher Scientific, Waltham, MA). Sterile microcentrifuge tubes (1.5 mL, low retention) were purchased (PN 3451, Thermo Fisher Scientific, Waltham, MA). Additional materials included citrate (PN C2404, Sigma-Aldrich, St. Louis, MO), sodium citrate dihydrate (PN BP327, Fisher Scientific, Waltham, MA), and carbonate-bicarbonate buffer (PN C3041, Sigma-Aldrich, St. Louis, MO).

[0352] Phosphate Two solids (83.01 g Na2HPO4 / 2 = 41.51 g and 12.29 g KH2PO4 / 2 = 6.15 g) were added to a beaker and dissolved in 400 mL of Milli-Q water. The pH was adjusted to 7.4 with 1 M HCl or 1 M NaOH as needed. The solution was brought to 500 mL in a graduated cylinder and filtered using a 0.2 μm filter flask. The solution was transferred to a 50 mL centrifuge tube and stored at 4°C in a safety cabinet. KH2PO4 (catalog number 3248-01, lot number 0000163254) and Na2HPO47H2O (catalog number 3817-01, lot number 0000201905) were purchased from JT Baker (Fisher Scientific, Waltham, MA).

[0353] Dynamic light scattering (DLS) DLS was used to measure EV aggregation; that is, DLS is a stability assay. Each sample was prepared and performed using the following method.

[0354] Samples were run on a Malvern Zetasizer Nano ZS dynamic light scattering (DLS) instrument, model ZEN3600, serial number MAL1036117 (Malvern, Worcestershire, UK), and analyzed with Malvern Zetasizer software version 7.13 (Malvern Panalytical). Malvern DLS microcuvets and cap kits (PN ZEN0040) and zeta potential cuvettes (PN DTS1070) were purchased (Malvern, Worcestershire, UK). Exosomes were diluted from 1E11 P / mL to 1E12 P / mL in Gibco PBS 1X pH 7.2. Samples were measured using a small amount of Malvern cuvette (PN ZEN0040), equilibrated at 25°C for 4 minutes, and measured three times. For each EV sample, 20 μL of the sample was diluted in 180 μL of filtered Gibco PBS in a microcuvete, mixed by repeated pipetting, and measured.

[0355] The experiments described here used the following NIST polystyrene size standards from Polysciences Inc. [Table 5]

[0356] Visual inspection Each sample was tested against matte white and matte black backgrounds for at least 5 seconds on each surface. The tubes were gently agitated by hand to disperse any potential precipitates, and visible particles were examined using a Maglite Mini LED flashlight and a 5x magnifying glass. pH was measured using an Oakton Cole-Parmer pH Spear waterproof pocket pH Tester (Cole-Parmer, Vernon Hills, IL).

[0357] Test design The test design investigated pH values ​​of 3, 5, 7, 9, and 11. Measurements were performed immediately after pH adjustment. Concentrated solutions of natural and protein X exosomes were prepared in either MilliQ water or PBS, diluted with MilliQ water in an appropriate buffer, and / or adjusted to the correct pH at ambient laboratory temperature before the start of the test (Figure 2D). Citrate buffer was used for acidic pH, phosphate buffer for neutral pH, and sodium carbonate buffer for basic pH. The target osmotic pressure was 300 mOsm / kg. EV20 μL of 1E11–1E12 P / mL was used for DLS and zeta measurements. The result data for natural and protein X exosomes are shown in Tables 2, 3, and 4 below. [Table 6] [Table 7-1] [Table 7-2]

[0358] These data were generated by dialyzing the salt and then dispersing it in the associated buffer at the desired pH. It was observed that the presence of PBS protected exosomes from aggregation over a wider pH range. The results shown in the table above are presented as Figure 2A. [Table 8]

[0359] The results shown in Table 5 are also presented graphically as Figure 1B.

[0360] Example 2: Formulation of Buffer A Exosome buffer A for storing and administering EVs was prepared as follows. The EVs formulated for buffer A were engineered to express the PTGFRN protein.

[0361] To adjust the pH, 50 mL of 1N sodium hydroxide and 50 mL of 1N hydrochloric acid were prepared. 0.8 L of sterile water for injection was added to a 1 L beaker equipped with a stirring rod. While stirring with a stirring plate (not heated), the following components were added: (a) 50.00 g sucrose, (b) 0.70 g monobasic potassium phosphate, (c) 4.00 g dibasic sodium phosphate heptahydrate, and (d) 2.90 g sodium chloride. The pH was not adjusted until all the powder was dissolved. If the powder did not dissolve, the mixing rate was increased. Next, the pH was adjusted to 7.1–7.3. If the pH was above 7.3, it was adjusted using 1N hydrochloric acid. If the pH was below 7.1, it was adjusted using 1N sodium hydroxide. The solution was poured into a 1 L graduated cylinder. Sterile water for injection was added to make a total volume of 1 L. The pH and conductivity were recorded. The target pH was 7.1–7.3. The target conductivity is 6.5 ± 10% to 8.0 ± 10% mS / cm. Next, the solution was filtered and sterilized using a 0.2 μm bottle-top filter (catalog number 567-0020, Thermo Fisher Scientific, Waltham, MA). The final formulation of buffer A is shown in Table 6 below. [Table 9]

[0362] Example 3: Formulation of Buffer B Exosome buffer B for storing and administering EVs was prepared as follows. The EVs formulated for buffer B were modified to express the PTGFRN protein and further contain CL656.

[0363] To adjust the pH, 50 mL of 1N sodium hydroxide and 50 mL of 1N hydrochloric acid were prepared. 0.8 L of sterile water for injection was added to a 1 L beaker equipped with a stirring rod. While stirring with a stirring plate (not heated), the following components were added: (a) 50.00 g sucrose, (b) 2.10 g monobasic potassium phosphate, (c) 7.26 g dibasic sodium phosphate heptahydrate, and (d) 2.34 g sodium chloride. The pH was not adjusted until all the powder was dissolved. If the powder did not dissolve, the mixing rate was increased. Next, the pH was adjusted to 7.1–7.3. If the pH was above 7.3, it was adjusted using 1N hydrochloric acid. If the pH was below 7.1, it was adjusted using 1N sodium hydroxide. The solution was poured into a 1 L graduated cylinder. Sterile water for injection was added to make a total volume of 1 L. The pH and conductivity were recorded. The target pH was 7.1–7.3. The target conductivity is 6.5–8.0 mS / cm. Next, the solution was filtered and sterilized using a 0.2 μm bottle-top filter (catalog number 567-0020, Thermo Fisher Scientific, Waltham, MA). The final formulation of buffer solution B is shown in Table 7 below. [Table 10]

[0364] Example 4: Formulation of Buffer C Exosome buffer C was prepared according to the formulation shown in Table 8 below. EVs were engineered to express PTGFRN proteins fused to IL-12. [Table 11]

[0365] Example 5: Distribution of STING agonist concentrations in exosomes and supernatant over time. The distribution of the biologically active portion, i.e., the STING agonist, in the exosomes and supernatant was investigated using equilibration tests.

[0366] When present in exosomes, the biologically active portion (Figure 1A), such as a STING agonist, can be passively diffused from the exosome to the supernatant over time (Figures 4A-4C). The distribution of STING agonists in exosomes and supernatant was confirmed by calculating the concentration of STING agonists over time. Briefly, STING agonists were loaded into exosomes and stored in buffer B. The liquid buffer preparations containing exosomes were frozen at -80°C, partially frozen at 4°C, or stored at 22°C for 72 hours. After storage in buffer B at the stated temperatures for 12 hours, the concentration of STING agonists in exosomes was calculated and compared with the concentration of STING agonists in the supernatant. The results are shown in Figures 3A and 3B. As shown, when stored at -80°C for 72 hours, the final concentration of STING agonist in the exosome was approximately 5 μM, and the final concentration of STING agonist in the supernatant was approximately 4.3 μM. When stored at 4°C for 72 hours, the final concentration of STING agonist in the exosome was approximately 4.5 μM, and the final concentration of STING agonist in the supernatant was approximately 4.4 μM. When stored at 22°C for 72 hours, the final concentration of STING agonist in the exosome was approximately 4.1 μM, and the final concentration of STING agonist in the supernatant was approximately 6.5 μM. The data graphed in Figures 3A and 3B are shown in Tables 9, 10, and 11 below.

[0367] This example demonstrates that storage temperature does not significantly affect the concentration of STING agonists in exosomes compared to the concentration of STING agonists in the supernatant. [Table 12] [Table 13] [Table 14]

[0368] Example 6: Effect of STING agonist in buffer B on gene expression The effects of administering exosomes containing the STING agonist CL656 on gene expression in C57BL / 6 liver were investigated.

[0369] After thawing, exosomes in buffer B composition containing the STING agonist CL656 were stored at 4°C and 22°C for 24 hours or 72 hours, respectively, as described in Example 5. PBS, CL656 (20 μg), exosomes, or exosomes in buffer B containing the STING agonist CL656 incubated as described above (CL656 600 ng / mouse) were administered intravenously to C57BL / 6 mice. As a control, exosomes in buffer B composition containing the STING agonist CL656 stored at -80°C (6 ng, 60 ng, and 600 ng per mouse) were administered (considered as 0 hours). After 4 hours, the mice were euthanized and their livers were collected. Total RNA was isolated from the liver using the RNeasy Lipid Mini Kit (Qiagen), and IFNβ mRNA expression levels were measured by RT-qPCR. Relative expression was normalized relative to the housekeeping gene RPS13. Figure 3C provides the results of the liver study. As shown, 1) dose-dependent induction of IFNβ mRNA was observed in the 0-hour sample. 2) IFNβ mRNA levels were similar in all exosomes in Buffer B composition containing the STING agonist CL656 (600 ng per mouse injection) under all storage conditions. 3) Exosomes without the STING agonist did not induce IFNβ mRNA, while CL656 (20 μg) induced low levels of IFNβ mRNA.

[0370] These results indicate that administration of STING agonists contained in buffer B, which has been frozen, thawed, and administered to the subjects, is effective in inducing IFNβ gene expression in liver tissue without any significant difference.

[0371] Example 7: Effects of STING agonists and exosome-encapsulated STING agonists on intratumor concentrations The intratumoral concentration of STING agonist in buffer B over time was investigated.

[0372] Briefly, B16-F10 melanoma cells were subcutaneously transplanted into C57BL / 6 mice. When skin tumors were observed, each animal was administered either an intratumoral dose of free STING agonist (0.3 μg of CL656) or exosome-encapsulated STING agonist (0.3 μg of CL656). Intratumoral concentrations of free STING agonist and exosome-encapsulated STING agonist were measured at 5, 30, 120, 360, 1440, and 2880 minutes post-injection. Results are provided in Figure 3D. As shown, the intratumoral concentration of free STING agonist decreased significantly after administration (dashed line) and was undetectable at approximately 360 minutes. Furthermore, as shown in Figure 3D, the concentration of exosome-encapsulated STING agonist decreased slowly to approximately 100 nM at 1440 minutes. Subsequently, the concentration of the STING agonist encapsulated in the exosome remained stable at approximately 100 nM until the final measurement was performed at 2880 minutes.

[0373] This example demonstrates that administering a composition containing exosome-encapsulated STING agonists, compared to free STING agonists, has a stabilizing effect on the intratumoral concentration of STING agonists.

[0374] Example 8: Development of Exemplary Composition 02 Formulation Overview of Formulation Development

[0375] The development of the exosome-loaded exoSTING composition 02 (C-02) pharmaceutical formulation with a STING agonist was carried out concurrently with the formulation development of intermediate-1, which contained purified exosomes. The objectives of the concurrent formulation development were: a) to recognize that the stability of the purified exosome active ingredient in the pharmaceutical is likely to provide information for the selection of stabilizing excipients, as opposed to the stability of the agonist active ingredient; and b) that the manufacturing process may be easier because these excipients can be incorporated into the pharmaceutical by having the purified exosome formulation be the same as the C-02 pharmaceutical. The test methods used for testing were similar to, but not identical to, the release test methods. The final approved test methods were used for stability testing under final formulation stress conditions. Unless otherwise specified, testing was performed using the C-02 pharmaceutical (including intermediate-1 and intermediate-02).

[0376] Initial drug stress tests were conducted, including mechanical, oxidative, and pH stress conditions. These tests were performed using 15 mM monobasic potassium phosphate, 27 mM dibasic sodium phosphate buffer, 100 mM sodium chloride, 5% sucrose (w / v), and pH 7.2. The tests demonstrated acceptable stability under all stress conditions, except for extreme mechanical stress such as vigorous agitation. The data indicated that the PBS formulation containing 5% (w / v) sucrose provides protection against stress conditions.

[0377] Using intermediate-01, broad pH range testing (pH 3.0 to 11.0) with various buffers identified a pH range of 6.5 to 9.0 as acceptable (by dynamic light scattering (DLS)), confirming its suitability for phosphate buffer. Nine-month stability testing of intermediate-01 using DLS and additional analytical evaluations confirmed its stability at -80°C in PBS containing 5% (w / v) sucrose.

[0378] The final formulation compositions of both Intermediate-01 and C-02 pharmaceuticals were modified to achieve tonicity suitable for parenteral administration. The sodium chloride concentration in the PBS formulation was reduced to achieve the desired sucrose level and tonic target. The phosphate concentration in PBS was increased to improve the buffering capacity of the formulation. Furthermore, a mixture of sodium phosphate and potassium phosphate buffer was selected over sodium phosphate alone.

[0379] The selected formulation composition was 15 mM monobasic potassium phosphate, 27 mM dibasic sodium phosphate, 40 mM sodium chloride, 5% (w / v) sucrose, pH 7.2. This formulation is used in intermediate-01, C-02 pharmaceutical, and FB-01 diluent for C-02. The final formulation buffer is referred to as formulation buffer 01 (FB-01).

[0380] The stability assessment of the C-02 drug in the final formulation demonstrates that the drug is stable against freeze-thaw cycles and mechanical inversion. Degradation occurs only under extreme stress conditions.

[0381] Evaluation of antifreeze agents for the freeze-thaw stability of pharmaceuticals. Antifreezing agents such as sucrose, trehalose, and D-sorbitol were evaluated at different concentrations in drug development lots formulated in 310 mM dibasic sodium phosphate, 90 mM monobasic potassium phosphate buffer, pH 7.4. This study used development lots of PTGFRN-overexpressing exosomes and cyclic dinucleotide STING agonists. Antifreezing agents were evaluated at 1.0%, 2.5%, 5.0%, 7.5%, and 10.0% (w / v) concentrations. The theoretical osmotic pressure of all sucrose and trehalose formulations in phosphate buffer was calculated to be approximately 300 mOsm / kg. For D-sorbitol formulations, the osmotic pressure of 1% to 5% (w / v) formulations was also approximately 300 mOsm / kg, while the 7.5% and 10.0% D-sorbitol formulations were calculated to be approximately 400 and 600 mOsm / kg, respectively. All formulations were evaluated by appearance and size using dynamic light scattering (DLS) after 0, 3, and 10 freeze-thaw cycles.

[0382] Appearance tests of the two controls (PBS alone or water) showed more substantial appearance changes associated with increased freeze-thaw cycles compared to formulations containing antifreeze. These changes included increased turbidity and color (PBS) or an increase in visible particles due to sedimentation (water). Both sucrose and D-sorbitol formulations showed acceptable appearance results at several concentrations. Higher concentrations of trehalose were required to prevent appearance changes compared to sucrose or D-sorbitol alone.

[0383] The DLS test results showed that the size and polydispersity of the control formulations (PBS only, water only) increased during multiple freeze-thaw cycles. In general, when higher concentrations of antifreeze (2.5% (w / v) or higher) were used, no significant changes in size or polydispersity were observed after 3 or 10 freeze-thaw cycles.

[0384] Based on the appearance and DLS results from this freeze-thaw test, both sucrose and D-sorbitol are acceptable antifreeze agents when present at concentrations of 2.5% (w / v) or higher. 5% (w / v) sucrose provides sufficient antifreeze and was selected for future formulation studies, including the initial stress study described below.

[0385] Stress test using phosphate-buffered saline containing sucrose - initial test Stress tests were conducted using a phosphate buffer containing the selected antifreeze (5% (w / v) sucrose) and sodium chloride to confirm stability under different mechanical stress conditions and after oxidation. The formulations used in these tests were 43 mM phosphate buffer, 100 mM sodium chloride, 5% (w / v) sucrose, and pH 7.2.

[0386] In mechanical stress tests, samples were evaluated at ambient temperature using various levels of mechanical stress (stirring, mixing) for various durations. Samples were evaluated by appearance, pH, osmotic pressure, DLS, and nanoparticle tracking analysis (NTA). Size and polydispersity index remained unchanged under all test conditions compared to the control (no stirring). Only vigorous manual stirring altered the appearance, and foaming was observed under these conditions. Acceptable stability of the pharmaceutical formulation was observed under all conditions except extreme mechanical stress such as vigorous stirring. Stability of the formulation after multiple gentle inversions was also observed. The pH and osmotic pressure of the test samples remained constant.

[0387] The effect of oxidative stress on pharmaceuticals was evaluated by treating samples with different concentrations of hydrogen peroxide at 37°C for 4 hours. After treatment, samples were quenched with 100 mM sodium ascorbate and held at ambient temperature for 1 hour to neutralize the hydrogen peroxide before testing. Intermediate-01 loaded with STING agonist was used in this test. Samples were analyzed by appearance, DLS, NTA, and in vivo potency.

[0388] The drug remained stable and fully potent when exposed to oxidative stress under the conditions tested in a limited series of assays. No substantial changes were observed in appearance, size, or exosome concentration compared to the control (no hydrogen peroxide treatment) with exposure to different hydrogen peroxide concentrations. Qualitatively, no substantial difference in potency was observed in the spleen, as assessed by normalized gene expression. A tendency for decreased hepatic potency was observed with increasing hydrogen peroxide test concentrations, although a substantial loss of potency was observed in the ascorbic acid-only group, with relatively wide-ranging potency observed between and within groups. Therefore, potency was similar in the liver between the test groups and the control group, except for the control group (PBS). Based on the test methods employed, the data suggest that the drug is not sensitive to low levels of oxidative stress.

[0389] Subsequent stress tests were designed to further confirm the stability of the C-02 drug in the selected final formulation. Furthermore, accelerated condition testing was performed on the C-02 drug in the final formulation (data not shown).

[0390] pH selection / Intermediate-01 test The selection of the pH target and range for the pharmaceutical formulation focused on ensuring the stability of exosomes in the formulation, and testing was conducted using Intermediate-01. This testing evaluated stability at pH values ​​3, 5, 6, 6.5, 7, 9, and 11. pH values ​​3 and 5 were achieved using citrate / sodium citrate dihydrate buffer. For pH values ​​6, 6.5, and 7, monobasic potassium phosphate / dibasic sodium phosphate heptahydrate was used, and for pH values ​​9 and 11, carbonate buffer was used. Samples were analyzed by DLS for changes in size or size distribution, and the zeta potential of the surface charge. While these limited data combinations support a pH range of 6.5–9.0, a narrower range (±0.5) was actually selected for formulations around the pH 7.2 target. Based on these results, and based on acceptable DLS results and the expected buffering capacity of the phosphate buffer, the target pH 7.2 was selected.

[0391] Intermediate-01 and C-02 pharmaceutical preparations pH test data for Intermediate-01 support the selection of a PBS formulation for Intermediate-01. Testing of the antifreeze agent in the pharmaceutical identified 5% (w / v) sucrose in this formulation. Similar testing of Intermediate-01 also identified 5% (w / v) sucrose as the desirable antifreeze agent (data not shown). Both the formulation compositions for Intermediate-01 and the pharmaceutical maintain near-physiological tonicity (approximately 300 mOsm / kg). The salt concentration of the PBS formulation was reduced to achieve the desired sucrose level and tonic target. The phosphate concentration of the PBS was increased to improve the buffering capacity of the formulation. Furthermore, a mixture of sodium phosphate and potassium buffer was selected.

[0392] Based on these considerations, one formulation composition selected for the C-02 drug was 15 mM monobasic potassium phosphate, 27 mM dibasic sodium phosphate, 40 mM sodium chloride, 5% w / v sucrose, pH 7.2. This formulation is used for intermediate-01, the C-02 drug, and the FB-01 diluent for the C-02 drug. The formulation buffer is referred to as FB-01.

[0393] Intermediate-01 Stability Test Development stability tests were conducted to confirm the stability of intermediate-01 in FB-01 during long-term storage at -80°C.

[0394] Stress testing and follow-up studies in final pharmaceutical formulations.

[0395] To confirm the stability of the C-02 drug under various mechanical stress conditions and after oxidation, follow-up stress tests were conducted on the final formulation composition. These tests were performed using the C-02 drug in the final FB-01 formulation and included additional analytical methods related to the initial stress tests.

[0396] This test included holding controls (up to 24 hours at 25°C), multiple freeze-thaw cycles (up to 10 cycles of freezing at -80°C and thawing at ambient temperature), extreme pH (pH 5 and 9), oxidative stress (up to 24 hours of exposure to 3% hydrogen peroxide), and mechanical stress using mechanical inversion for up to 24 hours.

[0397] The freeze-thaw cycle results show that there was no change in the quality attributes of the drug throughout the 10 freeze-thaw cycles.

[0398] Example 9: Development of Exemplary Composition 03 Formulation The IL-12-loaded exosome (exoIL-12) composition 03 (C-03) pharmaceutical is prepared by incorporating the active ingredient exoIL-12 into a formulation buffer containing 5 mM monobasic potassium phosphate, 15 mM dibasic sodium phosphate, 50 mM sodium chloride, and 146 mM sucrose, at pH 7.2.

[0399] The development of C-03 was guided by several principles. The pharmaceutical formulation is intended for use as an injectable solution. Furthermore, the formulation is optimized for cryopreservation to minimize degradation during freeze / thaw operations. During formulation development testing, initial analytical tests focused on the stability and potency of exosomes in solution. These assays included appearance, dynamic light scattering (DLS), IL-12 AlphaLISA, and human embryonic kidney (HEK) cell-based reporter assays.

[0400] After purification, the exo-IL-12 preparation appears as a translucent solution free of visible particles. Color was determined by comparing the exosome sample to the European Pharmacopoeia color standard for glass ampoules. ExoIL-12 exosomes were found to have a diameter of approximately 171 nm and a PDI value of less than 0.25.

[0401] Based on investigations into buffers and antifreezes for C-03, it was decided to select a sodium phosphate / potassium buffer containing 146 mM (5% w / v) sucrose at pH 7.2 for both the CB-102 active pharmaceutical ingredient and the C-03 pharmaceutical formulation to optimize quality and stability. Forced degradation tests were conducted to obtain information on assays that indicate potential stability.

[0402] Selection of Buffers pH stability tests were conducted at high temperatures (37°C and 50°C) using various buffer solutions with pH values ​​of 3, 5, 7, and 9.

[0403] Buffer-102 was first buffer-exchanged with milliQ water and then spiked to a concentrated stock of the appropriate buffer to adjust the pH to the desired level. After pH adjustment, the sample was analyzed by appearance and dynamic light scattering (DLS) for changes in size and size distribution, and the free versus total content of IL-12 (free and exosome-related) was quantified using IL-12 AlphaLISA.

[0404] Selection of antifreeze The study involved repeated freeze-thaw (F / T) cycles using phosphate buffer containing exoIL-12, with and without 146 mM (5% w / v) sucrose. The concentration of the antifreeze was selected to achieve a physiological osmotic pressure (approximately 290 mOsm / kg) with sufficient phosphate buffering capacity. Only milliQ water (MQ) and PBS containing exoIL-12 were prepared as control samples and subjected to three freeze / thaw cycles (F / T). Phosphate buffer containing exoIL-12 with 146 mM sucrose (selected from the buffer selection test) was evaluated at 0, 1, 3, and 10 F / T. The collected samples were evaluated by appearance, DLS, and the IL-12 AlphaLISA test method.

[0405] Test samples containing sucrose remained stable in terms of size by DLS throughout 10 F / T cycles, measured at approximately 180 nm. Similarly, the distribution or polydispersity index (PDI) remained consistently low from 0.15 to 3 F / T cycles, but increased to 0.2 after 10 F / T cycles. No change in color or increase in turbidity was observed. Control exosomes were dispersed in either milliQ water or PBS and subjected to 3 F / T cycles, showing clear signs of aggregation and degradation. The milliQ controls became turbid and slightly changed to red / orange, but their size greater than 800 nm by DLS indicated clear aggregation. Exosomes in PBS alone were 187 nm in size, slightly larger than the test samples, and their PDI was approximately the same as that of the 10 F / T samples in the sucrose-containing test group. Exosomes in PBS alone showed a significant change in turbidity, indicated by an appearance of aggregation, but no change in color.

[0406] The results of IL-12 AlphaLISA showed that after 10 F / T in the presence of sucrose, both associated and free IL-12 remained similar, at approximately 2300 ng / mL and 1–3% IL-12, respectively. A significant decrease in associated IL-12 was observed in both milliQ and PBS-only exosomes, decreasing by 24% and 37%, respectively. The amount of free IL-12 increased slightly to 5% and 4%, respectively.

[0407] The osmotic pressure of the final phosphate / sucrose buffer formulation is approximately 300 mOsm / kg.

[0408] Forced decomposition test A forced degradation test was conducted in accordance with ICH Q1A(R2) to determine the stability of the pharmaceutical product under stress conditions including freeze-thaw cycles, extreme pH, oxidation, and mechanical stress.

[0409] The freeze-thaw test results generally did not show a significant trend throughout 10 F / T cycles. While the observed exosome size and PDI values ​​were highest after 10 F / T cycles, the absolute difference was not significant enough to indicate a true effect on exosome stability. Furthermore, other test results did not show a significant trend up to 10 F / T. To put it mildly, the stability of C-03 is confirmed for a maximum of 5 freeze-thaw cycles.

[0410] Example 10: Development of Exemplary Composition 04 Formulation Pharmaceutical formulations for exosomes loaded with antisense oligomers will be developed. The C-03 pharmaceutical formulation will be used as a starting point. The phosphate buffer concentrations (5 mM monobasic potassium phosphate and 15 mM dibasic sodium phosphate) and pH (pH 7.2) will remain unchanged compared to the C-03 pharmaceutical. Sodium chloride concentrations will be tested in the range of approximately 50 mM to approximately 150 mM, and sucrose concentrations will be tested in the range of approximately 2.5% to 5% (approximately 73 mM to approximately 146 mM). The state will be monitored according to the methods described in Examples 9 and 10 above. Various ASO-loaded exosome constructs will be analyzed, including exosomes loaded with ASOs targeting STAT6, as disclosed herein. In Tris EDTA buffered aqueous solution or pure water, the ASOs dissociate from the exosomes, so the combination of sodium chloride and sucrose may play a role in retaining the loaded ASOs.

[0411] It should be understood that the section describing modes for carrying out the invention, rather than the section describing the summary and abstract of the invention, is intended to be used to interpret the claims. The section describing the summary and abstract of the invention may describe one or more but not all of the embodiments of the disclosure as intended by the inventors(s), and does not limit the scope of the disclosure and the appended claims in any way.

[0412] This disclosure is described above using functional components that exemplify the implementation of the identified functions and their relationships. The boundaries of these functional components are arbitrarily defined herein for descriptive convenience. Different boundaries may be defined insofar as the implementation and relationships of those particular functions are adequately performed.

[0413] The above-mentioned descriptions of specific embodiments fully disclose the general characteristics of this disclosure, that by applying knowledge within the scope of the art, others may readily modify and / or adapt such specific embodiments for various applications without excessive experimentation and without deviating from the general concepts of this disclosure. Therefore, such adaptations and modifications are intended to fall within the scope and meaning of equivalents of the disclosed embodiments, based on the teachings and guidance presented herein. The expressions and terms herein are intended for illustrative purposes only, not limitation, and are therefore understood to be construed by those skilled in the art in light of the teachings and guidance.

[0414] The scope and breadth of this disclosure should not be limited by any of the exemplary embodiments described above, but should be defined solely in accordance with the following claims and their equivalents.

[0415] The claims of this application are separate from the claims of the parent application or any other related application. Therefore, the applicant invalidates any disclaimers in the claims of the parent application or any prior application relating to this application. Accordingly, the examiner should note that they may need to review any such prior disclaimers and any references prepared to circumvent them. Furthermore, the examiner should note that any disclaimers made in this application will not be incorporated into or contrary to the parent application.

[0416] All publications, patents, patent applications, and other documents referenced herein are incorporated herein by reference in whole for all purposes, to the same extent that each individual publication, patent, patent application, or other document is individually indicated to be incorporated by reference for all purposes.

[0417] While various specific aspects have been shown and described, the above specification is not restrictive. It should be understood that various modifications can be made without departing from the intent and scope of this disclosure.

Claims

1. 1. A pharmaceutical composition comprising: (a) extracellular vesicles (EVs); (b) sucrose at a concentration of about 4% w / v to about 6% w / v; (c) sodium chloride at a concentration of about 30 mM to about 50 mM; (d) potassium phosphate monobasic at a concentration of about 5 mM to about 25 mM; (e) sodium phosphate dibasic heptahydrate at a concentration of about 15 mM to about 35 mM; The composition is in a solution having a pH of 7.1 to 7.3, and the composition does not contain albumin or a chelating agent.

2. The composition of claim 1 , wherein the extracellular vesicle is an exosome.

3. 3. The composition of claim 1 or claim 2, wherein the composition can be stored at a temperature of 4° C. for at least about 4 hours, at least about 5 hours, at least about 6 hours, at least about 7 hours, at least about 8 hours, at least about 9 hours, at least about 10 hours, at least about 11 hours, at least about 12 hours, at least about 15 hours, at least about 20 hours, at least about 24 hours, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, or at least about 7 days.

4. The composition of any one of claims 1 to 3, wherein the composition can be frozen and thawed, and the thawed composition has a pH of 7.

2.

5. The composition of any one of claims 1 to 4, having a pI in the range of about 1 to about 6.

5.

6. 6. The composition of any one of claims 1-5, wherein the composition has (i) reduced aggregation, (ii) improved stability of the extracellular vesicles (EVs), (iii) improved EV structural integrity, and (iv) improved stability of an engineered protein contained on or within the EVs.

7. The composition of any one of claims 1 to 6, wherein the composition has a conductivity of about 6 mS / cm + / - 10% to about 10 mS / cm + / - 10%.

8. The composition of any one of claims 1 to 7, further comprising an antioxidant.

9. 9. The composition of claim 8, wherein the antioxidant comprises D-methionine, L-methionine, ascorbic acid, erythorbic acid, sodium ascorbate, thioglycerol, cysteine, acetylcysteine, cystine, dithioerythreitol, glutathione, tocopherol, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), sodium bisulfate, sodium dithionite, α-tocopherol, γ-tocopherol, propyl gallate, ascorbyl palmitate, sodium metabisulfite, thiourea, sodium thiosulfate, propyl gallate, or sodium thioglycolate.

10. The composition of any one of claims 1 to 9, wherein the composition is not lyophilized.

11. a. sucrose at a concentration of about 5% w / v; b. sodium chloride at a concentration of about 50 mM; c. potassium phosphate monobasic at a concentration of about 5 mM; d. sodium phosphate dibasic heptahydrate at a concentration of about 15 mM; A composition according to any one of claims 1 to 10, in a solution at pH 7.2 and with a conductivity of 7.23 mS / cm + / - 10%.

12. a. sucrose at a concentration of about 5% w / v; b. sodium chloride at a concentration of about 40 mM; c. potassium phosphate monobasic at a concentration of about 15 mM; d. sodium phosphate dibasic heptahydrate at a concentration of about 27 mM; A composition according to any one of the preceding claims, in a solution at pH 7.2 and with a conductivity of 8.8mS / cm + / - 10%.

13. The composition according to any one of claims 1 to 12, wherein the composition can be stored at a temperature of about -20°C to about -80°C without decreasing the stability of the extracellular vesicles.

14. 14. The composition of claim 13, wherein the composition can be stored for about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 12 months, about 1 year, about 2 years, about 3 years, or about 4 years.

15. The composition of any one of claims 1 to 14, wherein the extracellular vesicles further comprise a scaffold protein.

16. The composition of claim 14 or 15, wherein an antigen and / or adjuvant is linked to the scaffold protein.

17. The composition of claim 16, wherein the antigen and / or adjuvant is linked to the scaffold protein by a linker.

18. The composition of claim 17 , wherein the linker is a polypeptide.

19. The composition of claim 17 , wherein the linker is a non-polypeptide moiety.

20. A composition described in any one of claims 16 to 19, wherein the scaffold protein is capable of fixing the antigen and / or adjuvant to the outer surface of the extracellular vesicle.

21. The composition of any one of claims 15 to 20, wherein the scaffold protein comprises the PTGFRN protein or a fragment thereof.

22. The composition of any one of claims 15 to 20, wherein the scaffold protein comprises an amino acid sequence set forth in any one of SEQ ID NOs: 1-7 or 33.

23. 23. The composition of any one of claims 15-22, wherein the scaffold protein comprises an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% identical to SEQ ID NO:

1.

24. The composition of any one of claims 1 to 23, wherein the extracellular vesicle comprises a biologically active moiety.

25. The composition of claim 24 , wherein the scaffold protein is fused to the biologically active moiety.

26. The composition of claim 24 , wherein the scaffold protein is not fused to the biologically active moiety.

27. 25. The composition of claim 24, wherein the biologically active portion comprises a STING agonist selected from CL606, CL611, CL602, CL655, CL604, CL609, CL614, CL656, CL647, CL626, CL629, CL603, CL632, CL633, CL659, and pharma- ceutically acceptable salts thereof.

28. 28. The composition of claim 27, wherein the STING agonist is CL656.

29. 29. The composition of claim 28, wherein the STING agonist is isomer A, isomer B, isomer C, or isomer D of CL656.

30. 25. The composition of claim 24, wherein the biologically active moiety is IL-12, CD40L, FLT3L, or any combination thereof.

31. The composition of any one of claims 1 to 30, wherein the composition may be administered parenterally, topically, intravenously, orally, subcutaneously, intraarterially, intradermally, transdermally, rectally, intracranially, intraperitoneally, intranasally, intratumorally, intramuscularly or by inhalation.

32. The composition of any one of claims 1 to 23, wherein the extracellular vesicle comprises an IL-12 moiety.

33. 33. The composition of claim 32, wherein the IL-12 portion comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:11, 12, or 13.

34. (a) an extracellular vesicle comprising an ASO, wherein the ASO comprises a nucleic acid sequence selected from SEQ ID NOs: 91-193; and (b) sucrose at a concentration of about 2.5% to about 5%; (c) sodium chloride at a concentration of about 50 mM to about 150 mM; (d) potassium phosphate monobasic at a concentration of about 5 mM; (e) dibasic sodium phosphate at a concentration of about 15 mM; (f) the composition according to any one of claims 1 to 24, wherein the pH of the composition is 7.

2.

35. The composition of claim 34, wherein the ASO is associated with the extracellular vesicle by a linker.

36. 36. The composition of claim 35, wherein the linker comprises cholesterol, tocopherol, a fatty acid, or any combination thereof.

37. A method for preparing a pharmaceutical composition according to any one of claims 1 to 36, comprising combining extracellular vesicles and a sugar, wherein the sugar is sucrose at a concentration of about 5% w / v, and wherein the composition exhibits improved stability compared to a composition comprising sucrose or trehalose at a concentration of 1 to 4%.

38. A pharmaceutical composition according to any one of claims 1 to 36 for treating a disease or condition in a subject in need thereof.

39. Use of a composition described in any one of claims 1 to 36 in the manufacture of a medicament for treating a disease or condition.

40. The use of claim 39, wherein the disease or condition is cancer, fibrosis, hemophilia, diabetes, growth factor deficiency, eye disease, Pompe disease, lysosomal storage disorders, mucoviscidosis, cystic fibrosis, Duchenne and Becker muscular dystrophy, transthyretin amyloidosis, hemophilia A, hemophilia B, adenosine deaminase deficiency, Lieber congenital amaurosis, X-linked adrenoleukodystrophy, metachromatic leukodystrophy, OTC deficiency, glycogen storage disease 1A, Crigler-Najjar syndrome, primary hyperoxaluria type 1, acute intermittent porphyria, phenylketonuria, familial hypercholesterolemia, mucopolysaccharidosis type VI, alpha-1 antitrypsin deficiency, and hypercholesterolemia.

41. The use of claim 40, wherein the cancer is bladder cancer, cervical cancer, renal cell carcinoma, testicular cancer, colorectal cancer, lung cancer, head and neck cancer, ovarian cancer, lymphoma, liver cancer, glioblastoma, melanoma, myeloma, leukemia, pancreatic cancer, or a combination thereof.